

Practical guidelines for nursing and midwifery diabetes care – 2026. A position of the Polish Federation for Education in Diabetology

Praktyczne zalecenia w pielęgniarskiej i położniczej opiece diabetologicznej – 2026. Stanowisko Polskiej Federacji Edukacji w Diabetologii

Alicja Szewczyk^{1,A-B,D-E,G,J} , Natasza Tobiasz-Kałkun^{2,A-B,D-G,L} ,
 Anna Stefanowicz-Bielska^{3,A-B,D-E,G} , Ewa Kobos^{4,A-B,D-E,G,K} , Justyna Kapuściok^{5,A-B,D-E,G} ,
 Agnieszka Karczewska^{6,7,A-B,D-E,G}, Kamila Mazuryk^{8,A-B,D-E,G} , Beata Hornik^{9,A-B,D-G,L} 

¹Department of Endocrinology and Diabetology; Diabetes Clinic, Children's Memorial Health Institute in Warsaw, Poland/
 Klinika Endokrynologii i Diabetologii; Poradnia Diabetologiczna Instytutu „Pomnik-Centrum Zdrowia Dziecka” w Warszawie, Polska

²Institute of Health, Faculty of Applied Studies, University of Lower Silesia DSW in Wrocław, Poland/
 Instytut Zdrowia, Wydział Studiów Stosowanych, Uniwersytet Dolnośląski DSW we Wrocławiu, Polska

³Laboratory of Pediatric Nursing, Division of Internal and Pediatric Nursing, Institute of Nursing and Midwifery, Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, Medical University of Gdańsk; Department of Paediatrics Diabetology, Department of Pediatrics, Diabetology and
 Endocrinology, University Clinical Center in Gdańsk, Poland/

Pracownia Pielęgniarstha Pediatrycznego, Zakład Pielęgniarstha Internistyczno-Pediatrycznego, Instytut Pielęgniarstha i Położnictwa, Wydział Nauk o Zdrowiu z Instytutem Medycyny Morskiej i Tropikalnej, Gdańsk Uniwersytet Medyczny; Oddział Diabetologii Dziecięcej, Klinika Pediatrii, Diabetologii i Endokrynologii, Uniwersyteckie Centrum Kliniczne w Gdańskim, Polska

⁴Department of Development of Nursing, Social and Medical Sciences, Faculty of Health Sciences, Medical University of Warsaw, Poland/
 Zakład Rozwoju Pielęgniarstha, Nauk Społecznych i Medycznych, Wydział Nauk o Zdrowiu, Warszawski Uniwersytet Medyczny, Polska

⁵The Complex of Post-Secondary Medical and Social Schools in Bytom; Individual Nursing Practice, Poland/
 Centrum Kształcenia Zawodowego i Ustawicznego w Bytomiu; Indywidualna Praktyka Pielęgniarska, Polska

⁶University Clinical Hospital No. 1 in Lublin, Poland/Uniwersytecki Szpital Kliniczny nr 1 w Lublinie, Polska

⁷Faculty of Medicine, John Paul II Catholic University of Lublin, Poland/Wydział Medyczny, Katolicki Uniwersytet Lubelski im. Jana Pawła II, Polska

⁸Department of Hypertension and Diabetology, University Clinical Center in Gdańsk; Department of Surgical Nursing, Institute of Nursing and Midwifery, Faculty of Health Sciences with Institute of Maritime and Tropical Medicine, Medical University of Gdańsk, Poland/

Klinika Nadciśnienia Tętniczego i Diabetologii, Uniwersyteckie Centrum Kliniczne w Gdańskim; Zakład Pielęgniarstha Chirurgicznego, Instytut Pielęgniarstha i Położnictwa, Wydział Nauk o Zdrowiu z Instytutem Medycyny Morskiej i Tropikalnej, Gdańsk Uniwersytet Medyczny, Polska

⁹Department of Internal Medicine Nursing, Faculty of Health Sciences, Medical University of Silesia in Katowice, Poland/
 Katedra i Zakład Pielęgniarstha Internistycznego, Wydział Nauk o Zdrowiu, Śląski Uniwersytet Medyczny w Katowicach, Polska

CORRESPONDING AUTHOR:

Ewa Kobos

Zakład Rozwoju Pielęgniarstha, Nauk Społecznych i Medycznych, Wydział Nauk o Zdrowiu
 Warszawski Uniwersytet Medyczny
 ul. Ciołka 27, 01-445, Warszawa, Polska
 e-mail: ekobos@wum.edu.pl

STRESZCZENIE

PRAKTYCZNE ZALECENIA W PIELĘGNIARSKIEJ I POŁOŻNICZEJ OPIECIE DIABETOLOGICZNEJ – 2026. STANOWISKO POLSKIEJ FEDERACJI EDUKACJI W DIABETOLOGII

Cel pracy. Przygotowanie zestawu procedur opisujących sposób postępowania pielęgniarskiego w opiece diabetologicznej z uwzględnieniem aktualnie dostępnych dowodów naukowych oraz klinicznego doświadczenia specjalistów zaangażowanych w opiekę nad osobą z cukrzycą.

Materiał i metody. Dokonano przeglądu piśmiennictwa w wybranych obszarach praktyki pielęgniarki diabetologicznej. Priorytetem przy tworzeniu materiału było wykorzystanie danych kolejno z: badań z randomizacją i ich metaanaliz, przeglądów systematycznych, badań obserwacyjnych a także innych badań o niższym poziomie dowodów.

Wyniki. Analiza zgromadzonego materiału dała podstawę do opracowania 14 procedur oraz 4 wytycznych opisujących wybrane aspekty postępowania pielęgniarskiego, w opiece nad osobą z cukrzycą. W każdej z procedur wyszczególniono kluczowe dla opieki rekommendacje i usystematyzowano je zgodnie z przyjętym poziomem dowodów naukowych.

Wnioski. Praktyczne zalecenia w pielęgniarskiej i położniczej opiece diabetologicznej na rok 2026 rok są efektem ewaluacji dotychczas prezentowanych wersji i stanowią aktualizowany, znacznie rozszerzony, kompleksowy, oparty na dowodach naukowych zestaw praktyk. Niewątpliwie atutem jest interdyscyplinarność zaleceń wyrażających się między innymi w tym, iż ostateczna wersja została zaopiniowana przez konsultantów w dziedzinach pielęgniarstha oraz przez konsultanta w dziedzinie diabetologii i przedstawicieli środowiska lekarskiego z Polskiego Towarzystwa Diabetologicznego. Ważnym elementem w formułowaniu aktualnych zaleceń było wykorzystanie doświadczeń autorów zdobyte podczas prac przy międzynarodowych rekomendacjach (ang. *New Insulin Delivery Recommendations*).

Słowa kluczowe: procedury, pielęgniarka, położna, cukrzyca, zalecenia

ABSTRACT

PRACTICAL GUIDELINES FOR NURSING AND MIDWIFERY DIABETES CARE – 2026. A POSITION OF THE POLISH FEDERATION FOR EDUCATION IN DIABETOLOGY

Aim. Presenting a set of procedures describing nursing interventions in diabetes care, including currently available scientific evidence and clinical experience of specialists involved in the care of diabetic patients.

Material and methods. The study involved a literature review of selected areas of nursing practice in diabetes care. When compiling the material, the priority was to use data from: randomized controlled clinical trials and their meta-analyses, systematic reviews, observational studies and other studies with lower levels of evidence.

Results. Based on an analysis of the collected material, 14 procedures and 4 guidelines have been developed, describing selected aspects of nursing interventions in diabetic patients. Each of the procedures details key recommendations on diabetes care, arranged in accordance of the significance ascribed to the scientific evidence analyzed.

Conclusions. The 2026 PFED guidelines on nursing diabetes care are the effect of the evaluation of the previous versions and comprise an updated, considerably more extensive, comprehensive and evidence-based set of practices. The major asset of these guidelines is their interdisciplinarity, reflected in the fact that the final version of the publication was approved by consultants in nursing fields, a consultant in diabetology, and representatives of the medical community from the Polish Diabetes Society. The authors experience gained during work on international recommendations (*New Insulin Delivery Recommendations*) played an important role when formulating the present guidelines.

Key words:

procedures, recommendations, nurse, midwife, diabetes

INTRODUCTION

Since 2006, the Polish Federation for Education in Diabetology (PFED) has published guidelines on diabetes care for nurses and midwives working with diabetes patients [1,2]. The guidelines are recommended by consultants in nursing, epidemiological nursing, gynecological and obstetrical nursing, and diabetology, as well as the president of the Polish Diabetes Society. The guidelines are developed by a team of nurses and

■ Tab. 1. Research evidence classification system used by PFED to create Practical Guidelines for Nursing Diabetes Care – 2026 (A position of the Polish Federation for Education in Diabetology)

Level of evidence	Description
A	<ul style="list-style-type: none"> Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including: <ul style="list-style-type: none"> evidence from a well-conducted multicenter trial, evidence from a meta-analysis that incorporated quality ratings in the analysis. Compelling nonexperimental evidence, i.e. "all or none" rule developed by the Centre for Evidence Based Medicine at the University of Oxford Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including: <ul style="list-style-type: none"> evidence from a well-conducted trial at one or more institutions, evidence from a meta-analysis that incorporated quality ratings in the analysis.
B	<ul style="list-style-type: none"> Supportive evidence from well-conducted cohort studies <ul style="list-style-type: none"> evidence from a well-conducted prospective cohort study or registry, evidence from a meta-analysis of cohort studies. Supportive evidence from well-conducted case-control study.
C	<ul style="list-style-type: none"> Supportive evidence from poorly controlled or uncontrolled studies: <ul style="list-style-type: none"> evidence from randomized clinical trials with one or more major, or three or more minor methodological flaws that could invalidate the results evidence from observational studies with high potential for bias (such as case series with comparison with historical controls), evidence from case series or case reports. Conflicting evidence with the weight of evidence supporting the recommendation
E	<ul style="list-style-type: none"> Expert consensus or clinical experience

Source: Introduction and Methodology: Standards of Care in Diabetes – 2025. Diabetes Care 2025;48(Supplement_1):S1-S5.

midwives with extensive experience in diabetes care. The 2025 PFED guidelines on diabetes care have been updated based on the most recent scientific reports; key recommendations for care have been highlighted and assigned evidence levels A, B, C, and E, in line with the evidence classification described in Tab. 1.

Please, note that the guidelines are just one of multiple considerations involved in nurses' and midwives' decision-making process regarding patient care. All guidelines should be appropriately interpreted for a specific patient and specific circumstances, the patient's values and preferences, and the clinical situation, based on one's knowledge, skills, and clinical experience.

The updated version of the guidelines has been supplemented with recommendations regarding the prevention of type 1 and type 2 diabetes. These guidelines also address the implementation of new solutions in the provision of health-care services using telecommunication and information technologies in diabetology, as well as new diabetes therapies.

RECOMMENDATION OF GUIDELINES

Grażyna Iwanowicz-Palus – National consultant in gynecological and obstetrical nursing

Anna Szczęsna – National consultant in epidemiological nursing

Krzysztof Strojek – National consultant in diabetes

Irina Kowalska – President of the Polish Diabetes Society

Przemysława Jarosz-Chobot – Member of the Expert Panel for the Polish Diabetes Society Guidelines, Coordinator of the Therapeutic Education chapter

Dorota Zozulińska-Ziółkiewicz – Chair of the Social Diabetology and Education Section at the Polish Diabetes Society

REFERENCES

1. Szewczyk A, Tobiasz-Kałkun N, Stefanowicz-Bielska A, et al. Praktyczne zalecenia w pielęgniarskiej i położniczej opiece diabetologicznej – 2020: Stanowisko Polskiej Federacji Edukacji w Diabetologii. Pielęg. XXI w. 2020;3(72):184-207. <https://doi.org/10.2478/pielxxiv-2020-0022>
2. Szewczyk A, Tobiasz-Kałkun N, Stefanowicz-Bielska A, et al. Praktyczne zalecenia w pielęgniarskiej i położniczej opiece diabetologicznej – 2023. Stanowisko Polskiej Federacji Edukacji w Diabetologii. Pielęg. XXI w. 2023;4(81):267-312. <https://doi.org/10.2478/pielxxiv-2022-0035>

I. GLUCOSE LEVEL MEASUREMENT USING A GLUCOSE METER

Purpose: Measurement of glucose level in capillary blood using a glucose meter, providing results used in the therapeutic decision-making.

Individuals authorized to perform the measurement: nurse, midwife.

■ Tab. 2. Key recommendations. Glucose level measurement using a glucose meter

Each individual with diabetes should be trained in: technique for using the glucose meter and the dedicated accessories, self-care and self-examination of puncture sites, and principles of glucose monitoring oriented at diabetes self-management in cooperation with the treatment team. C
Individuals with diabetes performing self-monitoring of blood glucose should be continuously instructed and evaluated on their measurement technique, results, and ability to use data from self-monitoring of blood glucose to self-manage their diabetes in cooperation with the treatment team. C
Health care professionals should understand the impact of medication and other factors on the accuracy of measurement using a glucose meter, and should select devices for specific individuals with diabetes based on these factors. E
If it is necessary to use a single glucose meter for more than one patient, the device must be cleaned and disinfected after each use, according to the manufacturer's instructions. C
The first drop of blood is used for capillary blood glucose measurement, after the patient has washed their hands in a home setting or after skin disinfection in a healthcare facility. C
In a hospital setting, for measuring glucose levels in capillary blood, it is better to use individually packed test strips. C
The nurse/midwife should perform physical examination of the patient's skin at puncture sites. The physical examination of the skin of the individual with diabetes should be performed at least once every 6 months, considering the frequency of glucose self-monitoring. E
During each visit, the nurse/midwife should assess the frequency of glucose level measurements performed by the individual with diabetes and analyze the reasons for non-adherence to the recommended number of measurements. C

Selecting a glucometer

The type and selection of a glucometer for monitoring glucose levels in capillary blood should take into account the health needs and lifestyle, personal preferences, level of knowledge, and skills of the individual with diabetes or their carer. When selecting a glucometer for an individual with diabetes, the following should be considered:

- patient's age,
- manual dexterity,
- comorbidities,
- type of treatment being used,
- device size,
- screen font size,
- voice output functionality for test results,
- ease of handling a test strip and lancet,
- ability to connect with smartphone applications via Bluetooth, allowing automatic synchronization of glucose level data,
- insulin bolus calculator function,
- ability to monitor ketone bodies [1].

Frequency of measurements performed by the patient

The frequency of glucose level measurements performed by the individual with diabetes is linked to the outcomes of

metabolic control of diabetes. Therefore, during each visit, the nurse/midwife should assess the need and frequency of glucose monitoring by the individual with diabetes, as well as analyze the reasons for non-adherence to the recommended number of measurements, to ensure their effective use [2-4]. To obtain valuable information for therapy optimization, glucose measurements using a glucometer should be performed frequently, consistently, and in a structured manner (following a schedule of feasible blood glucose measurements conducted at specific times, to use the data for individual education of the individual with diabetes and therapeutic interventions) [2,5-7]. Individuals with diabetes should be taught how to use BGM (Blood Glucose Monitoring) data to adjust food intake, physical activity, or pharmacological therapy in order to achieve the care goals planned.

- Individuals with diabetes treated with non-insulin antihyperglycemic medications should perform a shortened glucose profile once a week or measurements as needed.
- Individuals with type 2 diabetes treated with fixed doses of insulin should conduct 1-2 measurements daily, a shortened glucose profile once a week (fasting and postprandial), and a 24-hour glucose profile once a month.
- Individuals with diabetes, regardless of type, treated with multiple daily insulin injections (at least 3 injections) or intensive functional insulin therapy, should perform self-monitoring of blood glucose at least 4 times a day. It is recommended to conduct 8 measurements daily, based on the individual's needs and the treatment guidelines established [8].

Adherence to recommendations regarding the frequency of glucose measurements using a glucometer

When assessing the reasons for non-adherence by an individual with diabetes to the recommended frequency of blood glucose measurements using a glucometer, the following factors should be considered:

- cost of test strips,
- lack of time for the measurement or forgetting to perform it,
- perceiving the measurement as unnecessary,
- complexity of the measurement,
- lack of knowledge or understanding of how to adjust insulin doses based on the measurement results,
- pain and anxiety associated with the measurement,
- missing or defective glucometer [4,9].

Sites for capillary blood sampling

In adults, the fingertip is typically the preferred site for capillary blood sampling. The puncture is performed on the palmar surface of the distal segment of finger, perpendicular to the lines of the fingerprint. Sides of the heel are only used in children and infants. The puncture is performed on the lateral or medial plantar surface, in the shaded

area outside the lines going from the middle of the big toe to the heel and from the point between the fourth and fifth toe to the heel [10-13].

In children, the capillary blood sampling site is typically selected based on the patient's age and body weight. Sampling capillary blood by finger-prick is recommended in children older than 6 months and weighing more than 10 kg. Recommended fingers: middle and ring finger. Avoid collecting blood from the thumb or index finger, which may be calloused, or from the little finger due to its thin tissue [13]. Before drawing blood from a child, ensure that the skin at the blood sampling site is warm [13]. However, excessive warming of the heel should be avoided to prevent skin injuries [14]. An adult with diabetes should wash their hands with warm water [12-13].

Do not sample capillary blood:

- from swollen or previously punctured sites, as the accumulated fluid may contaminate the sample;
- from fingers of the hand where intravenous infusion is being performed; or from fingers on the side of the body where mastectomy has been performed [12-13].

Alternate site testing (AST)

When selecting alternate sites for capillary blood sampling to measure glucose levels, make sure they are located away from dermal papillae, bones, areas without visible veins, hair, and nevi. Alternate puncture sites:

- palm surface below the thumb,
- palm surface below the little finger,
- inner and outer forearm,
- arm,
- calf,
- outer thigh [15-20].

One study determined that the earlobe can be an alternate site for capillary blood sampling to measure glucose levels [21].

Blood sampled from the palm surface can be used to measure the blood glucose level at all times [22-23]. Test results for other alternate sites may differ from those obtained with blood sampled by finger-prick. Such differences may occur when the blood glucose level changes rapidly [24]. AST is not recommended in the following circumstances:

- up to 2 hours after a meal, when there is a rapid increase in blood glucose [23],
- during the peak time for short-acting insulin or rapid-acting insulin analog,
- when very low glucose level is suspected [20],
- during an illness,
- during or after exercise [23],
- for continuous glucose monitoring (CGM) calibration.

Lancet length

Lancets ranging between 0.85 mm and 2.4 mm in length are typically available. Incision depth for a finger-prick should not exceed 2.4 mm. A 2.2 mm lancet is sufficient [13,25]. Incision depth for a heel-prick in children should not exceed 2.4 mm. In premature infants, a 0.85 mm lancet is sufficient [13]. Excessively deep puncture

may lead to calcaneal osteomyelitis [26-27]. The recommended incision depth for a finger-prick in children is: 1.5 mm in children aged 6 months to 8 years, and 2.4 mm in children older than 8 years [13]. Finger-pricks should not be performed in infants, as this could result in nerve damage. Using automatic lancets reduces pain levels and increases comfort of newborn during heel blood sampling [28].

When performing the puncture, excessive pressure should be avoided, as this could result in a deeper puncture than necessary for obtaining an adequate drop of blood [13]. Health care institutions should consider using retractable lancets with a blade slightly shorter than the recommended incision depth, as the pressure on the device when puncture is performed results in an incision depth exceeding the nominal blade length [13].

Note! Do not use surgical lancets or hypodermic needles for the puncture. Nurses in health care institutions should not perform multiple punctures using the same lancet.

Factors interfering with blood glucose measurement using a glucometer

- physical factors – these should be outlined in the user manual for each glucometer, e.g. air temperature and humidity, altitude above sea level [29],
- test strip-inherent factors: exposure to humidity, high temperatures, or leaving test strip vials open [29],
- patient-inherent factors:
 - endogenous factors, i.e. various physiological traits and substances produced by the body that are present in the blood: high concentrations of triglycerides, bilirubin, creatinine; hematocrit below 30% (pregnancy, anemia, chronic kidney disease, bleeding) – falsely decreased glucose readings; or above 60% (chronic respiratory diseases, dehydration from diarrhea, vomiting, diabetic ketoacidosis, hyperosmolar hyperglycemic nonketotic syndrome) – falsely elevated glucose readings. Glucometers using test strips with glucose oxidase should only be used for capillary blood testing in individuals with normal oxygen saturation. Elevated oxygen pressure (e.g. during oxygen therapy) may result in falsely decreased glucose readings, while low oxygen pressure (e.g. during hypoxia) may lead to falsely elevated glucose levels [30];
 - exogenous substances, e.g. due to improper hand hygiene – residual sugar from fruit or sweets; residues of disinfectants, hand cream, or medication; air temperature, altitude at which the glucometer is located [24,29,31-35];
 - extraneal solution for peritoneal dialysis contains icodextrin. Maltose, metabolite of icodextrin, may distort the readings from some glucose meters or test strips – falsely elevated glucose levels [30,36-38]. Systems based on glucose dehydrogenase with pyrroloquinoline quinone as a cofactor (GDH-PQQ) should not be used. To obtain information on compliance, please contact the manufacturer of the glucose meters and test strips used;

- pharmacological factors that may interfere with glucose readings using glucometers with glucose oxidase test strips include: paracetamol, uric acid, galactose, xylose, L-DOPA, and ascorbic acid [8,30].

Measurement technique

1. Check the expiration date on the test strips (write the opening date on the package once it is first opened, if the manufacturer has specified a time for using the strips after opening).
2. In a home setting, the patient should thoroughly wash his hands with warm water and soap, but no disinfectant, and then dry them well (heat causes blood vessels to dilate, increasing blood flow in the capillaries and making blood sampling easier; if the skin is wet, the blood drop may become diluted).
3. In health care facilities, it is recommended to disinfect the skin in the capillary puncture blood collection site. Apply the product and wait for the time specified in the manufacturer's material safety data sheet. Collecting a blood sample immediately after disinfection may result in a falsely decreased reading [39].
4. Before pricking the fingertip, massaging the palm is recommended, from its heel towards the finger being punctured (pressure on the fingertip causes the blood to become diluted by tissue fluid).
5. Place the test strip in the glucose meter and immediately close the test strip package.
6. Puncture the skin on the side of the fingertip, considering the following:
 - select incision depth based on the individual characteristics of the patient's skin,
 - perform punctures on the sides of fingertips so as to preserve their tactile function as long as possible.

Note! In infants who have not begun to walk yet, punctures can be also done on the toes and the heel (including the sides) [40-41].

7. Place the blood drop at the tip of the test strip or apply the blood drop to the test strip after the notification icon appears on the glucometer screen.
8. During the measurement, the test strip should not be touched or pressed.
9. Use the first blood drop for the measurement, as squeezing out multiple drops causes the blood to be diluted by tissue fluid. Some glucose meters have a function that allows for adding a second blood drop during a measurement (called "second chance" sampling) [31,42-46].
10. Secure the puncture site with a sterile gauze pad.
11. Record and interpret the measurement result.
12. Education of an individual with diabetes related to self-management of diabetes treatment in collaboration with the therapeutic team based on the measurement result.

Guidelines for glucose meter users in outpatient and inpatient care

- For measuring glucose levels in capillary blood using a glucose meter, only PN-EN ISO 15197:2015-10 compliant glucose meters must be used [35,47-49].
- In health care institutions and care facilities, only glucose meters with external strips must be used.
- Glucose meters should be assigned to individual patients and not shared. If it is necessary to use a single glucose meter for more than one patient, the device must be cleaned and disinfected after each use, according to the manufacturer's instructions, so as to prevent the transmission of blood and pathogens [50-57]. If the manufacturer has not specified a procedure for cleaning and disinfecting the device, it must not be shared between patients.
- In a hospital setting, individually packed test strips are preferred for blood glucose measurement [58-61]. Test strips should not be used if the container is damaged or improperly sealed.
- When the test strip package is first opened, the opening date should be marked on the package. The test strip manufacturer specifies the time for using the strips after opening.
- Do not expose the glucose meter or test strips to humidity, excessively high or low temperatures, dust, or dirt.
- Patients should be trained in using their glucose meter, and handling and storing the test strips, by the nurse or midwife at the place of care [61-70].
- Individuals with diabetes should receive information regarding the impact of physical factors, test strip-inherent factors, patient-inherent factors, and medications being taken [29].
- Patients should be assessed on their technique of blood glucose self-monitoring once a year [8].
- The proper function of the glucose meter should be checked whenever a malfunction is suspected, and at least once a year in an outpatient center [8,48,71-73]. The check should be recorded in the health care institution's documentation [8,27], and in the patient's self-monitoring journal.
- Before first use of the glucose meter, carefully read the instruction manual.
- Blood glucose measurement results should be reported in mg/dL or mmol/L.
- Set the current date and time on the glucose meter for data transmission purposes.
- If the diabetes patient does not have his own lancing device, the finger prick should be performed with a disposable lancing device. The use of reusable lancets increases the risk of accidental lancet-related needle-stick injuries to medical personnel [74-75].
- The patient should be informed about the possibility of using a mobile application and software to be used with a glucose meter, which support self-monitoring of blood glucose [70,76-77].

Important! The lancing device is a personal device.

REFERENCES

1. Sly B, Taylor J. Blood glucose monitoring devices: current considerations. *Aust. Prescr.* 2023;46(3):54-59. <https://doi.org/10.18773/austprescr.2023.013>
2. Zou Y, Zhao S, Li G, et al. The efficacy and frequency of self-monitoring of blood glucose in non-insulin-treated T2D patients: a systematic review and meta-analysis. *J. Gen. Intern. Med.* 2023;38(3):755-764. <https://doi.org/10.1007/s11606-022-07864-z>
3. Liang B, Koye DN, Hachem M, et al. Efficacy of flash glucose monitoring in type 1 and type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials. *Front. Clin. Diabetes Healthc.* 2022;3:849725. <https://doi.org/10.3389/fcdhc.2022.849725>
4. Carpenter R, Dichiaccio T, Barker K. Interventions for self-management of type 2 diabetes: an integrative review. *Int. J. Nurs. Sci.* 2018;6(1):70-91. <https://doi.org/10.1016/j.ijnss.2018.12.002>
5. Machry RV, Rados DV, Gregório GR, et al. Self-monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: A systematic review and meta-analysis. *Diabetes Res. Clin. Pract.* 2018;142:173-187. <https://doi.org/10.1016/j.diabres.2018.05.037>
6. Mannucci E, Antenore A, Giorgino F, et al. Effects of structured versus unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: A meta-analysis of randomized controlled trials. *J. Diabetes Sci. Technol.* 2018;12(1):183-189. <https://doi.org/10.1177/1932296817719290>
7. Logan AD, Jones J, Kuritzky L. Structured blood glucose monitoring in primary care: a practical, evidence-based approach. *Clin. Diabetes.* 2020;38(5):421-428. <https://doi.org/10.2337/cd20-0045>
8. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
9. Rahmatullah, Qutubuddin M, Abdul Rahman R, et al. Assessment of factors associated with non-compliance to self-management practices in people with type 2 diabetes. *Cureus.* 2021;13(10):e18918. <https://doi.org/10.7595/cureus.18918>
10. Noureldin M, Gowda H. Question 2: Is it safe to use the centre of the heel for obtaining capillary blood samples in neonates? *Arch. Dis. Child.* 2018;103(4):401-404. <https://doi.org/10.1136/archdischild-2017-314214>
11. Schreiber-Zamora J, Zielińska A, Wilkos E, et al. Safe capillary blood sampling in newborns. *Postępy Neonatologii.* 2019; 25(1): 37-40.
12. WHO guidelines on drawing blood best practices in phlebotomy (Eng) 2010. Accessed: 2025-05-10. <https://www.ncbi.nlm.nih.gov/books/NBK138650/>
13. Rodak BF. Diagnostic Hematology. Philadelphia: WB. Saunders; 1995.
14. Toennesen UL, Kierkegaard H, Kofoed PE, et al. Warming prior to heel stick: blood sample quality and infant comfort – a randomized controlled trial. *Adv. Neonatal Care.* 2023;23(6):E129-E138. <https://doi.org/10.1097/ANC.0000000000001110>
15. Jacoby MJ. An Analysis of alternate site tests to improve patient compliance with self-monitoring of blood glucose. *J. Diabetes Sci. Technol.* 2010;4(4):911-912. <https://doi.org/10.1177/193229681000400421>
16. Ellison JM, Stegmann JM, Colner SL, et al. Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites. *Diabetes Care.* 2002;25(6):961-964. <https://doi.org/10.2337/diacare.25.6.961>
17. Farmer L, Winfield C, Quatrara B, et al. Does site matter? Comparing accuracy and patient comfort of blood glucose samples taken from the finger and palm of the perioperative patient. *J. Perianesth. Nurs.* 2017;32(6):573-577. <https://doi.org/10.1016/j.jopan.2016.10.006>
18. Fedele D, Corsi A, Noacco C, et al. Alternative site blood glucose testing: a multicenter study. *Diabetes Technol. Ther.* 2003;5(6):983-989. <https://doi.org/10.1089/152091503322641033>
19. Lee DM, Weinert SE, Miller EE. A study of forearm versus finger stick glucose monitoring. *Diabetes Technol. Ther.* 2002;4(1):13-23. <https://doi.org/10.1089/15209150252924049>
20. Lucidarme N, Alberti C, Zaccaria I, et al. Alternate-site testing is reliable in children and adolescents with type 1 diabetes, except at the forearm for hypoglycemia detection MD1. *Diabetes Care.* 2005; 28(3): 710-711. <https://doi.org/10.2337/diacare.28.3.710>
21. Owida HA, Al-Nabulsi J, Ma'touq J, et al. Validation of earlobe site as an alternative blood glucose testing approach. *Technol. Health Care.* 2022;30(6):1535-1541. <https://doi.org/10.3233/THC-220033>
22. Anitha Pavithran A, Ramamoorthy L, BsS, et al. Comparison of fingertip vs palm site sampling on pain perception, and variation in capillary blood glucose level among patients with diabetes mellitus. *J. Caring Sci.* 2020;9(4):182-187. <https://doi.org/10.34717/jcs.2020.028>
23. Bina DM, Anderson RL, Johnson ML, et al. Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. *Diabetes Care.* 2003; 26(4): 981-985. <https://doi.org/10.2337/diacare.26.4.981>
24. Choukem SP, Efie DT, Djioque S, et al. Effects of hydroquinone-containing creams on capillary glycemia before and after serial hand washings in Africans. *PLoS One.* 2018;13(8):e0202271. <https://doi.org/10.1371/journal.pone.0202271>
25. Panek M, Kwinta P. Heel prick in neonates – the most important rules. *Postępy Neonatologii.* 2018;24(1):73-79. <http://mavipuro.pl/naklucie-piety-u-noworodka-najwazniejsze-zasady/>
26. Canale ST, Manugian AH. Neonatal osteomyelitis of the os calcis: a complication of repeated heel punctures. *Clin. Orthop. Relat. Res.* 1981;156:178-182.
27. Abril Martin JC, Aguilar Rodriguez L, Albiñana Cilveti J. Flatfoot and calcaneal deformity secondary to osteomyelitis after neonatal heel puncture. *J. Pediatr. Orthop.* 1999;8(2):122-124.
28. Merter OS, Bolişik ZB. The Effects of manual and automatic lancets on neonatal capillary heel blood sampling pain: a prospective randomized controlled trial. *J. Pediatr. Nurs.* 2021;58:e8-e12. <https://doi.org/10.1016/j.pedn.2020.11.015>
29. Erbach M, Freckmann G, Hinzmann MR, et al. Interferences and limitations in blood glucose self-testing. An overview of the current knowledge diabetes. *J. Diabetes Sci. Technol.* 2016;10(5):1161-1168. <https://doi.org/10.1177/1932296816641433>
30. American Diabetes Association Professional Practice Committee. 7. Diabetestechology: standards of care in diabetes – 2025. *Diabetes Care.* 2025;48(Suppl.1):S146-S166. <https://doi.org/10.2337/dc25-S007>
31. Hortensius J, Slingerland RJ, Kleefstra N, et al. Self-monitoring of blood glucose: the use of the first or the second drop of blood. *Diabetes Care.* 2011;34(3):556-560. <https://doi.org/10.2337/dc10-1694>
32. Hirose T, Mita T, Fujitani Y, et al. Glucose monitoring after fruit peeling: pseudohyperglycemia when neglecting hand washing before fingertip blood sampling: wash your hands with tap water before you check blood glucose level. *Diabetes Care.* 2011;34:596-597. <https://doi.org/10.2337/dc10-1705>
33. Omengue AM, Sobngwi E, Dehayem M, et al. Effect of body lotions on capillary blood glucose measurement: interference of hydroquinone-containing body lotion with capillary glucose measurement. *Eur. J. Endocrinol.* 2018;144:44-46. <https://doi.org/10.17925/EE.2018.14.1.44>
34. Grzych G, Pekar JD, Chevalier-Curt MJ, et al. Antioxidants other than vitamin C may be detected by glucose meters: Immediate relevance for patients with disorders targeted by antioxidant therapies. *Clin. Biochem.* 2021;92:71-76. <https://doi.org/10.1016/j.clinbiochem.2021.03.007>
35. Hauš O, Hinzmann R, Huffman B. Drug interference in self-monitoring of blood glucose and the impact on patient safety: we can only guard against. What we are looking for. *J. Diabetes Sci. Technol.* 2024;18(3):727-732. <https://doi.org/10.1177/19322968221140420>
36. Floré KM, Delanghe JR. Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. *Perit. Dial. Int.* 2009;29(4):377-383.
37. Frias JP, Lim CG, Ellison JM, et al. Review of adverse events associated with false glucose readings measured by GDH-PQQ – based glucose test strips in the presence of interfering sugars. *Diabetes Care.* 2010;33:728-772. <https://doi.org/10.2337/dc09-1822>
38. Al-Dorzi HM, Al-Sum H, Alqurashi S, et al. Severe hypoglycemia in peritoneal dialysis patients due to overestimation of blood glucose by the point-of-care glucometer. *Saudi J. Kidney Dis. Transpl.* 2011;22(4):764-768.
39. Jorica M, Krótki F, Tomasiak P. The effect of disinfecting procedure on the glucose concentration using a personal glucose meter. *Prim. Care Diabetes.* 2021;15(5):848-852. <https://doi.org/10.1016/j.pcd.2021.05.010>
40. Shas VS, Ohlsson A. Venepuncture versus heel lance for blood sampling in term neonates. *Cochrane Database Syst. Rev.* 2011;(10):CD001452. <https://doi.org/10.1002/14651858.CD001452.pub4>
41. Folk LA. Guide to capillary heel stick blood sampling in infants. *Adv. Neonatal Care.* 2007;7(4):171-178. <https://doi.org/10.1097/01.ANC.0000286333.67928.04>
42. Palese A, Fabbro E, Casetta A, et al. First or second drop of blood in capillary glucose monitoring: findings from a quantitative study. *J. Emerg. Nurs.* 2016; 42(5): 420-426. <https://doi.org/10.1016/j.jen.2016.03.027>
43. Johannis W, Meyer A, Elezajic D, et al. Measuring capillary blood glucose concentration: Is the first blood drop really the right blood drop? *Prim. Care Diabetes.* 2023;17(6):581-586. <https://doi.org/10.1016/j.pcd.2023.08.005>
44. Sagkal Midilli T, Ergin E, Baysal E, et al. Comparison of glucose values of blood samples taken in three different ways. *Clin. Nurs. Res.* 2019;28(4):436-455. <https://doi.org/10.1177/10547738171719379>
45. Saini S, Kaur S, Das K, et al. Using the first drop of blood for monitoring blood glucose values in critically ill patients: an observational study. *Indian J. Crit. Care Med.* 2016;20(11):658-661. <https://doi.org/10.4103/0972-5229.194006>
46. Li M, Wang X, Shan Z. Deciding between using the first or second drop of blood for the self-monitoring of blood glucose. *Prim. Care Diabetes.* 2014;8(4):365-369. <https://doi.org/10.1016/j.pcd.2014.03.003>
47. In vitro diagnostic test systems – Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. PN-EN ISO 15197: 2015-10.
48. Stacherzak-Pawlak J, Rak A, Smaciarcz J, et al. Tests in the point of care – glucose meter as a POCT tool. Implement a quality system control. *Diagn. Lab.* 2017;53(4):211-216. <https://doi.org/10.5604/01.3001.0013.7986>
49. Pleus S, Baumstark A, Jendrike N, et al. System accuracy evaluation of 18 CE-marked current-generation blood glucose monitoring systems based on EN ISO 15197:2015. *BMJ Open Diabetes Res. Care.* 2020;8(1):e001067. <https://doi.org/10.1136/bmjdrc-2019-001067>
50. Lin SP, Lin WY, Chang JT, et al. Demonstration of disinfection procedure for the development of accurate blood glucose meters in accordance with ISO 15197:2013. *PLoS One.* 2017;12(7):e0180617. <https://doi.org/10.1371/journal.pone.0180617>

51. Zhang X, Zhu X, Ji Y, et al. Increased risk of hepatitis B virus infection amongst individuals with diabetes mellitus. *Biosci. Rep.* 2019;39(3):BSR20181715. <https://doi.org/10.1042/BSR20181715>

52. Han B, Liu W, Yang S, et al. Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu province, China. *BMJ Open.* 2021;11(10):e048463. <https://doi.org/10.1136/bmjopen-2020-048463>

53. Hellinger WC, Grant RL, Hernke DA, et al. Glucose meters and opportunities for in-hospital transmission of infection: quantitative assessment and management with and without patient assignment. *Am. J. Infect. Control.* 2011;39:752-756. <https://doi.org/10.1016/j.ajic.2010.12.019>

54. Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis virus infection and the need for innovative glucose monitoring technologies. *J. Diabetes Sci. Technol.* 2009;3:283-288. <https://doi.org/10.1177/193229680900300208>

55. Thompson ND, Schaefer MK. "Never Events": hepatitis outbreaks and patient notifications resulting from unsafe practices during assisted monitoring of blood glucose, 2009-2010. *J. Diabetes Sci. Technol.* 2011;5:1396-1402. <https://doi.org/10.1177/193229681100500611>

56. Schaffzin JK, Southwick KL, Clement EJ, et al. Transmission of hepatitis B virus associated with assisted monitoring of blood glucose at an assisted living facility in New York State. *Am. J. Infect. Control.* 2012;40:726-731. <https://doi.org/10.1016/j.ajic.2011.11.002>

57. Geaghan SM. Infection transmission associated with point of care testing and the laboratory's role in risk reduction. *EJIFCC.* 2014;25(2):188-194.

58. Al-Rubeaan KA, Saeb AT, AlNaqeb DM, et al. The bacterial contamination rate of glucose meter test strips in the hospital setting. *Saudi Med. J.* 2016;37(9):985-995. <https://doi.org/10.1553/smj.2016.9.14950>

59. Vanhaeren S, Duport C, Magneney M. Bacterial Contamination of glucose test strips: Not to be neglected. *Am. J. Infect. Control.* 2011;39:611-613. <https://doi.org/10.1016/j.ajic.2010.11.006>

60. Pérez-Ayala M, Oliver P, Rodríguez Cantalejo F. Prevalence of bacterial contamination of glucose test strips in individual single-use packets versus multiple-use vials. *J. Diabetes Sci. Technol.* 2013;7(4):854-862. <https://doi.org/10.1177/193229681300700407>

61. Ng R, Koo S, Johnston R. Multicenter evaluation of bacterial contamination of glucose test strips. *Clin. Chim. Acta.* 2012;413:1485-1487. <https://doi.org/10.1016/j.cca.2012.06.019>

62. Chrváta CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. *Patient Educ. Couns.* 2016;99(6):926-943. <https://doi.org/10.1016/j.pec.2015.11.003>

63. Ernawati U, Wihastuti TA, Utami YW. Effectiveness of diabetes self-management education (DSME) in type 2 diabetes mellitus (T2DM) patients: systematic literature review. *J. Public Health Res.* 2021;10(2):2240. <https://doi.org/10.4081/jphr.2021.2240>

64. Cheng L, Sit JWH, Choi KC, et al. Effectiveness of a patient-centred, empowerment-based intervention programme among patients with poorly controlled type 2 diabetes: a randomised controlled trial. *Int. J. Nurs. Stud.* 2018;79:43-51. <https://doi.org/10.1016/j.ijnurstu.2017.10.021>

65. Lyu QY, Huang JW, Li YX, et al. Effects of a nurse led web-based transitional care program on the glycemic control and quality of life post hospital discharge in patients with type 2 diabetes: a randomized controlled trial. *Int. J. Nurs. Stud.* 2021;119:103929. <https://doi.org/10.1016/j.ijnurstu.2021.103929>

66. De la Fuente Coria MC, Cruz-Cobo C, Santi-Cano MJ. Effectiveness of a primary care nurse delivered educational intervention for patients with type 2 diabetes mellitus in promoting metabolic control and compliance with long-term therapeutic targets: randomised controlled trial. *Int. J. Nurs. Stud.* 2020;101:103417. <https://doi.org/10.1016/j.ijnurstu.2019.103417>

67. Yuksel M, Bektas H, Ozer ZC. The effect of nurse-led diabetes self-management programmes on glycosylated haemoglobin levels in individuals with type 2 diabetes: a systematic review. *Int. J. Nurs. Pract.* 2023;29(6):e13175. <https://doi.org/10.1111/ijn.13175>

68. Castillo-Merino YA, Ospina-Ayala C, Esquivel Garzón N, et al. Educational interventions in adults with type 2 diabetes mellitus in primary health care settings. A scoping review. *Invest. Educ. Enferm.* 2023;41(2):e15. <https://doi.org/10.17533/udea.iee.v41n2e15>

69. Lamptey R, Robben MP, Amoakoh-Coleman M, et al. Structured diabetes self-management education and glycaemic control in low- and middle-income countries: a systematic review. *Diabet. Med.* 2022;39(8):e14812. <https://doi.org/10.1111/dme.14812>

70. Cai J, Xu H, Jiang S, et al. Effectiveness of telemonitoring intervention on glycaemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Res. Clin. Pract.* 2023;201:110727. <https://doi.org/10.1016/j.diabres.2023.110727>

71. Al-Zahrani A, Alshareef R, Farahat F, et al. Assessing the accuracy of different glucometers based on the laboratory reference method. *Clin. Lab.* 2021;66(10):10.7754. <https://doi.org/10.7754/Clin.Lab.2020.200132>

72. Tomaszik P. What is new in ISO standards, recommendations and legal regulations in Polish POCT? *Clin. Lab.* 2018;54(1):45-52. <https://doi.org/10.5604/01.3001.0013.7555>

73. Choi S, Choi SJ, Jeon BR, et al. What we should consider in point of care blood glucose test; current quality management status of a single institution. *Medicina (Kaunas).* 2021;57(3):238. <https://doi.org/10.3390/medicina57030238>

74. An HS, Ko S, Bang JH, et al. Elimination of lancet-related needlestick injuries using a safety-engineered lancet: experience in a hospital. *Infect. Chemother.* 2018;50(4):319-327. <https://doi.org/10.3947/ic.2018.50.4.319>

75. Menezes JA, Bandeira CS, Quintana M, et al. Impact of a single safety-engineered device on the occurrence of percutaneous injuries in a general hospital in Brazil. *Am. J. Infect. Control.* 2014;42(2):174-177. <https://doi.org/10.1016/j.ajic.2013.07.017>

76. Wu IXY, Kee JCY, Threapleton DE, et al. Effectiveness of smartphone technologies on glycaemic control in patients with type 2 diabetes: systematic review with meta-analysis of 17 trials. *Obes. Rev.* 2018;19(6):825-838. <https://doi.org/10.1111/obr.12669>

77. Jamal A, Tharkar S, Babaier WS, et al. Blood glucose monitoring and sharing amongst people with diabetes and their facilitators: cross-sectional study of methods and practices. *JMIR Diabetes.* 2021;6(4):e29178. <https://doi.org/10.2196/29178>

II. MEASUREMENT OF GLUCOSE LEVELS USING CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS

Purpose: Measurement of glucose levels in interstitial fluid using CGM systems.

Individuals authorized to perform the measurement: nurse, midwife.

■ Tab. 3. Key recommendations. Continuous glucose monitoring (CGM)

Comprehensive, structured patient education on self-monitoring using an CGM system results in improved metabolic control of diabetes in patients receiving intensive insulin therapy. A
Each patient approved for CGM should receive education on: the technique for using the device, self-care and self-examination of sensor insertion sites, and principles of glucose level monitoring oriented at diabetes self-management in cooperation with the diabetes treatment team. A
Rotation of body areas and puncture sites is significant to preserving skin integrity in sensor insertion sites. E
The nurse/midwife should perform physical examination of the patient's skin at sensor insertion sites. Skin reactions associated with irritation and allergies should be assessed. The physical examination of the patient's skin should be performed at least once every 6 months. E

CGM systems enable real-time and continuous assessment of glucose levels in interstitial fluid using a sensor placed in subcutaneous tissue. Currently, the systems are classified as follows: CGM systems that measure and display glucose levels continuously in real time (*real-time CGM*, *rtCGM*), and CGM systems with or without alarms that measure glucose levels continuously but require scanning to visualize and store glucose data (*intermittently scanned CGM*, *isCGM*).

Two types of sensors are currently available: transcutaneous and subcutaneously implanted sensors. The sensor measures electrical currents in interstitial fluid, which are proportional to the glucose level in the blood. The transmitter sends glucose level data to the receiver (a smartphone application, device, or insulin pump), which displays the information. The Flash Glucose Monitoring (FGM) system also allows for the measurement of glucose levels in interstitial fluid using a sensor integra-

ted with a transmitter, placed in subcutaneous tissue, and a reader [1]. With dedicated computer software, data from the reader can be transferred to a computer and analyzed retrospectively. Reports generated from historical data collected by CGM systems enable retrospective analysis of glucose levels in individuals with diabetes. These systems have alarm features designed to warn against excessively low or high glucose values.

Available measurement technologies [2-9].

- enzymatic electrodes,
- microdialysis-based techniques,
- fluorescence-based techniques.

Electrode-based CGM system elements:

- sensor (measurement electrode),
- transmitter,
- receiver (monitor).

The measurement electrode, i.e. sensor, should be replaced per the manufacturer's instructions, every 7-14 days, depending on the device, and in the case of implantable sensors, every 180 days. Depending on the manufacturer of a given CGM system, after measurement electrode insertion, the sensor's warm-up time may range from 30 minutes to 2 hours. For subcutaneously implanted sensors, it is 24 hours. Some systems also require calibration using glucose level measurements from capillary blood obtained with a glucometer, while others offer an optional calibration function (factory calibration with the possibility of manual calibration if needed) [8]. The highest accuracy of readings is achieved by calibrating the system when glucose levels are stable (they do not necessarily have to be within the target range).

The FGM sensor is factory-calibrated, and measurements are performed every minute. Measurement results are saved into the sensor memory every 15 minutes, and at each scan, data from the preceding 8 hours are transmitted to the reader memory [10]. The FGM sensor can be used for up to 14 days without capillary blood testing [10-14]. Current readings from the FGM sensor should be verified against a capillary blood test using a glucose meter when there is a rapid change in glucose levels, when the system shows hypoglycemia or imminent hypoglycemia, and when the patient experiences symptoms inconsistent with the reading [10,15-16]. Calibration should not be performed:

- after a meal,
- after a dose of insulin,
- during exercise,
- after exercise,
- when trend arrows are displayed on the screen.

CGM Sensor Location. Practical guidelines.

- When choosing a site for inserting the CGM sensor, avoid areas with scars, nevi, stretch marks, lumps, inflammatory or allergic lesions (i.e. diseased skin). Choose an area of skin that usually remains flat during daily activities (not bending).
- Prior to sensor insertion make sure that the skin in the insertion site is not covered with body lotion or soap and that the skin is clean and any excessive hair has been trimmed.

- It is recommended to select a site in a different area of the body than the insulin injection site.
- Skin must be disinfected before sensor insertion.

When selecting the site for CGM sensor insertion, manufacturer guidelines should be followed. The recommended insertion sites specified by manufacturers are [17-20]:

- subcutaneous tissue on the buttock, upper part. Relatively flat surface, suitable for side sleepers and for lean children. Avoid sensor insertion in the waistline/pan-line (to prevent discomfort, skin irritation or unintended sensor compression); place the tape horizontally (follow the contour of gluteal muscles), which helps to minimize sensor dislodging with clothing change. Sensor insertion in this site may cause artificially low glucose readings from the sensors, which occur when the sensors hit the muscle tissue (PISA – Pressure Induced Sensor Attenuation). This is very common when sleeping, laying or sitting on the sensor, and may be resolved by strategic placement and position changes in lean individuals or back sleepers. Site difficult for self-insertion.
- subcutaneous tissue on the abdomen. Large surface with the possibility to insert the sensor above and below the umbilicus. Insert the sensor 2.5 cm away from the umbilicus. Avoid sensor insertion in sites where the skin creases. Ask the patient to hunch over and check where the skin folds. In the case of lean individuals, sensor placement may be easier in a sitting or hunched position. In lean individuals, it might be easier to insert the cannula at an acute angle. In excessively lean individuals, the sensor may abut the muscle causing discomfort or PISA. Sensitive skin is more prone to injury caused by mechanical damage.
- subcutaneous tissue on the thigh, upper part. Discrete site, concealed under clothing, relatively flat surface. In excessively lean individuals, the sensor may abut the muscle causing discomfort or PISA (lower likelihood of contact with the muscle if the sensor is placed on the outer or inner thigh as compared to the front).
- subcutaneous tissue on the arm. Good adhesion for longer sensors, good site for CGM in lean children using buttocks solely for insulin infusion sets, comparable CGM accuracy to buttocks and abdomen. Avoid placing the sensor too close to the axilla (increased risk of skin irritation by the tape). This site is less discrete, visible when wearing shirts with short sleeves. In excessively lean individuals, the sensor may abut the muscle causing discomfort or PISA.
- the recommended site for FGM sensor insertion is the subcutaneous tissue of the posterior lateral part of the upper arm [21-22].
- for subcutaneously implanted sensors, the recommended site is the back of the upper arm [23-24].

The CGM measurement electrode should not remain in the subcutaneous tissue longer than specified in the manufacturer's instructions. Consequences of leaving the CGM sensor in the tissue for too long may include [25-28]:

- no reading,
- increased infection risk,
- skin irritation,
- scarring.

Guidelines on sensor insertion sites:

- obtain patient's history of allergies and skin sensitivities [17,29],
- transmitters are secured with tapes and adhesives, different products can be tested to find the best fit for the patient,
- routine monitoring of the skin at the insertion site is recommended with each sensor replacement. Monitor the site for events related to sensor insertion: bleeding, swelling, or hardening, as well as issues associated with sensor use: redness, itching, pain, rash, swelling, erythema, localized increased skin temperature, or abscesses [27,30-35],
- skin at the planned sensor insertion site should be examined; skin with wounds, redness, irritation, abscesses, scars, bruises, cuts, as well as skin in the immediate proximity of other infusion sites should be avoided [36-37],
- allergic contact dermatitis is the most commonly reported adverse event caused by the adhesive tapes used in glucose sensor kits for securing the device to the patient's body [35,38-39],
- contact dermatitis in the FGM system may be caused by the presence of isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) in the sensor, which can sensitize the skin [25,32,38,40-42]. Patients should be informed about these issues, and the sensor application sites should be regularly inspected. Irritant contact dermatitis occurs as a result of direct damage to the skin by chemical or physical agents, leading to a non-immunological inflammatory reaction,
- patients with an implantable sensor may experience mild dermatological symptoms: skin irritation caused by the adhesive patch, redness, skin atrophy, hypopigmentation, and infection, as well as hematologic symptoms: bruising and bleeding [7]. Daily replacement of the adhesive patch is associated with occasional cases of localized skin irritation [23]. In a single case report, a patient was suspected of having contact allergy to platinum, which manifested as persistent, non-itchy subcutaneous lesions [23,43-44],
- it has been demonstrated that CGM may cause dermatological problems: erythema, pruritus, eczema, chronic dry skin, pigmentation changes, wounds [45-46],
- leave a previous sensor insertion site to heal for at least 1 week before placing a new adhesive on it;
- rotating insertion sites enables preserving skin integrity for a longer time [47-48],
- when planning an insertion site, the following factors should be considered: subcutaneous tissue volume, musculature, the patient's preferred sleeping position (side, back), activities, clothing [29]. An CGM sensor

should not be placed in sites with insufficient subcutaneous tissue, or in areas subject to pressure (e.g. under straps or cuffs) or intensive movement,

- some patients may prefer a discreet placement of the sensor [49].

Guidelines on skin protection:

- before sensor insertion, the skin should be cleansed using oil-free antibacterial soap, and thoroughly dry,
- products and swipes available in the market can be used to cleanse and prepare the skin before insertion,
- an alcohol-based disinfectant without moisturizing agents should be used for skin disinfection,
- the sensor should not be inserted immediately after a shower/bath or in a steamy bathroom – a dry environment is required,
- avoid using body lotion in the site where a tape will be placed,
- fragrance-free antiperspirant can be applied to perspiration-prone skin. Apply a thin layer, wait 10-15 minutes, and wipe off the excess [48,50],
- to minimize the risk of hypersensitive response and irritant contact dermatitis, various techniques and barrier agents can be used. Barrier films/patches used under the sensor tape may help prevent allergies and skin irritation caused by adhesives. Leave a small circle on the skin without a film/patch for CGM insertion [17,25,28-29,48-50],
- if skin around or under the sensor becomes severely irritated, the patient should remove the sensor and discontinue use of the system. Before resuming use of the system, the patient should consult a health care professional. Use of the sensor may cause bruising or bleeding. If the bleeding persists, remove the sensor and apply a new one in another site,
- after tape placement, press it around the edges so that they adhere well to the skin,
- carefully remove tapes and adhesives to minimize the risk of tissue damage. Self-adhesive tapes should be removed slowly and with low energy. Removal aids available in the market can be used to remove adhesives and tapes; following sensor removal, the skin should be carefully and thoroughly cleansed of adhesive residues [29],
- in patients with adverse events including skin symptoms (including severe ones), these can be mitigated by using barrier agents, medication therapy or changing the insertion site [32,34].

Factors affecting the accuracy of glucose measurement results using CGM [51-56]

- measurement in different spaces – delay between glucose levels in capillary blood and interstitial fluid – (physiological time delay of approx. 5-20 minutes),
- delay resulting from the physical properties of the sensor (hardware time lag),
- weakened sensor signal,
- delay resulting from the interpretation of the signal by the CGM system (software time lag),
- errors during calibration of systems that require it,

- chemical substances interfering with the results obtained by sensors utilizing the glucose oxidase reaction: endogenous substances such as oxygen, hemoglobin concentration, high levels of bilirubin, creatinine, or triglycerides; exogenous factors such as medications and other substances: heparin, acetaminophen (Dexcom G6, G7, Medtronic Guardian – higher readings), hydroxyurea (Dexcom G6, G7, Medtronic Guardian – higher readings), ascorbic acid (>500 mg/day of vitamin C – higher readings with the FreeStyle Libre sensor), dopa/methyldopa, salicylic acid, and sugar alcohols. Ever-sense fluorescence-based sensor: tetracyclines or mannitol [56-58].

Note! Before undertaking any therapeutic intervention, or to verify the reading when the high or low glucose level reported by the CGM system is inconsistent with the symptoms, the patient and/or his carer/health care provider should perform an additional capillary blood glucose test using a glucose meter [57].

Insertion technique

- Wash and disinfect your hands.
- Prepare the materials.
- Prepare the transmitter and receiver.
- Prepare the sensor along with the applicator, or the sensor and sensor insertion device (senser), and the adhesive patch (if required).
- Select and assess the skin (visual inspection, palpation) at the sensor insertion site.
- Disinfect the puncture site (if numbing cream is used, remove any residue with a gauze pad).
- Leave the disinfected skin to dry as required for the disinfectant to work.
- Connect the receiver to the transmitter (in accordance with the manufacturer's instructions).
- Insert the sensor and remove the applicator or senser according to the user manual.
- Dispose of the used sensor in a closed medical waste container.
- Examine the old sensor removal site.
- Record the sensor replacement in the medical documentation of the healthcare facility.
- Calibrate using the glucose level measurement from capillary blood obtained with a glucometer, if required (as indicated in the user manual).

Note! The sensor may only be placed by a nurse, midwife trained in CGM installation and education. The competencies of healthcare teams in the field of diabetes technology are described in the literature [59].

- During X-ray examination, magnetic resonance imaging (MRI), computed tomography (CT) or any other radiographic examination, the transmitter and sensor should be disconnected and removed from the area subjected to radiation (per the manufacturer's specification). An evaluation of FGM sensor functionality demonstrated that it retains its functionality after exposure to X-rays and computed tomography (CT) scans. A non-clinical MRI study showed that sensors can be

worn under specific conditions during MRI procedures [60].

- The sensor and transmitter are water-resistant (per the manufacturer's specification).
- The device should not be used onboard aircraft (in accordance with the instruction manual).

Patient education

The patient needs preparation for the use of CGM systems. Diabetes education should include: the technique for using the device, interpretation of the current and retrospective results, development of skills allowing for modifying treatment based on glucose level trend arrows, care and self-examination of sensor insertion sites, and principles of glucose level self-monitoring. The education should additionally include: sensor calibration (if required), and the selection and programming of alarm thresholds and notifications [13,15,61-70]. An important aspect of the education is learning how to transmit data from the receiver (generating a report), which is essential for analysis during a follow-up visit or a teleconsultation. Data from reports (at least 14 days) enable retrospective interpretation of the patient's results by members of the therapeutic team and therapy adjustments based on these findings. The analysis of report results involves discussing personalized treatment goals with the patient during the visit.

REFERENCES

- Cowart K. Expanding flash continuous glucose monitoring technology to a broader population. *Clin. Diabetes.* 2021;39(3):320-322. <https://doi.org/10.2337/cd20-0066>
- Chen GY, Lancaster DG, Monro TM. Optical microfiber technology for current, temperature, acceleration, acoustic, humidity and ultraviolet light sensing. *Sensors.* 2018;18:72. <https://doi.org/10.3390/s18010072>
- Irace C, Cutruzzola A, Twedt K, et al. Device profile of the Eversense continuous glucose monitoring system for glycemic control in type-1 diabetes: overview of its safety and efficacy. *Expert Rev. Med. Devices.* 2021;18(10):909-914. <https://doi.org/10.1080/17434440.2021.1982380>
- Deiss D, Szadkowska A, Gordon D, et al. Clinical practice recommendations on the routine use of Eversense, the first long-term implantable continuous glucose monitoring system. *Diabetes Technol. Ther.* 2019;21(5):254-264. <https://doi.org/10.1089/dia.2018.0397>
- Deiss D, Irace C, Carlson G, et al. Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. *Diabetes Technol. Ther.* 2020;22(1):48-52. <https://doi.org/10.1089/dia.2019.0159>
- Christiansen MP, Klaaff LJ, Brazg R, et al. A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. *Diabetes Technol. Ther.* 2018;20(3):197-206. <https://doi.org/10.1089/dia.2017.0142>
- Garg SK, Liljenquist D, Bode B, et al. Evaluation of accuracy and safety of the next-generation up to 180-day long-term implantable Eversense continuous glucose monitoring system: The PROMISE Study. *Diabetes Technol. Ther.* 2022;24(2):84-92. <https://doi.org/10.1089/dia.2021.0182>
- Edward R, Priefer R. A comparison of continuous glucose monitors (CGMs) in diabetes management: a systematic literature review. *Prim. Care Diabetes.* 2023; 17(6):529-534. <https://doi.org/10.1016/j.pcd.2023.10.009>
- Zelada H, Perez-Guzman MC, Chernavsky DR, et al. Continuous glucose monitoring for inpatient diabetes management: an update on current evidence and practice. *Endocr. Connect.* 2023;12(10):e230180. <https://doi.org/10.1530/EC-23-0180>
- Abbott Diabetes Care. FreeStyle Libre sensor adhesion guide. Accessed: 2025-06-15. <https://www.bcparmacy.ca/system/files/assets/content/brochure%2C-welcome-guide-to-freestyle-libre-%2C-fsl2%2C-adc-61755-%281.pdf>
- Alva S, Bailey T, Brazg R, et al. Accuracy of a 14-day factory calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. *J. Diabetes Sci. Technol.* 2022;16(1):70-77. <https://doi.org/10.1177/1932296820958754>
- Tsoukas M, Rutkowski J, El-Fathi A, et al. Accuracy of FreeStyle Libre in adults with type 1 diabetes: The effect of sensor age. *Diabetes Technol. Ther.* 2020;22(3):203-207. <https://doi.org/10.1089/dia.2019.0262>

13. Alva S, Brazg R, Castorino K, et al. Accuracy of the third generation of a 14-day continuous glucose monitoring system. *Diabetes Ther.* 2023;14(4):767-776. <https://doi.org/10.1007/s13300-023-01385-6>
14. Ólafsdóttir AF, Attvall S, Sandgren U, et al. A clinical trial of the accuracy and treatment experience of the flash glucose monitor FreeStyle Libre in adults with type 1 diabetes. *Diabetes Technol. Ther.* 2017;19:164-172. <https://doi.org/10.1089/dia.2016.0392>
15. Dzida G, Fichna P, Jarosz-Chobot P, et al. Expert opinion: recommendation of diabetes experts on the use of FreeStyle Libre in diabetic patients in Poland. *Clin. Diabetol.* 2019;8:2. <https://doi.org/10.5603/DK.2019.0003>
16. Hall RM, Dyhrberg S, McTavish A, et al. Where can you wear your Libre? Using the FreeStyle Libre continuous glucose monitor on alternative sites. *Diabetes Obes. Metab.* 2022;24(4):675-683. <https://doi.org/10.1111/dom.14630>
17. Messer LH, Berget C, Beatson C, et al. Preserving skin integrity with chronic device use in diabetes. *Diabetes Technol. Ther.* 2018;20(S2):S254-S264. <https://doi.org/10.1089/dia.2018.0080>
18. Faccioli S, Del Favero S, Visentin R, et al. PedArPan Study Group. Accuracy of a CGM sensor in pediatric subjects with type 1 diabetes. Comparison of three insertion sites: arm, abdomen, and gluteus. *J. Diabetes Sci. Technol.* 2017;11(6):1147-1154. <https://doi.org/10.1177/1932296817706377>
19. Wu PT, Segovia DE, Lee CC, et al. Consistency of continuous ambulatory interstitial glucose monitoring sensors. *Biosensors (Basel)*. 2018;8(2):49. <https://doi.org/10.3390/bios8020049>
20. Steineck IIK, Mahmoudi Z, Ranjan A, et al. Comparison of continuous glucose monitoring accuracy between abdominal and upper arm insertion sites. *Diabetes Technol. Ther.* 2019;21(5):295-302. <https://doi.org/10.1089/dia.2019.0014>
21. Fokkert MJ, van Dijk PR, Edens MA, et al. Performance of the FreeStyle Libre flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. *BMJ Open Diabetes Res. Care.* 2017;5(1):e000320. <https://doi.org/10.1136/bmjdrc-2016-000320>
22. Charleers S, Mathieu C, Nobels F, et al. Accuracy and precision of flash glucose monitoring sensors inserted into the abdomen and upper thigh compared with the upper arm. *Diabetes Obes. Metab.* 2018;20(6):1503-1507. <https://doi.org/10.1111/dom.13239>
23. Christensen MO, Berg AK, Ryttner K, et al. Skin problems due to treatment with technology are associated with increased disease burden among adults with type 1 diabetes. *Diabetes Technol. Ther.* 2019;21(4):215-221. <https://doi.org/10.1089/dia.2019.0007>
24. Eversense 2025. Accessed: 2025-06-11. <https://global.eversensediabetes.com/patient-education/eversense-user-guides/>
25. Kamann S, Aerts O, Heinemann L. Further evidence of severe allergic contact dermatitis from isobornyl acrylate while using a continuous glucose monitoring system. *J. Diabetes Sci. Technol.* 2018;12:630-633. <https://doi.org/10.1177/1932296818762946>
26. Seget S, Rusak E, Partyka M, et al. Bacterial strains colonizing the sensor electrodes of a continuous glucose monitoring system in children with diabetes. *Acta Diabetol.* 2021;58(2):191-195. <https://doi.org/10.1007/s00592-020-01601-w>
27. Berg AK, Olsen BS, Thyssen JP, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. *Pediatr. Diabetes.* 2018;19:733-740. <https://doi.org/10.1111/pedi.12652>
28. Kamann S, Oppel E, Liu F, et al. Evaluation of isobornyl acrylate content in medical devices for diabetes treatment. *Diabetes Technol. Ther.* 2019;21(10):533-537. <https://doi.org/10.1089/dia.2019.0163>
29. McNichol L, Lund C, Rosen T, et al. Medical adhesives and patient safety: state of the science: consensus statements for the assessment, prevention, and treatment of adhesive-related skin injuries. *J. Wound Ostomy Continence Nurs.* 2013;40:365-380. <https://doi.org/10.1097/WON.0b013e3182995516>
30. Freckmann G, Buck S, Waldenmaier D, et al. Skin reaction report form: development and design of a standardized report form for skin reactions due to medical devices for diabetes management. *J. Diabetes Sci. Technol.* 2021;15(4):801-806. <https://doi.org/10.1177/1932296820911105>
31. Rigo RS, Levin LE, Belsito DV, et al. Cutaneous reactions to continuous glucose monitoring and continuous subcutaneous insulin infusion devices in type 1 diabetes mellitus. *J. Diabetes Sci. Technol.* 2021;15:786-791. <https://doi.org/10.1177/1932296820918894>
32. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Cutaneous adverse events related to FreeStyle Libre device – authors' reply. *Lancet.* 2017;389:1396-1397. [https://doi.org/10.1016/S0140-6736\(17\)30893-0](https://doi.org/10.1016/S0140-6736(17)30893-0)
33. Castellana M, Parisi C, Di Moffetta S, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. *BMJ Open Diabetes Res. Care.* 2020;8(1):e001092. <https://doi.org/10.1136/bmjdrc-2019-001092>
34. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *Lancet.* 2016;388(10057):2254-2263. [https://doi.org/10.1016/S0140-6736\(16\)31535-5](https://doi.org/10.1016/S0140-6736(16)31535-5)
35. Asarani NAM, Reynolds AN, Boucher SE, et al. Cutaneous complications with continuous or flash glucose monitoring use: systematic review of trials and observational studies. *J. Diabetes Sci. Technol.* 2020;14(2):328-337. <https://doi.org/10.1177/1932296819870849>
36. O'Neal DN, Adhya S, Jenkins A, et al. Feasibility of adjacent insulin infusion and continuous glucose monitoring via the Medtronic Combo-Set. *J. Diabetes Sci. Technol.* 2013;7(2):381-388. <https://doi.org/10.1177/193229681300700214>
37. Ward WK, Castle JR, Jacobs PG, et al. Can glucose be monitored accurately at the site of subcutaneous insulin delivery? *J. Diabetes Sci. Technol.* 2014;8(3):568-574. <https://doi.org/10.1177/1932296814522805>
38. Hyry HSI, Liippo JP, Virtanen HM. Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients. *Contact Dermatitis.* 2019;81(3):161-166. <https://doi.org/10.1111/cod.13337>
39. Lombardo F, Passanisi S, Caminiti L, et al. High prevalence of skin reactions among pediatric patients with type 1 diabetes using new technologies: the alarming role of colophonium. *Diabetes Technol. Ther.* 2020;22(1):53-56. <https://doi.org/10.1089/dia.2019.0236>
40. Aerts O, Herman A, Bruze M, et al. FreeStyle Libre: contact irritation versus contact allergy. *Lancet.* 2017;390:1644. [https://doi.org/10.1016/S0140-6736\(17\)32142-6](https://doi.org/10.1016/S0140-6736(17)32142-6)
41. Velasco-Amador JP, Prados-Carmona Á, Navarro-Triviño FJ. [Translated article] Medical devices in patients with diabetes and contact dermatitis. *Actas Dermosifiliogr.* 2024;115(3):T280-T287. <https://doi.org/10.1016/j.ad.2024.01.016>
42. Herman A, Darrigade AS, de Montjoye L, et al. Contact dermatitis caused by glucose sensors in diabetic children. *Contact Dermatitis.* 2020;28(2):105-111. <https://doi.org/10.1111/cod.13429>
43. Kropff J, Choudhary P, Neupane S, et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. *Diabetes Care.* 2017;40(1):63-68. <https://doi.org/10.2337/dc16-1525>
44. Xiong M, Neeley AB. Adverse cutaneous reaction to the Eversense E3 continuous glucose monitor in a platinum-allergic patient. *Contact Dermatitis.* 2022;87(6):535-536. <https://doi.org/10.1111/cod.14200>
45. Berg AK, Olsen BS, Thyssen JP, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. *Pediatr. Diabetes.* 2018;19: 733-740. <https://doi.org/10.1111/pedi.12652>
46. von Kobyletzki LB, Ulriksdotter J, Sukakul T, et al. Prevalence of dermatitis including allergic contact dermatitis from medical devices used by children and adults with type 1 diabetes mellitus: a systematic review and questionnaire study. *J. Eur. Acad. Dermatol. Venereol.* 2024;38(7):1329-1346. <https://doi.org/10.1111/jdv.19908>
47. Bryant RA. Saving the skin from tape injuries. *Am. J. Nurs.* 1988; 88:189-191.
48. Medtronic Diabetes: tape tips and site management. Accessed: 2025-06-13. <https://www.medtronicdiabetes.com/sites/default/files/library/download-library/workbooks/Tape%20Tips%20and%20Site%20Management.pdf>
49. Englert K, Ruedy K, Coffey J, et al. Skin and adhesive issues with continuous glucose monitors: a sticky situation. *J. Diabetes Sci. Technol.* 2014;8:745-751. <https://doi.org/10.1177/1932296814529893>
50. Ives B, Sikes K, Urban A, et al. Practical aspects of realtime continuous glucose monitors: the experience of the Yale Children's Diabetes Program. *Diabetes Educ.* 2010;36:53-62. <https://doi.org/10.1177/0145721709352010>
51. Bailey T, Bode BW, Christiansen MP, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. *Diabetes Technol. Ther.* 2015;17(1):787-794. <https://doi.org/10.1089/dia.2014.0378>
52. Freckmann G, Pleus S, Grady M, et al. Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices. *J. Diabetes Sci. Technol.* 2019;13(3):575-583. <https://doi.org/10.1177/1932296818812062>
53. Basu A, Dube S, Veetttil S, et al. Time lag of glucose from intravascular to interstitial compartment in type 1 diabetes. *J. Diabetes Sci. Technol.* 2015;9(1):63-68. <https://doi.org/10.1177/1932296814554797>
54. Scuffi C. Interstitium versus blood equilibrium in glucose concentration and its impact on subcutaneous continuous glucose monitoring systems. *Eur. J. Endocrinol.* 2014;10(1):36-42. <https://doi.org/10.17925/EE.2014.10.01.36>
55. Müller-Korbsch M, Rega-Kaun G, Fasching P, et al. RrtCGM performance at different sensor wear sites during prolonged aerobic exercise – can the rtCGM sensor be worn anywhere on the body? *J. Diabetes Sci. Technol.* 2022;16(1):250-251. <https://doi.org/10.1177/19322968211036756>
56. Bellido V, Freckman G, Pérez A, et al. Accuracy and potential interferences of continuous glucose monitoring sensors in the hospital. *Endocr. Prac.* 2023;29(11):919-927. <https://doi.org/10.1016/j.eprac.2023.06.007>
57. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
58. American Diabetes Association Professional Practice Committee; 7. Diabetes technology: Standards of care in diabetes – 2025. *Diabetes Care.* 2025;48(1):S146-S166. <https://doi.org/10.2337/dc25-S007>
59. Patil SP, Albanese-O'Neill A, Yehl K, et al. Professional competencies for diabetes technology use in the care setting. *Sci. Diabetes Self Manag. Care.* 2022;48:437-445. <https://doi.org/10.1177/263501062211020889>
60. Matievich W, Kiae N, Dunn TC. Safety and functional integrity of continuous glucose monitoring sensors when used during radiologic procedures under high exposure conditions. *J. Diabetes Sci. Technol.* 2023;17(6):1634-1643. <https://doi.org/10.1177/19322968221106206>

61. Pemberton JS, Kershaw M, Dias R, et al. DYNAMIC: Dynamic glucose management strategies delivered through a structured education program improves time in range in a socioeconomically deprived cohort of children and young people with type 1 diabetes with a history of hypoglycemia. *Pediatr. Diabetes.* 2021;22(2):249-260. <https://doi.org/10.1111/pedi.13155>
62. Schlüter S, Freckmann G, Heinemann L, et al. Evaluation of the SPECTRUM training programme for real-time continuous glucose monitoring: a real-world multicentre prospective study in 120 adults with type 1 diabetes. *Diabet. Med.* 2021;38(2):e14467. <https://doi.org/10.1111/dme.14467>
63. Kim JY, Jin SM, Sim KH, et al. Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial. *Diabetologia.* 2024;67(7):1223-1234. <https://doi.org/10.1007/s00125-024-06152-1>
64. Romero-Castillo R, Pabón-Carrasco M, Jiménez-Picón N, et al. Effects of a diabetes self-management education program on glucose levels and self-care in type 1 diabetes: a pilot randomized controlled trial. *Int. J. Environ. Res. Public Health.* 2022;19(23):16364. <https://doi.org/10.3390/ijerph192316364>
65. Borot S, Benhamou PY, Atlan C, et al. Practical implementation, education and interpretation guidelines for continuous glucose monitoring: a French position statement. *Diabetes Metab.* 2018;44(1):61-72. <https://doi.org/10.1016/j.diabet.2017.10.009>
66. Hermanns N, Ehrmann D, Schipfer M, et al. The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: results of a randomized controlled trial. *Diabetes Res. Clin. Pract.* 2019;150:111-121. <https://doi.org/10.1016/j.diabres.2019.03.003>
67. Pintus D, Ng SM. FreeStyle Libre flash glucose monitoring improves patient quality of life measures in children with type 1 diabetes mellitus (T1DM) with appropriate provision of education and support by healthcare professionals. *Diabetes Metab. Syndr.* 2019;13(5):2923-2926. <https://doi.org/10.1016/j.dsx.2019.07.054>
68. Mauri A, Schmidt S, Sosero V, et al. A structured therapeutic education program for children and adolescents with type 1 diabetes: an analysis of the efficacy of the „Pediatric Education for Diabetes“ project. *Minerva Pediatr. (Torino).* 2021;73(2):159-166. <https://doi.org/10.23736/S2724-5276.17.04634-5>
69. Yuksel M, Bektas H, Ozer ZC. The effect of nurse-led diabetes self-management programmes on glycosylated haemoglobin levels in individuals with type 2 diabetes: a systematic review. *Int. J. Nurs. Pract.* 2023;6:e13175. <https://doi.org/10.1111/ijn.13175>
70. Yoo JH, Kim G, Lee HJ, et al. Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes: a randomized controlled trial. *Diabetes Res. Clin. Pract.* 2022;184:109209. <https://doi.org/10.1016/j.diabres.2022.109209>

III. SUBCUTANEOUS INSULIN INJECTION USING A PEN INJECTOR

Purpose: Subcutaneous administration of insulin using an ISO-compliant pen injector (PN-EN ISO 15197:2015-10).

Individuals authorized to perform the procedure: nurse, midwife.

■ Tab. 4. Key recommendations. Subcutaneous insulin injection using a pen injector

Before initiating insulin therapy, the patient should undergo assessment for pain anxiety and psychological preparation for injections. B
Before initiating insulin therapy, the optimal injection technique should be selected, including the injection angle, needle type, and whether to use a lifted skin fold. B
Each patient treated with insulin and/or their carer should be trained in using the injector and following the correct injection technique, at the health care center where they were prescribed the insulin therapy. B
The nurse/midwife (diabetes educator) should verify the patient's technique for injecting insulin using a pen injector and check the condition of their equipment during each visit, and at least once a year. E
Insulin should be injected using a dedicated injector, compliant with the ISO standard for medical devices, in accordance with the manufacturer's instructions. E
The injector and insulin cartridge may only be used by one patient, and must not be shared with another person even if the needle is replaced. B
Insulin injection with a pen injector in adults does not require lifting a skin fold if a 4 or 5 mm needle is used, but may be required if a 6, 8, or 12.7 mm needle is used. B
Regardless of patient age and subcutaneous tissue thickness, short needles (4 mm, 5 mm, and 6 mm) are preferred. C
Each patient should be informed about the need to replace the pen needle for each new injection and about the principles of needle reimbursement. E
Single use of the needle is associated with a lower risk of cutaneous complications, pain, and episodes of unexplained hypoglycemia. B
Correct insulin injection technique using a pen injector is one of the factors contributing to glycemic control and reduced cutaneous complications. A
The injector and other diabetes treatment devices should be selected individually, taking into account: clinical effectiveness, the manual and intellectual capabilities of the individual with diabetes, and their preferences, as well as environmental benefits and policies. E
Switching to a smart injector with the ability to calculate and record insulin doses may, for some individuals, extend the time spent within the target glucose range and minimize missed bolus injections. C

For the purposes of the procedure discussed, pen injectors have been divided into two groups based on two criteria:

A) duration of use:

- a) single-use multi-dose injector – contains a built-in, non-removable insulin ampoule, without the possibility of replacement. After the insulin contained in the ampoule has been used, the injector is not fit for further use.
- b) reusable injector – contains an insulin ampoule, which can be replaced multiple times depending on the insulin use and needs.

B) mechanism of insulin release:

- a) automatic,
- b) semi-automatic,
- c) with the possibility of transferring data about medication dosing to a compatible mobile application.

Correct subcutaneous injection of insulin using an injector involves depositing the insulin in subcutaneous tissue and minimizing such risk factors as [1-4]:

- insulin leakage from the skin (insufficient injection depth),
- intramuscular infusion (excessive injection depth),
- intravascular infusion,
- cutaneous complications.

Pen injector

Each insulin pen injector consists of: a cap (protecting the medication against sunlight); the insulin cartridge (in disposable pens the cartridge is integrated with the device); and the injector body with a plunger, a knob or dial to select dosage, and a dose window. Disposable and reusable injectors may be used with 3 mL (300 units at a concentration of 100 U/mL and 600 units at 200 U/mL) and 1.5 mL (450 units at 300 U/mL) insulin cartridges. Each insulin manufacturer specifies the injector it should

be used with. The injector must be used in accordance with the injector manufacturer's instructions. Injectors should be compliant with international ISO standards for medical devices.

Pen injector insulin injection sites

Insulin should be injected in areas of the body with sufficient loose subcutaneous tissue.

In children [5-7]:

- a. Abdomen within the following boundaries: ~1 cm over the pubic symphysis, ~1 cm below the lowest rib, ~1 cm away from the navel, and flanks.
- b. Thighs: upper third of the anterior lateral surface of both thighs.
- c. Buttocks: upper, posterior lateral surface of buttocks and flanks.
- d. Arms: mid-third of the posterior surface of the upper arm.

In adults [1,3,5,8-11]:

- a. Abdomen – excluding 1–2 cm around the navel and palpable bone structures. The injection should be performed while the patient is seated.
- b. Thighs (**upper third of the anterior lateral** surface, starting a hand width below the great trochanter of the femur and a hand width above the knee joint). The injection should be performed while the patient is seated.
- c. Buttocks (**the upper exterior surface of the buttock or flank**, demarcated by a vertical line going through the midpoint of the buttock and a horizontal line at the level of the intergluteal cleft).
- d. Arm – **mid third of the posterior** surface of the upper arm (the mid third of the upper arm is an area between 4 fingers placed above the elbow joint and 4 fingers placed below the shoulder joint, on the middle posterior surface).

Before initiating insulin therapy, the optimal injection sites for the individual patient should be selected, also considering the type of insulin prescribed.

Examination of insulin injection sites [5,9-10,12]

Each injection of insulin by the patient, carer, or health care provider should be preceded by a meticulous examination of the injection site (by palpation and visually), and the patient should be informed of the technique and purpose of this examination. The examination and any observed lesions should be recorded in the patient's records and self-monitoring journal.

When injecting insulin, avoid sites with any pathological lesions (scars, damaged skin, lipohypertrophy or lipodystrophy, allergy symptoms), visible blood vessels, birthmarks. Do not inject insulin into lipohypertrophic tissue. The patient should be informed about the contraindication and the potential consequences of insulin administration into unhealthy tissue. The physical examination technique is described in detail within procedure XI, Physical examination of the skin at subcutaneous insulin injection sites in primary and secondary prevention of lipohypertrophy (LH).

Rotation of injection sites and anatomical areas [5,8-9]

To minimize complications resulting from incorrect technique of insulin injection with a pen injector (daily glucose fluctuations and cutaneous complications), injection sites and areas should be rotated.

Injection site rotation: change the injection site within an area of the body for each insulin injection, moving 1 cm away from the previous injection site. An injection site may be used again no sooner than after 6 weeks of the previous injection.

Injection area rotation: the anatomical area for injections should be rotated at least every 4 weeks, e.g. injecting on the left side of the body for a week or two weeks, and then injecting on the right side of the body for a week or two weeks. When changing the area of the body used to inject insulin, consider the potential change in the speed of absorption and its impact on blood glucose levels.

Injection technique [1-2,5,8-9,13]

Insulin injection with a pen injector may be performed at a 90-degree (most common) or 45-degree angle, with or without lifting a skin fold. Before initiating insulin therapy, the optimal injection technique should be selected, including the injection angle, needle type, and whether to use a lifted skin fold. A skin fold is correctly lifted with the thumb and index finger (or middle finger). When using an injector, insulin injection into a skin fold at a 45-degree angle should be considered when:

- using a needle longer than 5 mm (with the exception of obese patients),
- administering insulin to patients younger than 6 years (even when using a 4 mm needle),
- administering insulin to patients with little subcutaneous tissue.

Insulin can be injected at a 90-degree angle without using a raised skin fold:

- when using a short needle (4 mm),
- when using 5 mm needles in adults, except in very lean individuals,
- in patients older than 6 years,
- in pregnant women who continue abdominal administration of insulin using a short needle,
- for self-injection into the upper arm using a short needle.

Injection technique using a skin fold [1-2,5,8-9,13]

1. Prepare the insulin injector – remove the injector cap, disinfect the rubber stopper on the insulin cartridge, wait for the disinfectant to dry, attach a previously selected sterile needle, prime the needle by pushing 1 unit of insulin (or the amount specified in the injector manufacturer's instructions).
2. Prepare the insulin: check the name of the insulin and its appearance, set the required dose of insulin, agitate gently (in the case of cloudy insulin).
3. Lift a skin fold.

4. Introduce the needle into the middle of the fold at a 90- or 45-degree angle (when using the 45-degree angle, position the needle bevel-up).
5. While holding the skin fold, inject the insulin.
6. Wait 10-15 seconds or count to 10.
7. Withdraw the needle, maintaining the same angle.
8. Release the skin fold.
9. Visually assess any insulin leakage.

Injection technique without using a skin fold

[1-2,5,8-9,13]

1. Prepare the injector and insulin.
2. Introduce the needle into the skin at a 90- or 45-degree angle (in the latter case, position the needle bevel-up).
3. Inject the insulin.
4. Wait 10-15 seconds or count to 10.
5. Withdraw the needle, maintaining the same angle.
6. Visually assess any insulin leakage.

Note! When performing the above steps, inform the patient about the correct sequence, regardless of the written instructions provided.

Guidelines for injector users and medical personnel

- Before insulin injection using a pen injector, performed either by the patient or by another authorized person, the patient should undergo assessment for pain anxiety and psychological preparation for injections [1-2,4-5,8,14].
- Insulin can be injected with a pen injector by an authorized medical professional, or by the patient or their carer if they have been trained in the correct injection technique [1,8,15].
- Practical training in the insulin injection technique should be provided at the health center where the insulin therapy has been initiated, and should include: use of the injector with needle selection, technique for injection at the selected angle with and without lifting a skin fold, and injection site rotation and self-examination [1,5,8].
- Optimal insulin injection technique (injection angle and whether to use a lifted skin fold) should be selected individually, considering the needle length used, subcutaneous tissue thickness, and injection site, among other factors. Guidelines on injection technique should be provided to the patient/his carer/family member in writing [1,5,8,10,13,16].
- At least once every 6 months, the nurse or midwife should perform physical examination of the insulin injection sites and assess the patient's skills in terms of insulin injection technique and injection site rotation.
- Pregnant diabetic patients who continue abdominal administration of insulin should perform the injections into a lifted skin fold. In the last trimester of the pregnancy, injection sites around the navel must be avoided, but injections can be performed into a lifted skin fold on the outer edges of the abdomen [5,17].
- Pen injectors, both disposable and reusable, are personal devices.
- Use a different pen injector for each insulin type. To avoid errors, different-colored injectors can be used, and each injector should be clearly labeled with the patient's first and last name, the name of the insulin, and the date of cartridge insertion.
- The pen injector should be used and stored at room temperature. Polish standards specify the expected temperature indoors (also referred to as "room temperature") depending on the type of room and the work performed there. For office rooms, this temperature is 20-24°C in the winter and 20-26°C in the summer [5,18].
- Do not use the injector if any of its parts is damaged.
- When replacing the insulin cartridge, remove it from the fridge 1-2 hours before an injection [19-20].
- Clear insulin should not be agitated before injection, while cloudy insulin requires resuspension. To resuspend the insulin, agitate it gently in a swinging motion (30 times), until the solution becomes uniform [5].
- Store the currently used insulin at room temperature, according to the manufacturer's recommendations listed in the patient information leaflet and/or the summary of product characteristics (SmPC), no longer than 4-6 weeks [11,20].
- Do not administer the insulin if: its appearance is changed, it has been shaken, it has been exposed to high temperatures, or the vial is damaged [5].
- Regardless of patient age and subcutaneous tissue thickness, short needles (4, 5 and 6 mm) are preferred [3,5,6,9,21].
- Insulin injection using a pen injector should not be performed through clothing, as this prevents verifying successful injection or examining the injection site visually, and increases the risk of needle damage or infection [5,22].
- During insulin injections with a pen injector performed in health care facilities, aseptic and antiseptic technique must be strictly followed [5,23].
- Daily insulin injections with a pen injector, performed by the patient outside of health care facilities, does not require previous skin disinfection provided that proper hygiene is maintained [5].
- For short-term administration of insulin prescribed by the physician during a patient's hospitalization, insulin syringes are used [5].
- Multi-dose and reusable pen needle is a sterile medical product intended for single use [24-25].
- Since 2022, diabetic patients in Poland treated with insulin or GLP-1 analogues via subcutaneous injections can have their pen needles reimbursed from public funds [26].
- During intensive insulin therapy with the use of injectors, the patient may use subcutaneous ports. Needles used for insulin administration in such cases should be of the following size: 5-8 mm length and 28-32 gauge [27].
- Switching to a smart injector with the ability to calculate and record insulin doses may, for some individuals, extend the time spent within the target glucose range and minimize missed bolus injections [28].

¹Described in more detail within the procedure "Physical examination of the skin in prevention of LH".

- Safety and effectiveness are essential when selecting injectors and other medical devices used in the care of individuals with diabetes. Minimizing their environmental impact is becoming increasingly important [29-30].

REFERENCES

- Gorska-Ciebiada M, Masierek M, Ciebiada M. Improved insulin injection technique, treatment satisfaction and glycemic control: results from a large cohort education study. *J. Clin. Transl. Endocrinol.* 2020;19:100217. <https://doi.org/10.1016/j.jcte.2020.100217>
- Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. *Diabetes Obes. Metab.* 2014;16(10):971-976. <https://doi.org/10.1111/dorm.12304>
- Leonardi L, Vigano M, Nicolucci A. Penetration force and cannula sliding profiles of different pen needles: the PICASSO study. *Med. Devices.* 2019;12:311-317. <https://doi.org/10.2147/MDER.S218983>
- McKay M, Compion G, Lytzen LA, et al. Comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. *Diabetes Technol. Ther.* 2009;11(3):195-201. <https://doi.org/10.1089/dia.2008.0054>
- Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. *Mayo Clin. Proc.* 2016;91(9):1231-1255. <https://doi.org/10.1016/j.mayocp.2016.06.010>
- Lim STJ, Hui YCA, Lim PK, et al. Ultrasound-guided measurement of skin and subcutaneous tissue thickness in children with diabetes and recommendations for giving insulin injections. *J. Clin. Transl. Endocrinol.* 2018;12:26-35. <https://doi.org/10.1016/j.jcte.2018.04.004>
- Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving the injection. *Pediatr. Diabetes.* 2012;13(7):525-533. <https://doi.org/10.1111/j.1399-5448.2012.00865.x>
- Gentile S, Guarino G, Della Corte T, et al. The durability of an intensive, structured education-based rehabilitation protocol for best insulin injection practice: The ISTERP-2 study. Study Group on Injection Technique; Nefrocenter Research and NyxStart-Up Study Group. *Diabetes Ther.* 2021;12(9):2557-2569. <https://doi.org/10.1007/s13300-021-01108-9>
- Hirsch LJ, Strauss KW. The injection technique factor: What you don't know or teach can make a difference. *Clin. Diabetes.* 2019;37(3):227-233. <https://doi.org/10.2337/cd18-0076>
- Misnikova IV, Gubkina VA, Lakeeva TS, et al. A randomized controlled trial to assess the impact of proper insulin injection technique training on glycemic control. *Diabetes Ther.* 2017;8(6):1309-1318. <https://doi.org/10.1007/s13300-017-0315-y>
- Pettis RJ, Muchmore D, Heinemann LJ. Subcutaneous insulin administration: sufficient progress or ongoing need? *J. Diabetes Sci. Technol.* 2019;13(1):3-7. <https://doi.org/10.1177/1932296818817011>
- La Rosa C, Makkar H, Grant-Kels JM. Approach to the total body skin examination in adults and children: kids are not just little people. *Clin. Dermatol.* 2017;35(6):500-503. <https://doi.org/10.1016/j.cldermatol.2017.08.001>
- Rini C, Roberts BC, Morel D, et al. Evaluating the impact of human factors and pen needle design on insulin pen injection. *J. Diabetes Sci. Technol.* 2019;13(3):533-545. <https://doi.org/10.1177/1932296819836987>
- McKay M, Compion G, Lytzen LA, et al. Comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. *Diabetes Technol. Ther.* 2009;11(3):195-201. <https://doi.org/10.1089/dia.2008.0054>
- Regulation of the Minister of Health of February 28, 2017 on the kind and scope of preventive, diagnostic, treatment, and rehabilitation services provided by a nurse or midwife independently, without a medical order (Journal of Laws 2017, item 497).
- Misnikova IV, Dreval AV, Gubkina VA, et al. The risks of repeated use of insulin pen needles in patients with diabetes mellitus. *J. Diabetol.* 2011;2(1):2.
- Soltani H, Fraser R. A longitudinal study of maternal anthropometric changes in normal weight, overweight and obese women during pregnancy and postpartum. *Br. J. Nutr.* 2000;84(1):95-101. <https://doi.org/10.1017/s0007114500001276>
- Regulation of the Minister of Infrastructure of 12 April, 2002 on technical conditions which must be fulfilled by buildings and their location. *Journal of Laws.* 2002;75:690.
- WHO Expert Committee on Specifications for Pharmaceutical Preparations. Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products. *World Health Organ Tech Rep. Ser.* 2011;961(9):321-378.
- Vimalavathini R, Gitanjali B. Effect of temperature on the potency & pharmacological action of insulin. *Indian J. Med. Res.* 2009;130(2):166-169.
- Heinemann L, Nguyen T, Bailey ST. Needle technology for insulin administration: a century of innovation. *J. Diabetes Sci. Technol.* 2021;2(17):1-9. <https://doi.org/10.1177/19322968211059564>
- Fleming D, Jacober SJ, Vanderberg M, et al. The safety of injecting insulin through clothing. *Diabetes Care.* 1997;20:244-247. <https://doi.org/10.2337/diacare.20.3.244>
- Gorman KC. Good hygiene versus alcohol swabs before insulin injections (Letter). *Diabetes Care.* 1993;16:960-961. <https://doi.org/10.2337/diacare.16.6.960>
- Olmo DZ, Vlacho B, Fernández J, et al. Safety of the reuse of needles for subcutaneous insulin injection: a systematic review and meta-analysis. *Int. J. Nurs. Stud.* 2016;60:121-132. <https://doi.org/10.1016/j.ijnurstu.2016.04.010>
- International Organization for Standardization. Needle-based injection systems for medical use – requirements and test methods (ISO11608-1:2022). <https://www.iso.org/standard/70733.html>. Published 2022. Accessed: 2025-06-11.
- Notice of the Minister of Health of December 20, 2021 on the list of reimbursed drugs, foodstuffs intended for particular nutritional use and medical devices as of January 1, 2022. *Journal of Laws.* 2021; 82.
- Hanas R. I-Port indwelling catheter alleviates injection pain in children with diabetes. *Pediatr. Diabetes.* 2013;14(18):114.
- Simpson V, Jones A. Switching to reusable cartridge insulin pens can reduce National Health Service costs while delivering environmental benefits. *Diabet. Med.* 2024;41:e15409. <https://doi.org/10.1111/dme.15409>
- Jendle J, Ericsson Å, Gundgaard J, et al. Smart insulin pens are associated with improved clinical outcomes at lower cost versus standard-of-care treatment of type 1 diabetes in Sweden: a cost-effectiveness analysis. *Diabetes Ther.* 2021;12(1):373-388. <https://doi.org/10.1007/s13300-020-00980-1>
- Nguyen KT, Zhang JY, Heinemann L, et al. The diabetestechologysocietygreendeclaration. *J. Diabetes Sci. Technol.* 2022;16:215-217. <https://doi.org/10.1177/19322968211051721>

IV. SUBCUTANEOUS INJECTION OF GLP-1 RECEPTOR AGONISTS AND A DUAL GLP-1/GIP RECEPTOR AGONIST USING AN INJECTOR

Purpose: Administering GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist by subcutaneous injection using an injector.

Individuals authorized to perform the procedure: nurse, midwife.

■ Tab. 5. Key recommendations Administering GLP-1 receptor agonists by subcutaneous injection

Treatment with GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist should be supported by lifestyle changes (diet and exercise). A
Combination of insulin, sulfonylureas and/or metformin with subcutaneous GLP-1 receptor agonist and a dual GLP-1/GIP receptor agonist injections may be associated with hypoglycemia. Blood glucose self-monitoring is recommended for these patients. A
To maximize the benefits of drugs from the GLP-1 and a GLP-1/GIP group, injectors must be used correctly. Failure to follow the correct subcutaneous injection procedure may result in incorrect dosage, damage to the injector, and infection at the injection site. E
Health education provided to patients treated with subcutaneous GLP-1 receptor agonist and a dual GLP-1/GIP receptor agonist injections is an indispensable part of therapy that contributes to a reduced risk of adverse effects. E

Incretins are gastrointestinal hormones that stimulate insulin secretion and reduce the secretion of glucagon, which acts in opposition to insulin. Incretin-based drugs reduce blood glucose levels, normalize or even reduce body weight, and do not increase the risk of hypoglycemia. There is risk of hypoglycemia when the patient is additionally treated with insulin or another antihyperglycemic agent that may cause hypoglycemia. Some incretin groups are suitable for subcutaneous administration. These include glucagon-like peptide 1 receptor agonists (GLP-1 analogues) and a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors [1-9].

- In accordance with the proposed classification of GLP-1 receptor agonists (GLP-1 analogues) and a dual GLP-1/GIP receptor agonist by duration of activity, these substances are broken down into first-generation agents, administered multiple times a day (short-acting exenatide); second-generation agents, administered once daily (liraglutide, lixisenatide); and third-generation agents which can be administered once weekly (extended-release exenatide, dulaglutide, semaglutide, tirzepatide). Most of the once-daily drugs should be administered 60 minutes before the same meal every day – preferably, before breakfast of the most carbohydrate-rich meal. Some drugs, however, can be used once daily and independently of meals (e.g. Victoza). Immediate-release drugs taken twice daily can be administered 60 minutes before the morning and evening meal (or two major meals during the day, with a break of at least 6 hours between the doses). Immediate-release products should not be taken after a meal. Extended-release products can be administered at any time of the day, with a meal or between meals (dulaglutide, tirzepatide) [10-16].
- In some products, a GLP-1 analogue is combined with a long-acting insulin analogue in a single injector (e.g. insulin degludec and liraglutide or insulin glargine and lixisenatide). These are administered once daily [10].

Recommended injection sites

In accordance with the summary of product characteristics:

- thigh,
- abdomen,
- upper arm.

The injection site should be changed (rotated) for each injection, and anatomical areas should be rotated depending on the frequency of administration. For daily medications, the area should be changed every month. For weekly medications, the area may be changed less frequently.

Administration technique

All GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist for subcutaneous injection are administered using disposable semi-automatic injectors containing one or multiple doses. The outward appearance of selected injectors and some of their basic technical parameters are shown in Figure 1 (Fig. 1). Principles for needle length selection and using or not using a lifted skin fold are the identical as those applicable to insulin injections.

General rules for the use of the different semi-automatic injector types

- Administration of GLP-1 receptor agonists by subcutaneous injection requires the use of semi-automatic injectors, which differ considerably both in appearance and in important technical details. Some only contain a single dose of the medication (e.g. dulaglutide), while others contain enough doses for 2-4 weeks of treatment (e.g. liraglutide, semaglutide, tirzepatide). They may have a single-chamber or dual-chamber construction – in the latter, the diluent and powdered medicine are kept separate [11-14].
- Due to the many details in which the injectors may differ, the information leaflet provided must be carefully read before the use of a pre-filled injector.

GLP-1 receptor agonists								GLP-1 receptor agonist / basal insulin fixed-dose combinations	
Drug name	Albiglutide	Dulaglutide	Exenatide b.i.d	Exenatide once weekly	Lixisenatide	Liraglutide	Semaglutide	Degludec / liraglutide (IDegLira)	Glargine / lixisenatide (iGlarLixi)
Pen devices for injection									
Pen devices available (maximum dose)	30 mg 50 mg	0.75 mg 1.5 mg	5 µg 10 µg	2 mg	2 mg	10 µg 20 µg	1.8 mg	0.25 mg 0.5 mg 1 mg	up to 1.8 mg (+ up to 50 IU degludec) up to 20 µg (+ up to 60 IU glargin)
Pen for single / multiple use	single	single	multiple	single	single	multiple	multiple	multiple	multiple
Pen for pre-determined single dose / variable dosing	single	single	single	single	single	variable (0.6; 1.2 or 1.8 mg)	single	variable, for titration	variable, for titration
Resuspension before injection necessary?	yes	no	no	yes	no, but thorough mixing	no	no	no	no

Fig 1. Injectors for GLP-1 receptor agonists and fixed-dose combinations of GLP-1 receptor agonists with basal insulin formulations

Source: developed by Hornik B. based on [10,14].

- Before first use of any new injector, check the flow by holding the injector with the needle pointing upwards, pressing the injection button and holding until the dose counter returns to “0” or another appropriate symbol. A drop of the medication should appear on the tip of the needle. If there is no drop, flow should be checked again. This check is performed up to 6 times. If the drop of medication still does not appear, discard the injector and use a new one.
- For subsequent injections with a multiple-dose injector, the dose may be set immediately. The injector need not be tested before each subsequent use, as this could cause the medication to run out before 30 full days of treatment [12].
- Before administration, check the appearance of the medication in the chamber. The liquid should be clear and colorless, with no solid particles. Do not use if the appearance is changed.
- Excessive pressure on the skin fold or release of the injection button before fully removing the needle from the subcutaneous tissue may cause some tissue to be aspirated into the injector, with some solid particles or a pink coloration visible in the chamber, especially in patients who bleed more easily or undergo anticoagulant treatment. If this happens, dispose of the injector and use a new one for subsequent injections. Proceed the same way if the button is accidentally pressed before removal of the cap.
- Dispose of all sharps (needles) safely.
- Store multiple-use injectors without a needle. This prevents medication leakage and contamination, air bubble formation, and needle clogging, and reduces the risk of injection site infection.
- Use a new disposable needle for each injection. This reduces the risk of needle clogging, medication contamination, injection site infection, or incorrect dosage.
- To ensure correct dosage, the number in the dose counter window must be aligned exactly with the indicator. In most injectors, the injection button should be pressed and held down until the dose counter returns to “0” or another appropriate symbol. A click may be heard then.
- When the dose counter returns to “0” or another appropriate symbol, leave the needle inserted into the subcutaneous tissue while counting slowly to 10 to make sure that the full dose has been administered. If the needle is removed sooner, the solution may leak out of the needle tip, and the full dose will not be administered.
- While removing the needle from the skin, the injection button should remain pressed down to keep the remaining solution in the chamber clear.
- During injection, never touch the dose counter. This could interrupt the injection.
- After administration, detach the needle and carefully dispose of it in a puncture-resistant container. Do not dispose of the injector with the needle attached.
- After each use of a multiple-dose injector, put the cap on to protect the solution from light.
- Do not press the injection button if no needle is attached. This could damage the injector.
- If the dose window shows a symbol and the dosage knob does not turn, this may mean there is not enough medication in the injector chamber to administer a full dose [11-14,17].

Technique for using semi-automatic GLP-1 and dual GLP-1/GIP receptor agonist analogue injectors

- Wash your hands with soap and water.
- If the injector has been stored in a refrigerator, leave it at room temperature for at least 15 minutes before use.
- Before each use, check the medication label and expiration date to ensure this is the correct medication and that it has not expired. Check the injector for damage.
- Make sure there is enough medication left in the injector to load the correct dose.
- Check the appearance of the medicine and make sure the solution inside the injector is clear, with no solid particles. For products that require the diluent and powder to be mixed, check the resulting suspension after mixing. Only use the product if the suspension is white or off-white and milky in appearance. Clumps or dry powder adhering to the injector walls are a sign of incorrect mixing. If a medication requires mixing, it must be injected immediately once mixed.
- Select the injection site – examine the skin for lipohypertrophy, inflammation, edema, ulceration, or infection. Avoid injecting around nodules, scars, tattoos, hernias, or stomas.
- Then, disinfect the injection site and allow it to dry (for approximately 60 seconds).
- Attach the needle after having disinfected the rubber stopper, and remove the outer needle shield – do not dispose of the outer needle shield, as it will be used when detaching the needle from the injector after the injection.
- Remove and discard the inner needle shield. A small drop of liquid may appear. This is normal.
- Insert the needle into the skin or press the injector firmly against the skin (depending on injector type), at a 90-degree angle from its surface, and administer the medicine in accordance with the instruction manual.
- After the plunger has been completely depressed, hold the needle in the subcutaneous tissue while counting to 10.
- Then, remove the needle from the subcutaneous tissue, maintaining the same angle as that used to insert it.
- If a small vessel is accidentally damaged, a few drops of blood may appear.
- After the needle has been removed, press a dry swab over the injection site, but do not massage the site, and if a lifted skin fold has been used, release it.
- After the injection is complete, dispose of the single-dose injector or detach the needle from the multiple-dose injector and dispose of it in a puncture-resistant container.
- If insulin administration is needed at the same time, space the injection sites at least 5 cm apart.
- Never store the injector with the needle attached. If the needle is left attached to the injector, the medicine may leak or air bubbles may form inside the chamber.

- If using a multiple-dose injector, write down the date of first use [11-14,17].

Additional guidelines for use of single-dose semi-automatic injectors (filled with dulaglutide)

- Before administering the medicine, make sure the injector is locked. If you accidentally unlock the injector and press the injection button before removing the cap, the injector must be disposed of correctly, and a new one used instead.
- Remove and discard the gray cap. Do not put the cap back on, as this could damage the needle.
- Firmly place the clear base flat against the skin at the injection site, unlock the injector by turning the lock ring, then press and hold the injection button; you will hear a loud click.
- Hold the clear base of the injector firmly against the skin until you hear a second click. This happens after 5-10 seconds, when the needle starts retracting.
- Do not remove the injector from the skin until you have heard the second, louder click. The dose has been delivered correctly if the gray part can be seen in the injector chamber. Only then can you remove the injector from the skin [13].

Semi-automatic injector storage

- Injectors contain glass parts and require caution during storage. Do not use an injector that has been dropped onto a hard surface. If any glass part of an injector is damaged, use a new one for any subsequent injections.
- Store injectors in a refrigerator, at a temperature between 2 and 8°C.
- If you do not have access to a refrigerator, you may store the injector at room temperature (below 30°C), away from direct light, for 14 to 30 days, depending on the medication (see the manufacturer's leaflet). If the expiration date has passed, discard the injector even if there is still medicine left inside.
- Do not freeze the injectors. Do not use any injector that has been accidentally frozen.
- Store the injector in its original packaging to protect it from light.
- During travel, injectors should be carried in hand luggage and protected from temperature changes, such as extreme heat or cold.
- Keep injectors out of sight and reach of children [11-14].

Note:

- Extended-release GLP-1 analogues, e.g. exenatide, are administered once weekly with a dual-chamber semi-automatic injector. They are supplied as powder and diluent (liquid) for injectable suspension, in a pre-filled injector. One chamber contains white or off-white powder, and the other contains clear diluent liquid that is colorless, pale yellow, or pale brown. Each single-dose pre-filled injector comes with a single needle. Each carton also contains one spare needle.
- Before use, attach the needle, turn the knob to allow the medicine to mix with the diluent (stop turning when

you hear a click), tap the injector firmly against the palm of your hand until the medicine has mixed well (80 times or more), turn the knob again until the injection button has been released, remove the needle cover, and then perform the injection. Make the injection right after the powder has been mixed well with the diluent. Use a new injector for each injection. Dispose of used injectors safely [11].

- An alternative administration method requires connecting a vial to a syringe using a special connector, mixing the suspension, removing the connector, attaching a needle to the syringe, filling the syringe, replacing the needle, and injecting the medicine [11].

Possible adverse effects with subcutaneous injection of GLP-1 receptor agonists

Exact adverse effects vary depending on the product, but the most common ones include:

- Nausea and vomiting which should resolve after 7-10 days (these can be minimized by following the physician's recommendations on dosage and its gradual increasing, and by performing the injections immediately prior to eating).
- Abdominal pain (which can be minimized by having a meal right after administration).
- Dehydration (monitor your hydration level and drink additional fluids if symptoms of dehydration occur).
- Formation of pea-sized fatty lumps at the injection sites, especially with extended-release formulations (these should resolve spontaneously after about six weeks).
- Anaphylaxis, which is a rare, but very dangerous complication (observe the patient, especially at the beginning of treatment, for symptoms such as trouble breathing, face and throat swelling, rapid heartbeat); if symptoms of anaphylaxis occur, seek immediate medical attention [9-10,17].

Education guidelines

- GLP-1 analogues rarely cause hypoglycemia if used as single agents, but hypoglycemia is more common when they are used in combination with insulin or other anti-hyperglycemic drugs. Single-agent therapy with these products does not require additional blood glucose monitoring if the patient feels well; additional blood glucose monitoring may be needed to adjust the dose of insulin or sulfonylurea derivatives. If sulfonylureas are added to the treatment protocol, the patient must be aware of the increased risk of hypoglycemia [17].
- The patient must be aware that discontinuing immediate-release GLP-1 analogues and switching to an extended-release product may result in a transient increase in glycemia, which typically resolves within 2 weeks.
- Self-monitoring of blood glucose should be performed in accordance with the general self-monitoring guidelines for diabetic patients.
- The patient must be informed that their appetite will decrease during treatment, and that they should eat slower and take smaller meals. Satiety might be a new

state that the patient needs to adapt to. If the patient feels full, they should not continue eating out of habit (overeating can cause vomiting) [17].

- The patient must be informed of the need to self-monitor for symptoms of persistent, intense abdominal pain, which may also be felt in one's back and may be accompanied by vomiting; the patient must be informed that if this happens, they should stop the injections immediately and urgently seek medical advice. Treatment may only be resumed after proper examination and tests, in accordance with the physician's decision (there is a risk of pancreatitis).
- If a dose of an extended-release product is missed, the patient should take it as soon as possible if there are at least 3 days left until the next scheduled dose; if fewer than 3 days are left until the next scheduled dose, the missed dose should be skipped, and the next dose administered normally.
- Before each injection, the patient must examine their skin visually and by palpation:
 - Extended-release formulations may cause pea-sized fatty lumps to form at injection sites, which should resolve spontaneously after approximately six weeks.
 - Symptoms such as red nodules that are warm to the touch, rash, edema, itching, pain, hardening, or rarely necrotic abscesses, may appear at injection sites [18].
 - Patients must be educated on the risk of nodule formation; preventively, injection sites should be rotated and new needles used every time; injections should never be performed in areas where skin is pitted, thickened, bumpy, tender, bruised, peeling, hardened, scarred, or damaged.
 - Multiple subcutaneous nodules present in some patients suggest that the nodules are slow to resolve; in some cases, they may persist indefinitely; these symptoms can be minimized by following the guidelines for correct administration [18].
 - Any lesions observed by the patient require assessment by a nurse and/or physician who will decide whether the GLP-1 analogue should be discontinued and the injection site lesions should be treated (with antibiotics; corticosteroids — topical, systemic, injected directly into nodules; antihistamines; surgically, if needed) [17].

REFERENCES

1. Huthmacher JA, Meier JJ, Nauck MA. Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis. *Diabetes Care*. 2020;43:2303-2312. <https://doi.org/10.2337/dc20-0498>
2. Wang L. Designing a dual GLP-1R/GIPR agonist from Tirzepatide: comparing residues between Tirzepatide, GLP-1, and GIP. *Drug Des. Devel. Ther.* 2022;16:1547-1559. <https://doi.org/10.2147/DDDT.S358989>
3. Dąbrowska L. Modern antidiabetic medications – a review excluding insulins, sulfonylureas, biguanides, and α-glucosidase derivatives. Review paper developed in the course of specialist training in Retail Pharmacy. Zielona Góra; 2019, p. 1-13.
4. Frias JP, Bonora E, Nevarez Ruiz LA, et al. Efficacy and safety of Dulaglutide 3 mg and 4.5 mg vs. Dulaglutide 1.5 mg: 52-week results from AWARD- 11. *Diabetes Care*. 2020;69(Suppl. 1):357. <https://doi.org/10.2337/dc20-1473>
5. le Roux CW, Astrup A, Fujioka K, et al. 3 years of Liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389:1399-1409. [https://doi.org/10.1016/S0140-6736\(17\)30069-7](https://doi.org/10.1016/S0140-6736(17)30069-7)
6. Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet*. 2021;398(10295):143-155. [https://doi.org/10.1016/S0140-6736\(21\)01324-6](https://doi.org/10.1016/S0140-6736(21)01324-6)
7. American Diabetes Association Professional Practice Committee; 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes – 2025. *Diabetes Care*. 2025;48(Suppl.1):S181-S206. <https://doi.org/10.2337/dc25-5009>
8. Smolarek I, Jabłcka A. Drugs acting on the incretin system in the treatment of type 2 diabetes mellitus. *Farm. Współcz.* 2016;9:61-66.
9. Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. *Obesity (Silver Spring)*. 2020;28:529-536. <https://doi.org/10.1002/oby.22726>
10. Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? *Eur. J. Endocrinol.* 2019;181(6):211-234. <https://doi.org/10.1530/EJE-19-0566>
11. Summary of product characteristics. Bydureon. Accessed: 2025-06-25. https://ec.europa.eu/health/documents/community-register/2011/20110617103730/anx_103730_pl.pdf
12. Summary of product characteristics. Byetta. Accessed: 2025-06-25. https://ec.europa.eu/health/documents/community-register/2016/20160722135247/anx_135247_pl.pdf
13. Summary of product characteristics. Trulicity. Accessed: 2025-06-25. https://leki.urpl.gov.pl/files/49_Trulicity.pdf
14. Summary of product characteristics. Victoza. Accessed: 2025-06-25. https://www.ema.europa.eu/en/documents/product-information/victoza-epar-product-information_pl.pdf
15. Roszkiewicz M. New technologies and medications in type 1 and 2 diabetes treatment. Review paper developed in the course of specialist training in Retail Pharmacy. Gdańsk; 2019, p. 1-25.
16. Kostrzewska-Zabłocka E. Pharmaceutical methods. Oral medication treatment. In: Szewczyk A. (ed.) *Diabetes nursing*. Warsaw: PZWL; 2019.
17. Walden E. Insulin and non-insulin injectable therapy administration policy. Diabetes specialist nurse team. Lincolnshire Community Health Services NHS Trust. 2020;1:57.
18. Jones SC, Ryan DL, Pratt VS, et al. Injection-site nodules associated with the use of exenatide extended-release reported to the US Food and Drug Administration Adverse Event Reporting System. *Diabetes Spectr.* 2015;28(4):283-288. <https://doi.org/10.2337/diaspect.28.4.283>

V. USE OF AN INFUSION SET IN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) THERAPY USING A PERSONAL INSULIN PUMP

Purpose: Correct use of infusion sets with a personal insulin pump for the purposes of continuous subcutaneous insulin infusion (CSII) therapy.

Individuals authorized to perform the procedure: nurse, midwife.

■ Tab. 6. Key recommendations. Use of an infusion set in continuous subcutaneous insulin infusion (CSII) therapy using a personal insulin pump
Before initiating insulin therapy, the patient should undergo assessment for pain anxiety and psychological preparation for infusion set insertion. B
Each patient undergoing therapy using a personal insulin pump should have his infusion set individually selected. E
The infusion set should be replaced as planned, every 24-72 hours or in accordance with the manufacturer's requirements. B
Incorrect insertion and use of infusion sets, as well as failing to rotate insertion sites, may cause skin lesions. B
Education on infusion set use is prerequisite for successful care for patients using CSII, and contributes to successful diabetes self-management. A
Due to the rapid advancement of diabetes technology, nurses/midwives and diabetes educators are required to regularly update their knowledge and skills. B

A personal infusion pump is a small programmable insulin-delivery device, which automatically delivers the individually selected base insulin dose, 24 hours a day. It also allows for administering various boluses to cover increased demand for insulin (after a meal or during a blood glucose level increase).

Both tubed and tubeless pumps are available in Poland. Tubed pumps deliver insulin through a thin tube that connects the insulin reservoir to the infusion set placed in the subcutaneous tissue. In a tubed pump, the infusion set consists of two parts: the tubing and the cannula (metal or PTFE). Tubeless insulin pumps do not have tubing connecting the insulin reservoir to the cannula. The insulin reservoir is directly connected to the cannula, which delivers insulin subcutaneously. In a tubeless insulin pump, the reservoir pod is directly attached to the infusion set, which is adhered to the skin using an adhesive patch.

The infusion set consists of two parts: the tubing and the cannula (metal or PTFE). Infusion sets differ in shape, cannula and tubing length, adhesive size, connection location, and insertion angle. Each patient undergoing CSII using a personal insulin pump should have his infusion set type selected individually (based on his age, adipose tissue thickness, physical activity, proneness to skin allergies) by a physician or nurse [1].

Infusion set insertion sites:

- arm,
- abdomen,
- thigh,
- buttock [1].

When inserting an infusion set, avoid:

- areas subject to pressure (e.g. under straps or cuffs) or intensive movement,
- sites with any pathological lesions (redness, irritation, abscesses, scars, hypertrophy, bruises, cuts etc.),
- areas with little subcutaneous tissue [2-3].

Incorrect selection, insertion, and use of infusion sets, as well as failing to rotate insertion sites, may cause skin lesions that ultimately lead to blood glucose fluctuations and diabetes treatment failure. Failure to replace the cannula regularly may result in:

- increased infection risk,
- unpredictable insulin absorption,
- lipohypertrophy,
- lipoatrophy,
- skin irritation,
- scarring [1-2,4-7].

Infusion set installation technique

1. Stop the pump (if specified by the manufacturer) and disconnect the tubing from the cannula.
2. Remove the reservoir from the pump.
3. Open the package containing a syringe and the infusion set.
4. Disinfect the rubber stopper on the insulin vial and wait for the disinfectant to dry.
5. Fill the syringe/reservoir with insulin according to the manufacturer's instructions.
6. Remove any air from the syringe/reservoir (do not tap!).
7. Tubed pump – Connect the reservoir to the infusion set tubing and install the reservoir in the pump. Using the appropriate pump function, fill the tubing until a drop of insulin is formed at the point of the needle.
8. Disinfect the puncture site (if numbing cream is used, remove any residue with a gauze pad).
9. Leave the disinfected area of skin to dry for a time specified in the manufacturer's instructions.
10. Place the catheter manually or using the dedicated automatic device (loaded with the infusion set as per the manufacturer's instructions), taking care to correctly position the tubing.
11. With a tubeless insulin pump, attach the infusion set directly to the skin. The insulin reservoir is directly connected to the cannula, which delivers insulin subcutaneously.
12. If a PTFE cannula is used: withdraw the introducer needle and fill the resulting space with insulin (depending on cannula length, per the manufacturer's instructions).
13. Dispose of the used equipment in a closed waste container.
14. Disinfect your hands.
15. Record the catheter replacement in the medical records and the self-monitoring journal.
16. Remove the previously used catheter 2-3 hours after placement of the new one. To make adhesive removal more comfortable, use baby oil or a dedicated adhesive remover.
17. Examine the old catheter removal site.
18. Measure blood glucose using a glucose meter 2-3 hours after placement of the new catheter.

Guidelines on duration of use

- Cannulas must be replaced after: 48–72 hours for PTFE cannulas, 24–48 hours for metal cannulas, 24–48 in pregnant patients or in accordance with the manufacturer's recommendations [1,7-8].
- The infusion set must be replaced as planned every 24–72 hours, and in case any of the following occurs: infection symptoms at the insertion site (redness, swelling, pain, itching), blood in the tubing, blood glucose increase despite correct insulin dosage [1,7-9].
- To increase patient safety, the planned infusion set replacements should be performed during the day (between 4 and 6 PM).
- Take the insulin out of the refrigerator at least 30 minutes before the planned infusion set replacement so as to prevent the formation of air bubbles.

- Measure blood glucose levels 2-3 hours after the replacement to verify whether the set works correctly.
- After placing a new catheter, leave the previous one in the subcutaneous tissue for 2-3 hours so that the deposited insulin can be absorbed.
- If any cutaneous complications occur, remove the catheter and initiate the appropriate procedure recommended by the treatment team, or contact a physician.
- Using equipment and accessories other than those recommended by the insulin pump manufacturer may pose a health hazard!
- Each patient undergoing CSII therapy should have the following items on hand in case of pump malfunction or other unforeseen circumstances associated with this treatment method:
 - fast-absorbing carbohydrates, e.g. glucose tablets, glucose solution,
 - blood glucose testing kit,
 - glucagon,
 - blood or urine ketone test strips,
 - spare infusion set, insulin reservoir, and device for placing infusion set (if applicable),
 - injector, insulin (rapid-acting and long-acting), and physician's orders regarding insulin dosage in case of pump malfunction,
 - spare batteries for the pump and glucose meter,
 - phone numbers for the health care center where the patient is treated and for the manufacturer's help line.

Guidelines for personal insulin pump users and medical personnel

- Before initiating insulin therapy, the patient should undergo assessment for pain anxiety and psychological preparation for infusion set insertion [2,5].
- Each patient undergoing therapy using a personal insulin pump should have his infusion set individually selected [1-2].
- During infusion set installation, aseptic technique must be used [1,9].
- Skin disinfectants should be oil-free and colorant-free.
- Infusion sets and syringes are for single use only [2].
- Infusion sets must be replaced regularly per the manufacturer's instructions to ensure proper insulin absorption while minimizing the risk of skin irritation or infection.
- Incorrect insertion and use of infusion sets, as well as failing to rotate insertion sites, may cause skin lesions [1-2,7-9].
- Each time before inserting an infusion set, the planned insertion site must be carefully examined (visually and by palpation) [2]. Physical examination of injection sites is described in detail within Procedure X.
- The examination and any observed lesions should be recorded in the patient's records and self-monitoring journal. The patient should be informed about the contraindication and the potential consequences of insulin administration into unhealthy tissue.
- Education on infusion set use is prerequisite for successful care for patients using CSII, and contributes to successful diabetes self-management [1,10-11].

- Infusion sets that can be used for up to 7 days are available in Poland [12].
- Hybrid Closed Loop (HCL) systems represent the most beneficial therapeutic option for individuals with diabetes who require intensive insulin therapy. Automated Insulin Delivery (AID) systems utilize data from Continuous Glucose Monitoring (CGM) systems in real time (real-time CGM, rtCGM), integrated with a control algorithm that automatically adjusts the rate of insulin delivery via Continuous Subcutaneous Insulin Infusion (CSII). Currently available HCL systems can automatically reduce or suspend basal insulin infusion when glucose levels decrease, and increase insulin supply when glucose levels rise, with the aim of maintaining a predetermined target glucose levels. AID systems significantly improve metabolic control, reduce glycated hemoglobin levels, and decrease the number of hypoglycemic events, while also extending the time spent within the recommended glucose range [13,14].

REFERENCES

- Heinemann L, Krinkel I. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. *J. Diabetes Sci. Technol.* 2012;6(4):954-964. <https://doi.org/10.1177/193229681200600429>
- Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. *Mayo Clin. Proc.* 2016;91(9):1231-1255. <https://doi.org/10.1016/j.mayocp.2016.06.010>
- Conwell LS, Poppe E, Artiles AM, et al. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. *J. Pediatr.* 2008;152(5):622-662. <https://doi.org/10.1016/j.jpeds.2007.10.006>
- Overland J, Molyneaux L, Tewari S, et al. Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. *Diabetes Obes. Metab.* 2009;11(5):460-463. <https://doi.org/10.1111/j.1463-1326.2008.00972.x>
- Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care.* 2007;30(6):1653-1662. <https://doi.org/10.2337/dc07-9922>
- Schmid V, Hohberg C, Borchert M, et al. Pilot study for assessment of optimal frequency for changing catheter in insulin pump therapy-trouble starts on day 3. *J. Diabetes Sci. Technol.* 2010;4(4):976-982. <https://doi.org/10.1177/193229681000400429>
- Thethi TK, Rao A, Kawji H, et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. *J. Diabetes Complications.* 2010;24(2):73-78. <https://doi.org/10.1016/j.jdiacomp.2009.03.002>
- Kerr D, Morton J, Whately-Smith C, et al. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. *J. Diabetes Sci. Technol.* 2008;2(3):450-455. <https://doi.org/10.1177/19322968080200314>
- van Faassen J, Razenberg PP, Simoons-Smit AM, et al. Carriage of *Staphylococcus aureus* and inflamed infusion sites with insulin-pump therapy. *Diabetes Care.* 1989;12(2):153-155. <https://doi.org/10.2337/diacare.12.2.153>
- American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of care in diabetes – 2025. *Diabetes Care.* 2025;48(Suppl.1):S146-S166. <https://doi.org/10.2337/dc25-S007>
- Ehrmann D, Kulzer B, Schipfer M, et al. Efficacy of an education program for people with diabetes and insulin pump treatment (INPUT): results from a randomized controlled trial. *Diabetes Care.* 2018;41(12):2453-2462. <https://doi.org/10.2337/dc18-0917>
- Zhang JY, Shang T, Chatteraj S, et al. Advances in insulin pump infusion sets symposium report. *J. Diabetes Sci. Technol.* 2021;15(3):705-709. <https://doi.org/10.1177/1932296821999080>
- Szadkowska A, Chobot A, Głowirska-Olszewska B, et al. Guidelines of the Polish Society of Pediatric Endocrinology and Diabetology and Pediatric Section of Diabetes Poland on insulin therapy using hybrid closed-loop systems in children and adolescents with diabetes in Poland. *Pediatr. Endocrinol. Diabetes. Metab.* 2024;30(3):132-147. <https://doi.org/10.5114/pedm.2024.144041>
- Gallen G, Rosso A, Alonso-Carril N, et al. Expert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensus. *Acta Diabetol.* 2025; 62(5):685-694. <https://doi.org/10.1007/s00592-024-02388-w>

VI. MANAGEMENT OF HYPOGLYCEMIA IN A DIABETIC PATIENT

Purpose: Instructions for correct management of hypoglycemia in a diabetic patient, depending on severity.

Individuals authorized to perform the procedure: nurse, midwife.

■ **Tab. 7. Key recommendations. Management of hypoglycemia in a diabetic patient**

Duration of hypoglycemia in a diabetic patient may be shorter if real-time continuous glucose monitoring (real-time CGM) is used. A
The use of a continuous blood glucose monitoring system and self-monitoring may reduce the risk of hypoglycemic incidents in patients with type 1 diabetes. A
Structured education on diabetes self-monitoring reduces the risk of severe hypoglycemia, decreases psychological stress, and improves the patient's wellbeing. A
Any person at a high risk of hypoglycemia should carry glucagon on them. Family members and carers should be trained in the glucagon administration technique. E
Given the patient's consent, the nurse or midwife should encourage other individuals from the patient's environment to undergo education on providing assistance to a hypoglycemic patient. E

Hypoglycemia is an acute, life-threatening complication of diabetes. The International Hypoglycemia Study Group (2017) distinguishes three levels of hypoglycemia:

- level 1 – glucose alert level. Glucose level ≤ 70 mg/dL (≤ 3.9 mmol/L), which requires treatment with simple carbohydrates, and may require adjusting the dose of antihyperglycemic medication,
- level 2 – clinically significant hypoglycemia. Glucose level <54 mg/dL (<3.0 mmol/L), indicating clinically significant hypoglycemia,
- level 3 – severe hypoglycemia. No specific threshold glucose level, instead, it is defined as hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery [1].

Hypoglycemia management always depends on the patient's clinical situation. If the patient is unconscious, the European Resuscitation Council guidelines should be followed. Anyone providing assistance should be aware that loss of consciousness may also be caused by life-threatening conditions other than hypoglycemia.

Hypoglycemia risk factors:

- excessive doses of insulin and/or oral hypoglycemics,
- improper diet (missed meal, reduced carbohydrate intake),
- excessive, unplanned physical activity,
- alcohol use,
- attempt to quickly normalize glycated hemoglobin (HbA1c) levels,
- hypoglycemia unawareness,
- comorbidities (hypoalbuminemia, kidney failure, hyperthyroidism, hypothyroidism, adrenal insufficiency, eating disorders, cancer, septicemia, anemia, liver failure, heart failure),
- longer duration of diabetes, insulin therapy,
- low body mass index [2-3].

Management of hypoglycemia when the diabetic patient is conscious, cooperative, and able to swallow.

1. Measure blood glucose using a glucose meter (to confirm hypoglycemia).
2. Give 15 g of glucose orally, in the form of a glucose tablet, glucose solution, or glucose-sweetened drink.

Sublingual administration of liquid glucose causes a more pronounced blood glucose level increase than swallowing a sweetened beverage [4].

1. Measure blood glucose after 15 minutes to make sure that the intervention was effective and blood glucose levels are increasing (the "15/15" rule) [5].
2. If hypoglycemia persists, administer 15 g of glucose again and measure glycemia after 15 minutes, or half the glucose dose in cases of automatic insulin delivery via hybrid pumps [6].
3. Establish the cause of the hypoglycemia and the risk of recurrence.
4. If blood glucose levels are increasing, give the patient a sandwich (complex carbohydrates) or advance a meal planned for later, limit physical activity, and repeat the glucose measurement after 60 minutes.
5. If a diabetic patient shows symptoms indicative of hypoglycemia, but does not have a glucose meter, assume the hypoglycemia to be confirmed.
6. Record the hypoglycemic symptoms, measured glucose levels, and type and amount of carbohydrates given to the patient in his self-monitoring journal (also electronic).
7. Inform the diabetic patient that he must not exercise until all symptoms have subsided and his glucose levels have returned to normal.
8. Inform the patient's carers/relatives about the hypoglycemic episode.
9. Educate the patient and others in their environment on self-monitoring for hypoglycemia symptoms and on hypoglycemia management.
10. Always attempt to verify the cause of hypoglycemia and develop a strategy for its prevention with the patient.
11. Pay attention to controlling the insulin doses taken by the diabetic patient.
12. Develop a strategy for minimizing fear of hypoglycemia with the patient and his family.

Nursing management of hypoglycemia when the diabetic patient is unconscious, has impaired consciousness, or is unable to swallow.

Nursing management should be performed in line with the cardiopulmonary resuscitation guidelines of the European Resuscitation Council, physician's orders, and/or the locally applicable procedures for Rapid Response Teams.

1. When ordered by the physician, administer a 10-20% solution of glucose (0.2-0.5 g of glucose per

1 kg BW) intravenously. If there is a risk of another drop in blood glucose level, maintain the intravenous infusion of a 10% glucose solution, while monitoring glycemia [6].

2. Measure the blood glucose level using a glucose meter or another available method.
3. Observe the patient's physical status parameters.
4. Document all nursing interventions.
5. Establish the cause of hypoglycemia, assess the risk of recurrence, and continue management in accordance with the diagnosis.

In case of difficulty in peripheral intravenous cannulation, administer one of two glucagon formulations:

- 1 mg of glucagon for intramuscular or subcutaneous injection (0.5 mg in children weighing less than 25 kg or aged below 6-8 years; 1 mg in children weighing more than 25 kg or aged above 6-8 years) [7],
- 3 mg of nasal glucagon powder in diabetic patients aged 4 years and older [8].

Management of hypoglycemia in an unconscious diabetic patient in a community setting (home, workplace, school, public place, other)

- A. A witness of the incident should call an emergency service and follow the emergency dispatcher's instruction, if he has not completed first aid training.
- B. A witness of the incident who has completed first aid training should:
 1. Administer one of two glucagon formulations:
 - 1 mg of glucagon for intramuscular or subcutaneous injection (0.5 mg in children weighing less than 25 kg or aged below 6-8 years; 1 mg in children weighing more than 25 kg or aged above 6-8 years),
 - 3 mg of nasal glucagon powder may be administered in diabetic patients aged 4 years and older.
 2. Place the diabetic patient in the recovery position.
 3. Not give the patient anything to eat or drink.
 4. Perform a blood glucose level measurement using a glucose meter or use another available method of blood glucose level determination.
 5. Call an emergency service.
 6. Monitor the blood glucose level, breathing, and consciousness of the patient.
 7. Once the symptoms have subsided and the diabetic patient has regained consciousness, they must not undertake any exercise.
 8. Always attempt to establish the cause of hypoglycemia.
 9. Assistance from another individual is absolutely necessary, including observation for hypoglycemia recurrence.
 10. After a hypoglycemic episode with loss of consciousness and/or impaired consciousness, the patient must always consult a physician.

Glucagon administration in cases of hypoglycemia with loss of consciousness and/or impaired consciousness

1. A subcutaneous or intramuscular injection of glucagon at the appropriate dose typically increases glucose levels within 8-10 minutes.
2. Glucagon does not cross the placental barrier, and has no adverse effects towards the pregnancy or the health of the fetus or newborn. In breastfeeding mothers, very small amounts of glucagon are naturally released into the milk. Glucagon nasal powder may be used during pregnancy and breastfeeding [7-8].
3. Injectable glucagon should be stored at between 2°C and 8°C. It may be stored below 25°C for 18 months, subject to the expiration date. Protect from light [7].
4. Glucagon nasal powder in its intranasal dispenser must be stored under 30°C. The single-dose container should be stored in the shrink-wrap protected tube until it is needed for use, to protect it from moisture [8].
5. Store the glucagon in accordance with the manufacturer's instructions. The patient should always have glucagon on hand.
6. In patients with type 2 diabetes treated with sulfonylurea derivatives, glucagon administration is not contraindicated, but the patients require hospitalization due to the risk of hypoglycemia recurrence.
7. Contraindications to glucagon administration include:
 - non-pancreatic malignancies,
 - hypersensitivity to glucagon or lactose,
 - hypersensitivity to the active ingredient or any excipient,
 - insulinoma,
 - pheochromocytoma [7-8].

After alcohol consumption, glucagon may not be effective. Keep in mind that injected or nasally administered glucagon may not produce the intended therapeutic effect in patients who had fasted for a prolonged period; are hypothermic; have a low adrenalin concentration, adrenal insufficiency, chronic hypoglycemia (low blood glucose levels persisting over a long period), or low blood glucose level due to alcohol consumption; or have been diagnosed with a glucagon- or insulin-secreting tumor. In accordance with the summary of product characteristics, glucagon should not be administered to patients diagnosed with an adrenal tumor [7].

Preparation instructions for intramuscular or subcutaneous glucagon injections

1. Check the expiration date on the package.
2. The kit contains a glucagon vial and a syringe with a solution used to dilute the glucagon.
3. The glucagon may be injected subcutaneously or intramuscularly, preferably into the patient's buttock, arm, or thigh.
4. Remove the orange cap from the glucagon vial.
5. Inject all the solution from the syringe into the vial.
6. When the glucagon has fully dissolved in the solution, draw the mixture back into the syringe.
7. Children weighing less than 25 kg or aged below 6-8 years should be administered 0.5 mg (half the dose), while other patients should receive 1 mg of glucagon (full dose) [7].

Preparation instructions for glucagon nasal powder

Glucagon nasal powder is ready to use and does not need to be mixed or measured. The medication does not need to be inhaled. It is absorbed through the nasal mucosa.

1. Check the expiration date on the package.
2. Remove the shrink wrap by pulling on the red stripe.
3. Remove the single-dose container from the tube without pressing down the plunger.
4. Hold the single-dose container between your thumb and fingers.
5. Remember that the intranasal dispenser only contains a single dose of glucagon. It can be used only once.
6. Gently insert the tip of the single-dose container in one of the nostrils.
7. Push the plunger all the way in. The dose is complete when the green line is no longer showing [8].

Guidelines and notes for the treatment team

- Severe hypoglycemia requires the assistance of a third person.
- In patients treated with acarbose, give pure glucose orally.
- In patients with type 2 diabetes treated with insulin and sulfonylurea derivatives, prolonged hypoglycemic episodes may occur, sometimes requiring prolonged infusions of glucose solution.
- If glucagon administration is required in diabetic patients and in individuals under the influence of alcohol, hospitalization is necessary.
- Consider hospitalization whenever a severe hypoglycemic incident occurs.
- In patients undergoing intensive insulin therapy, using insulin analogs or a personal insulin pump, give 15 g of glucose orally and measure blood glucose levels after 15 minutes. If glucose levels remain low, repeat glucose administration and measure blood glucose levels after another 15 minutes (the "15/15" rule) [5-6,9]. In patients treated using a personal insulin pump, if oral administration of simple carbohydrates is not possible, discontinue insulin administration (stop and/or disconnect the pump), and perform a blood glucose measurement again.
- Duration of hypoglycemia in a diabetic patient may be shorter if real-time continuous glucose monitoring (real-time CGM) is used [10-12].
- The use of a continuous blood glucose monitoring system and self-monitoring may reduce the risk of hypoglycemic incidents in patients with type 1 diabetes [13-14].
- Structured education on diabetes self-monitoring reduces the risk of severe hypoglycemia, decreases psychological stress, and improves the patient's wellbeing [15-18].
- Any person at a high risk of hypoglycemia should carry glucagon on them. Family members and carers should be trained in the glucagon administration technique [5, 19].
- Given the patient's consent, the nurse or midwife should encourage other individuals from the patient's

environment to undergo education on providing assistance to a hypoglycemic patient [19].

- Repeat education on preventing hypoglycemia at each follow-up visit and hospitalization.
- Train the diabetic patient in self-monitoring for early signs of hypoglycemia, and in hypoglycemia prevention and management.
- Hypoglycemia can cause anxiety, reduce the quality of life for individuals with diabetes and their carers, and contribute to difficulties with self-management and diabetes treatment [20-23].
- Structured patient education on hypoglycemia prevention and treatment improves outcomes in managing this condition [24-25].

Guidelines for patients and carers

- Wear an identifier (wristband, emergency card, ICE card).
- The ICE card informs first responders who to contact in case of an accident or another emergency. Two common formats are used:
 - it is advisable to enter the phone number of a chosen person as an ICE contact in the address book of one's mobile phone. If there are multiple such individuals, they are designated as ICE 1, ICE 2, etc.
 - the full name and contact number of the person is written on a business-card sized piece of cardboard or plastic (an actual "ICE card"). The card should be carried on one's person, but not in the wallet.
- Always carry simple carbohydrates (glucose tablets, glucose solution) and an additional sandwich.
- Always carry glucagon (in the case of children with diabetes, the glucagon should be available on site: at their pre-school, school, kept by a trained member of the staff) [5-19].
- Always carry a glucose meter.

REFERENCES

1. International Hypoglycemia Study Group. Glucose concentrations of less than 3 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and European Association for the Study of Diabetes. *Diabetes Care*. 2017;40(1):155-157. <https://doi.org/10.2337/dc16-2215>
2. International Hypoglycemia Study Group. Minimizing hypoglycemia in diabetes. *Diabetes Care*. 2015;38(8):1583-1591. <https://doi.org/10.2337/dc15-0279>
3. Pratiwi C, Mokoagow MI, Made Khantia IA, et al. The risk factors of inpatient hypoglycemia: a systematic review. *Heliyon*. 2020;6(5):1-6. <https://doi.org/10.1016/j.heliyon.2020.e03913>
4. De Buck E, Borra V, Carlson JN, et al. First aid glucose administration routes for symptomatic hypoglycaemia. *Emergencias*. 2021;33(2):135-136. <https://doi.org/10.1002/14651858.CD013283.pub2>
5. American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes – 2025. *Diabetes Care*. 2025;48(Suppl.1):S128-S145. <https://doi.org/10.2337/dc25-S006>
6. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
7. Product leaflets and usage instructions: https://www.novonordisk.pl/content/dam/nncorp/pl/pl/pdfs/products/GlucaGen_ulotka_dla_pacjenta.pdf Accessed: 2025-06-19.
8. Package leaflet: https://ec.europa.eu/health/documents/community-register/2019/20191216146478/anx_146478_pl.pdf Accessed: 2025-06-15.
9. Sequist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a work group of the American Diabetes Association and the Endocrine Society. *Diabetes Care*. 2013;36(5):1384-1395. <https://doi.org/10.2337/dc12-2480>

10. Gimenez M, Tannen AJ, Reddy M, et al. Revisiting the relationships between measures of glycemic control and hypoglycemia in continuous glucose monitoring data sets. *Diabetes Care.* 2018;41(2):326-332. <https://doi.org/10.2337/dc17-1597>
11. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes. *Diabetes Care.* 2012;35(8):1638-1642. <https://doi.org/10.2337/dc11-1579>
12. Reddy M, Jugnee N, El Laboudi A, et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. *Diabet. Med.* 2018;35(4):483-490. <https://doi.org/10.1111/dm.13561>
13. Pratley RE, Kanapka LG, Rickels MR, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes a randomized clinical trial. *JAMA.* 2020;323(23): 2397-2406. <https://doi.org/10.1001/jama.2020.6928>
14. Hermanns N, Heinemann L, Freckmann G, et al. Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study. *J. Diabetes Sci. Technol.* 2019;13:636-644. <https://doi.org/10.1177/1932296819831695>
15. Chantal M. Minimising hypoglycaemia in the real world: the challenge of insulin. *Biabetologia.* 2021;64(5):978-984. <https://doi.org/10.1007/s00125-020-05354-7>
16. Hermanns N, Kulzer B, Krichbaum M, et al. Long-term effect of an education program (HypOPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. *Diabetes Care.* 2010;33(3):e36. <https://doi.org/10.2337/dc09-1656>
17. Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. *Diabetes Care.* 2015;38(6):1016-1029. <https://doi.org/10.2337/dc15-0090>
18. Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPASS). *Diabetes Care.* 2014;37(8):2114-2122. <https://doi.org/10.2337/dc15-0090>
19. Deeb LC, Dulude H, Guzman CB, et al. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. *Pediatr. Diabetes.* 2018;19(5):1007-1013. <https://doi.org/10.1111/pedi.12668>
20. Bloomfield HE, Greer N, Newman D, et al. Predictors and consequences of severe hypoglycemia in adults with diabetes – a systematic review of the evidence. Washington, DC, Department of Veterans Affairs, 2012.
21. Barendse S, Singh H, Frier BM, et al. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review. *Diabet. Med.* 2012;29:293-302. <https://doi.org/10.1111/j.1464-5491.2011.03416.x>
22. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. *Endocr. Pract.* 2013;19:792-799. <https://doi.org/10.4158/EP12382.0R>
23. Leiter LA, Boras D, Woo VC. Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. *Can. J. Diabetes.* 2014;38:38-44. <https://doi.org/10.1016/j.jcjd.2013.08.270>
24. Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. *Diabetes Care.* 2020;43:1636-1649. <https://doi.org/10.2337/dc20-0023>
25. LaManna J, Litchman ML, Dickinson JK, et al. Diabetes education impact on hypoglycemia outcomes: a systematic review of evidence and gaps in the literature. *Diabetes Educ.* 2019;45:349-369. <https://doi.org/10.1177/0145721719855931>

VII. REDUCING PERIOPERATIVE COMPLICATION RISK

Purpose: Preparing a diabetic patient for a surgical procedure.

Authorized individuals: nurse, midwife.

Tab. 8. Key recommendations. Reducing perioperative complication risk
Correct psychological and physical preparation of a diabetic patient for a surgical procedure reduces the risk of intraoperative and postoperative complications or acute complications of diabetes. E
Insulin administered by intravenous infusion should be used in accordance with the information leaflet. E
Infusion pump settings and the intravenous catheter insertion site should be checked at the beginning of each shift, during shift handover, and at every syringe/infusion line replacement. E

In diabetic patients, any surgical procedure carries more risk of life-threatening complications than in the general population. This risk increases particularly in patients with diabetes complications or with multiple risk factors, including coronary artery disease, history of myocardial infarction, or heart failure. In diabetic patients, as in the case of other patients, surgical procedures may be elective or emergent. It is recommended that a patient with diabetes be scheduled first on the operating list [1].

Perioperative management depends on the mode of admission (elective or emergency), type of diabetes, anti-hyperglycemic treatment used, and type of procedure [2-4]. Preparation of a diabetic patient for surgery and/or tests should include both psychological and physical preparation. The patient should be made aware that all the preparation activities reduce their complication risk.

Important components include hygienic preparation, and specifically dental care, treatment of skin inflammations, antibacterial bath before the procedure and on the day of the procedure, ongoing oral hygiene; as well as other preparations, e.g. protection against hypothermia during the procedure.

Blood glucose monitoring in surgical patients with diabetes reduces complication risk [5-9]. Recommended blood glucose targets in the perioperative period are 100-180 mg/dL [4].

Patients treated with insulin in the preoperative period should continue this type of treatment, whereas patients treated with oral antihyperglycemic agents in type 2 diabetes usually require temporary insulin therapy [4].

- Elective same-day surgery may be planned in patients treated with intensive insulin therapy, with good metabolic control, and in patients with type 2 diabetes who do not require temporary insulin treatment in the perioperative period, i.e. in patients who undergo minor surgeries that do not require any nutritional changes. In patients who are required to fast for >12 hours preoperatively, it is recommended to administer intravenous infusion of glucose-insulin-potassium solution.
- Major elective surgeries require hospitalization and treatment changes. In patients with type 2 diabetes treated with 2-3 antihyperglycemic medications, who will not be eating their meals on the day of the procedure, or who are being prepared to undergo major surgery with an increased risk of hemodynamic instability, it is recommended to administer temporary insulin therapy [4].

- Patients who use insulin pumps should continue their current treatment until the day of surgery.
- If preparation for surgery requires patients to follow a strict (nil by mouth) regimen on the day/days preceding the surgery, it is recommended to use intravenous infusion of 10% glucose solution with 12 units of short-acting (rapid-acting) insulin and 10 mmol of KCl instead of meal.
- On the day of the surgery, intravenous infusion of glucose, insulin, and potassium is used with glucose level monitoring:
 - in patients with absolute insulin deficiency, it is recommended to administer separate continuous intravenous infusion of insulin using infusion pumps. Solution concentration: 1 unit of short-acting human insulin in 1 mL 0.9% NaCl and 5-10% glucose solution,
 - in patients with type 2 diabetes and preserved insulin secretion, glucose, insulin, and potassium solution can optionally be administered: 500 mL of 10% glucose with 12–16 units of short-acting insulin and 10-20 mmol of KCl [4].

Intravenous insulin infusion preparation technique

1. Prepare the insulin solution for infusion with the following proportions: 1 unit of short-acting insulin/fast-acting insulin analog per 1 mL of 0.9% NaCl.
2. For instance, draw 50 units of short-acting insulin/fast-acting insulin analog, or 0.5 mL, into an insulin syringe (1 mL insulin syringe = 100 units, insulin concentration 100 units/mL).
3. Transfer the insulin to the 50 mL light-protected syringe used in the infusion pump. Add 49.5 mL of 0.9% NaCl up to 50 mL total, attach light-protected tubing, mix in a swinging motion, and manually remove air while filling the tubing.
4. For infants and small children, prepare a less concentrated insulin solution, e.g. 10 units in 20 mL (1 mL = 0.5 units), or even 2 units in 20 mL (1 mL = 0.1 units).
5. Depending on the type of infusion pump used, the syringe should be clearly marked with the date and time of preparation and the composition. For example: Concentration: 50 units of insulin in 50 mL.
6. Fit the syringe on the pump, making sure that the cylinder flange and base are firmly pressed in.

A diabetic patient should bring the following items to the hospital:

- glucose meter and test strips,
- insulin injectors and a supply of insulin,
- CGM system, if used,
- chronically used medication,
- infusion sets and insulin reservoirs for the insulin pump,
- spare batteries for the pump and glucose meter,
- self-monitoring journal,
- test results from before the hospitalization (medical records).

Guidelines for medical personnel

- Prepare medication as prescribed in writing by the physician.

- Check the insulin manufacturer's recommendations on the specific type of infusion pump to be used.
- The stability time for a solution with a given concentration is specified by the insulin manufacturer, in accordance with the summary of product characteristics.
- Insulin solutions should be protected against light (using light-protected syringes and tubing or by covering the system).
- If possible, the intravenous catheter used for the insulin infusion should not be used for administering any other medication (so as not to interfere with blood glucose monitoring).
- Use short-acting insulin or fast-acting insulin analogs for intravenous infusion.
- Check infusion pump settings and the intravenous catheter insertion site at the beginning of each shift, during shift handover, and at every syringe/infusion line replacement.
- During intravenous insulin infusion, it is recommended to monitor glucose level every 1 hour, and with a stable glucose level obtained in 3 consecutive measurements – every 2 hours [4].

Nursing personnel tasks, performed to increase diabetic patients' safety in the perioperative period, include [10-12]:

- monitoring the patient's vital signs and consciousness,
- monitoring blood glucose levels,
- monitoring fluid balance,
- examining the postoperative wound and dressing,
- keeping medical records,
- monitoring the patient for clinical symptoms indicative of acute diabetes complications (impaired consciousness, vomiting, increased thirst, polyuria, abdominal pain, dry mucous membranes, tachycardia, Kussmaul breathing, acetone smell in breath).

REFERENCES

1. Crowley K, Scanail PÓ, Hermanides J, et al. Current practice in the perioperative management of patients with diabetes mellitus: a narrative review. *Br. J. Anaesth.* 2023;131(2):242-252. <https://doi.org/10.1016/j.bja.2023.02.039>
2. Copanitsanou P, Dafogianni C, Iraklianou S. Perioperative management of adult patients with diabetes mellitus. *Int. J. Caring. Sci.* 2016;9(3):1167-1176.
3. Galway U, Chahar P, Schmidt MT, et al. Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery. *World J. Diabetes.* 2021;12(8):1255-1266. <https://doi.org/10.4239/wjd.v12.18.1255>
4. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
5. Kang ZQ, Huo JL, Zhai XJ. Effects of perioperative tight glycemic control on postoperative outcomes: a meta-analysis. *Endocr. Connect.* 2018;7(12):R316-R327. <https://doi.org/10.1530/EC-18-0231>
6. Boreland L, Scott-Hudson M, Hetherington K, et al. The effectiveness of tight glycemic control on decreasing surgical site infections and readmission rates in adult patients with diabetes undergoing cardiac surgery: a systematic review. *Heart Lung.* 2015;44:430e-440e. <https://doi.org/10.1016/j.hrtlng.2015.06.004>
7. Hweidi IM, Zytoo AM, Hayajneh AA. Tight glycaemic control and surgical site infections post cardiac surgery: a systematic review. *J. Wound Care.* 2021;30(Suppl.12):S22-S28. <https://doi.org/10.12968/jowc.2021.30.Sup12.S22>
8. Kotagal M, Symons RG, Hirsch IB, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. *Ann. Surg.* 2015;261:97-103. <https://doi.org/10.1097/SLA.0000000000000688>
9. Martin ET, Kaye KS, Knott C, et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. *Infect. Control. Hosp. Epidemiol.* 2016;37:88-99. <https://doi.org/10.1017/ice.2015.249>

10. Rutan L, Sommers K. Hyperglycemia as a risk factor in the perioperative patient. *AORN Journal*. 2012;95(3):352-61. <https://doi.org/10.1016/j.aorn.2011.06.010>
11. Talyancich O. Type 1 diabetes mellitus in the perioperative environment. *The Dissector*. 2021;49(2):33-37. <https://link.gale.com/apps/doc/A698648652/AONE?u=anon~557f441e&sid=googleScholar&xid=c232eb77>
12. Ayas NT, Jeklin AT, Tholin H, et al. Consecutive nursing shifts and the risk of hypoglycemia in critically ill patients who are receiving intravenous insulin: a multicenter study. *J. Clin. Sleep Med.* 2020;16(6):949-953. <https://doi.org/10.5664/jcsm.8382>

VIII. PREVENTION OF DIABETIC FOOT DISEASE

Purpose: Preparing the patient for self-monitoring and self-care of their feet, reducing the risk of developing diabetic foot disease, and examining the feet to identify patients at risk of amputation.

Authorized individuals: nurse, midwife.

■ Tab. 9. Key recommendations. Diabetic patient foot examination and care

Health care providers should perform foot examinations to identify diabetic patients at risk of lower extremity ulceration and amputation at least once a year, and more frequently in high risk patients. B
The examination should include assessment for neuropathy, skin lesions (e.g. calluses, ulcers, infection), peripheral artery disease (e.g. pulse and skin temperature), and structural abnormalities (e.g. range of motion in ankle and toe joints, bone deformities). B
All diabetes patients require basic education on foot self-examination and self-care. B
Diabetic patients at high risk of foot ulceration should be educated on foot care (including counseling on avoiding foot injury), and should be provided with professionally fitted footwear. B
If foot complications occur, the patient should be promptly referred to a health care professional trained in foot care. B

Foot self-examination and self-care is one of the basic preventive procedures in diabetic patients. Regular foot examination, as well as developing patients' ability to perform foot self-care, are key components that directly contribute to a lower risk of developing the so-called diabetic foot syndrome – diabetic foot disease and to better quality of life in diabetic patients [1].

Factors increasing the risk of foot ulcers or amputation:

- uncontrolled diabetes,
- peripheral neuropathy,
- smoking,
- foot deformities,
- hyperkeratosis, corns, calluses,
- peripheral vascular disease,
- history of foot ulcers,
- previous history of amputation,
- Charcot neuroarthropathy in the foot,
- mechanical injuries (abrasions and cuts caused by improper footwear, walking barefoot, or a foreign object in the shoe),
- thermal injuries (burns caused by direct exposure to high temperatures, e.g. hot water, heated sand, radiator),
- chemical injuries (chemical additives used in footwear production, application of foot care products containing exfoliating acids),
- improper foot care and neglect of foot hygiene (e.g. lack of or improper use of foot care products for nails and skin, such as creams and ointments not recommended

for individuals with diabetes, as well as absence of or inappropriate nail trimming, and removal of corns by the patient),

- impaired vision,
- chronic kidney disease (especially in patients on dialysis),
- social and economic factors (e.g. limited access to health care facilities, limited access to reimbursements, non-adherence to medical recommendations, low socioeconomic status, low level or lack of education).

Foot examination by medical personnel

In type 2 diabetes and adult type 1 diabetes patients, the foot exam should include the following components:

Assessment for neuropathy:

- Vibration sensation – the dysfunction of nerve fibers that transmit vibration sensation is an early symptom of diabetic neuropathy. The test is performed using a traditional calibrated tuning fork or a 128 Hz Rydel-Seiffer tuning fork to produce vibration.
- Pressure sensation – using a Semmes-Weinstein monofilament (5.07/10 g) to apply standardized pressure to the skin (10 g/cm²).
- Pain sensation test – using a sharply tipped Neurotip pin in the Neuropen.
- Temperature sensation – using a TIP-THERM device.
- Examination of deep tendon reflexes with a Tromner neurological reflex hammer.
- Assessment of peripheral neuropathy symptoms (burning, tingling, numbness – location, exacerbation and alleviation of symptoms) with NSS – Neuropathy Symptom Score.
- Assessment of the occurrence and/or exacerbation of pain during the day and night using NRS – Numeric Rating Scale [2-9].

In the field of early detection of lower limb ischemia:

- Pulse measurement includes: femoral and popliteal arteries and foot arteries (dorsalis pedis, posterior tibial and hallucal).
- Foot temperature examination – it should be performed symmetrically using a non-contact thermometer and compared with the tissues above the foot.
- Skin assessment for ischemia (thin, parchment-like, tight, shiny, cool, pale or bluish).
- ABI (ankle-brachial index) measurement.
- TBI (toe-brachial index) measurement [2-3,7-9].
- Transcutaneous oxygen pressure measurement – tcpO₂.

Assessment for the anatomy and function of the feet:

- Visual foot assessment for overload-related defects and changes (toes: hammer, mallet, claw toes; feet: pes cavus, planus, valgus, varus; big toe: hallux valgus, rigidus; hyperkeratoses: calluses, corns).
- Anthropometric measurements of the feet: Clarke's angle and the Wejsflog index measurements, static and dynamic foot imprinting, measurements with computer-assisted devices: podoscope with in-built camera, foot scanner, tensometric mats for measuring plantar pressure (these measurements allow for rapid detection of changes indicating structural degradation – increased contour and circumference of the foot, fallen arches) [7-9].

Assessment of skin and toenail condition:

- Toenail assessment for lesions (the observation allows for detecting bacterial or fungal toenail infections, ingrown nails, involuted nails, claw nails).
- Foot skin assessment for lesions (the observation allows for detecting fissures and cracks, viral, bacterial and fungal skin infections, calluses, injuries and wounds on the feet) [7-9].

Next, the patient should be classified into a risk group according to the classification system of the International Working Group on the Diabetic Foot (IWGDF) [10].

GROUP 0	no peripheral artery disease (PAD) and no loss of protective sensation (LOPS)	very low risk
GROUP 1	PAD or LOPS	low risk
GROUP 2	PAD and LOPS, or PAD and foot deformity, or LOPS and foot deformity	moderate risk
GROUP 3	PAD or LOPS and history of a foot ulcer, or a lower-extremity amputation or end-stage renal disease	high risk

A comprehensive foot treatment program includes patient education, regular foot examinations, and risk categorization for ulcer development. These actions contribute to a significant reduction in foot complications. Each diabetes care facility should implement a system for assessing the risk of diabetic foot disease, based on evaluating the condition of patients' feet in accordance with the frequency recommended by the IWGDF:

- GROUP 0 no traits of sensory neuropathy – check-up once a year.
- GROUP 1 traits of sensory neuropathy – check-up every 6 months.
- GROUP 2 traits of sensory neuropathy and symptoms of peripheral artery disease (PAD) and/or foot deformity – check-up every 3 months.
- GROUP 3 history of a foot ulcer – check-up every 1-3 months [10].

Education on diabetic foot prevention

Education aims at developing patients' health-related behaviors and motivating patients to comply with physicians' and nurses' recommendations regarding diabetes self-monitoring. Education is based on setting individual foot care goals, considering risk factors for diabetic foot syndrome development, including improper foot hygiene, improper footwear, and presence of calluses or foot deformities.

Lack of metabolic control of diabetes (resulting in advanced diabetic neuropathy and/or lower extremity ischemia) is also a significant contributor to diabetic foot syndrome development. Structured, organized, and recurrent education plays a major role in the prevention of foot ulcerations in diabetes.

A health care team member should provide structured education to patients, individually or in small groups, over several sessions, with regular reinforcement, using a variety of teaching methods. It is important to verify whether the diabetic patient (and optimally, every family member or carer) understands the purpose of education and is motivated to comply. Moreover, health care professionals who provide patient education should receive regular training themselves to enhance their skills in terms of care for patients at high risk of foot ulceration.

Individuals at higher risk of foot ulcers should learn to recognize the early symptoms and be aware of the necessary actions to take when problems arise [5,8]. All preventive measures should be initiated immediately upon the diagnosis of diabetes.

Scope of patient education

The scope of education provided by a nurse to a patient at risk of foot ulceration should include:

- Verifying whether the patient is able to perform a foot self-examination. If not, discuss who could assist him. Patients who have significantly impaired vision or are physically unable to examine their feet cannot properly perform self-monitoring.
- Explaining the need for daily examination of the entire surface of both feet, including the skin between the toes.
- Ensuring that the patient knows how to notify a health care professional if the measured foot temperature is elevated or if they notice blisters, cuts, scratches, or ulcers during a foot self-examination.
- Discussing the following practices with the patient:
 - avoiding walking barefoot, in socks but with no footware on, or in thin-soled slippers, both at home and outside,
 - avoiding footwear that is tight, has rough edges or protruding seams,
 - visually and manually checking the inside of footware before wearing it,
 - wearing seamless and non-binding socks and changing socks daily,
 - daily foot washing (always at a water temperature of 37°C) and careful drying of the interdigital spaces each time,
 - avoiding the use of radiators or hot water bottles to warm the feet,
 - avoiding the removal of calluses and corns by the patient with the use of sharp tools or pumice stones,
 - avoiding the removal of corns or calluses by the patient,
 - regularly trimming toenails straight across by filing,
 - principles of daily self-monitoring of the feet (the patient should immediately report any distressing symptoms to a nurse, physician) [8].

Scope of foot care

- Daily foot care.

Use of specialized products for daily foot care is recommended, including mild soaps with a pH of 5.5, clinically-tested foot skin and nail care products containing 10% or 25% of urea, and skin-neutral lipid products e.g. emollients. The composition should be selected based on the care problems observed in each individual patient. When selecting urea-containing products, consider the individual indications for each patient, as follows: 10%-urea foot care products for normal and thin skin, and 25%-urea products for dry skin with corns and calluses [11]. Feet should be washed in water below 37°C, for a short time: 2–3 minutes, after which they should be carefully dried, with particular attention to the skin between the toes.

- Foot care in case of hyperkeratosis and calluses.

Patients should not attempt to remove calluses on their feet manually using skin-cutting tools, pumice stones, or foot files, nor chemically with products containing substances such as salicylic acid. In case of difficulties in foot self-care, the patient should regularly visit a foot care specialist (podologist) or a nurse performing foot and nail care on a daily basis [8].

- Prevention of fungal infection.

This mainly includes following the general rules of proper foot hygiene and always carefully drying the feet and the skin between the toes after washing, as well as not leaving any foot care products on the skin between the toes. Pay particular attention to keeping skin between the toes clean and dry at all times. Wear protective footwear in swimming pools, saunas, physical therapy rooms and other places where the feet need to be protected against potential exposure to pathogenic fungi; only wear outdoor and indoor footwear and socks made from natural materials that ensure air flow to the skin and protect it from overheating. If necessary due to previous incidents of fungal foot or nail infection, use foot care products containing anti-fungal ingredients.

- Aseptic dressing of micro-injuries and minor skin injuries on the feet.

Patients are advised to have a personal first-aid kit containing an antiseptic agent, sterile gauze pads, and, in case of recurrent ulceration, specialized antibacterial dressings, a bandage, and adhesive tape. In case of ulceration in patients with diabetic foot syndrome, the wound healing process and the dressings applied by the patient should be assessed, and patients should be instructed on aseptic wound dressing technique and wound management at home.

- Socks.

It is recommended to use non-binding, seamless socks made from natural fibers – cotton, bamboo, or merino wool – along with active fibers that have an antifungal effect such as silver, algae, or chitin. Only individually-fitted insoles may be used.

- Toenail trimming.

Toenails should be trimmed once a month so as to ensure that the toe-tip is protected by the nail.

- Preparing feet for exercise.

Before engaging in physical activity, it is recommended for the patient to:

- have the condition of their feet assessed by medical personnel and have the training intensity adjusted to their abilities; examine the feet before and one hour after each training session to check for hematomas, skin abrasions, or nail injuries,
- gradually increase the intensity of physical activity,
- perform stretching exercises before training to enhance joint mobility and prevent injuries,
- choose and monitor the condition of footwear used for physical activity,
- make sure that footwear helps to redistribute pressure, especially in patients prone to injuries at the foot support points.

NOTE!

Starting increased physical activity should always be consulted with medical personnel. A foot care specialist will monitor the condition of the feet to prevent injuries and complications, provide guidance, and assist in selecting exercises based on the patient's risk group.

- Daily foot self-examination.

All signs of infection within the feet should be reported. If any alarming symptoms appear, e.g. inflammation, pain, redness, or blisters, the patient should immediately contact a diabetes specialist or primary care physician [8,12]. Patients who have difficulties in performing foot self-care and are unable to follow some basic hygiene practices, e.g. trim their toenails, can be referred to a foot care specialist (podologist).

- Selection of preventative footwear.

Diabetic patients should be reminded that their footwear needs to be adapted to the shape and function of the feet. Lack of sensation and ill-fitting footwear are one of the most common causes of neuropathic ulceration. Dynamic features of footwear are most important, as they change over time (new, used, worn out) and thus must be monitored in order to adjust the footwear or replace it with new one. The main purpose of footwear is to reduce plantar pressure below the threshold values that cause ulceration. Due to the high risk of skin damage in diabetic patients wearing preventative footwear, the latter should display the following features:

- inner upper and lining made from natural leather and padded heel counter,
- thicker flexible outsoles reducing pressure and allowing for unrestrained body weight shift from the heels to the toes when walking,
- footwear design must provide for full stability and amortization of the heel, as the heel bears the greatest load during the landing phase when walking,

- adequately wide and flexible vamp, preventing rubbing and pressure on the dorsal part of the foot, particularly recommended for patients with toe deformities,
- adequate size, well-fitting, but not too small and not too large; when using insoles, additional space is needed within the footwear,
- easy to put on and remove, best with flexible Velcro straps,
- fully enclosed, without inner seams and made from supple leather [4].
- footwear should be purchased in the afternoon, when the soft tissues of the feet may be slightly swollen, even in individuals who do not have diabetes. This rule helps prevent injuries caused by purchasing e.g. excessively tight footwear,
- in the early stages of foot deformities or tissue sensitivity to injuries, it is recommended to modify the patient's current footwear by e.g. using additional padding made of wool or cotton in areas of increased pressure or having the footwear professionally stretched by a shoemaker or orthopedic technician. In the case of significant deformities, it is recommended to use custom-made footwear.
- when patients use compression products, it is recommended to use those designed for individuals with diabetes with clinically proven efficacy.

Depending on the degree of foot deformity and the patient's activity level, footwear should be selected based on its fit to the shape of the feet and adequate lining, rather than biomechanical correction, to reduce the risk of injury. At different stages of the disease, patients can use various types of footwear as long as it does not lead to injuries or cause ulceration.

- Selection of therapeutic footwear.

If ulceration is not offloaded, it will not cure even with sufficient blood supply. Patients with ulceration should be instructed to limit walking to the minimum necessary and not to walk without appropriate offloading devices. Additional offloading can be achieved by instructing patients to use crutches, a walker or a wheelchair, depending on the degree of ulceration, or in most severe cases – to stay in bed 6,8.

- Use of insoles.

In-shoe orthoses called insoles are shaped in such a way as to be placed inside the footwear. The major principle of insole design is that it accommodates the foot, not the footwear. Therefore, it is necessary to allow for an adequately bigger size of the footwear, so that the insole can be placed in the shoe, or replace the insole in one's footwear with custom insole if possible.

Preventative and therapeutic function of insoles:

- maintaining correct foot placement,
- changing foot positioning,
- offloading the painful section of the foot,
- correcting deformations,

- changing the mobility range of the foot or its individual sections [4].

Insoles come in various shapes and forms, are used for preventative and therapeutic purposes, and can be classified as:

- **prefabricated** (orthotic inserts and pads, flat insoles, profiled insoles, and biomechanical orthotics); examples of orthotic inserts and pads include the commonly used metatarsal pads, corn cushions, longitudinal arch support orthotics, and heel cushions and cups; these are made from various materials such as felt, leather, silicone or polymer gel; a disadvantage of this type of solution is the difficulty in correct fitting,
- **custom** (accommodative and functional), functional insoles are most commonly used in the case of elastic deformations, which can be subjected to correction, and their role involves changing the way the foot comes in contact with the ground; accommodative insoles are usually used in the case of more stiff deformations, as they reduce pressure on the protruding osseous elements [4].

In young patients with newly diagnosed diabetes, with no symptoms of neuropathy and with the ligament-skeletal system preserving joint flexibility, custom functional insoles should be considered. Especially in patients already presenting signs of flat feet and/or forefoot deformities, like hallux valgus or hammer toe, claw toe, and mallet toe, who are at risk of calluses. This does not apply to patients with symptoms of neuropathy and/or considerable foot deformity, e.g. in the case of Charcot neuroarthropathy or after completed ulceration treatment in diabetic foot syndrome. In such cases, it is recommended to exclusively use accommodative insoles, whose purpose is to evenly distribute plantar pressure, preventing overload [4].

NOTE!

The use of ready-made products such as pads and various types of corrective insoles is not recommended for individuals with diabetes.

In children with diabetes:

- Education on proper foot care and signs of inflammation should start as soon as the disease is diagnosed, and education scope should be adjusted to the child's age. The purpose of such education is to minimize the adverse consequences of incorrect foot care and the lack of proper footwear while the motor system of the foot is developing.
- In children with diabetes under 12 years old, both the child and their guardians should be educated on basic foot care.
- Patients aged 12–17 years should have their feet screened annually by a pediatric diabetes care team, and should receive education on foot care. If a foot problem is identified or suspected, the pediatric care team should refer the young patient to the appropriate specialist.

Proper management of diabetic foot disease prevention should involve every patient as soon as they are diagnosed with diabetes. At the same time, an educational program should be implemented for patients already affected by this complication, with the aim of preventing further ulceration and limb amputation [10].

REFERENCES

1. Aalaa M, Tabatabaei Malazy O, Sanjari M, et al. Nurses' role in diabetic foot prevention and care; a review. *J. Diabetes Metab. Disord.* 2012;11:24. <https://doi.org/10.1186/2251-6581-11-24>
2. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes – 2025. *Diabetes Care.* 2025;48(Suppl.1):S252-S265. <https://doi.org/10.2337/dc25-S012>
3. Bus SA, Lavery LA, Monteiro Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update). *Diabetes Metab. Res. Rev.* 2020;36(S1):e3269. <https://doi.org/10.1002/dmrr.3269>
4. DiGiovanni ChW, Greisberg J. The foot and the talocrural joint. Wroclaw: Elsevier Urban & Partner; 2010, p. 18-31.
5. Klamczyńska M, Ciupińska M. Podology. Warsaw: PZWL; 2020, p. 258-279.
6. Levine D, Richard J, Whittle WM. Gait analysis. Wroclaw: Elsevier Urban & Partner; 2014, p. 87-90, 115-116, 181.
7. Diabetic foot problems: prevention and management. National Institute for Health and Care Excellence (NICE), 2023. Accessed: 2025-06-15. <https://www.ncbi.nlm.nih.gov/books/NBK53608/>
8. Rakowska B, Jawień A, Sopata M, et al. The organization of health care of patients with diabetic foot syndrome. Guidelines of Polish Wound Management Association. *Wound Treatment.* 2015;12(3):83-112. <https://doi.org/10.15374/LR20015011>
9. Schaper NC, van Netten JJ, Apelqvist J, et al. IWGDF Editorial Board. Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). *Diabetes Metab. Res. Rev.* 2020;36(S1):e3266. <https://doi.org/10.1002/dmrr.3266>
10. Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). *Health Technol Assess. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Health Technol. Assess.* 2015;19(57):1-210. <https://doi.org/10.3310/hta19570>
11. Young M, Townsend M, Hicks G. A photographic scale to aid appropriate foot skin care for people with diabetes. *Diab. Foot J.* 2015;3: 29-32.
12. Van Netten JJ, Price PE, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. *Diabetes Metab. Res. Rev.* 2016;32(1):84-98. <https://doi.org/10.1002/dmrr.2701>

IX. CARE SKIN HYGIENE IN INDIVIDUALS WITH DIABETES

Purpose: Assisting the patient and preparing them to maintain skin hygiene so as to reduce the risk of complications associated with skin dryness and itching.

Authorized individuals: nurse, midwife.

■ Tab. 10. Key recommendations. Skin hygiene in individuals with diabetes

Diabetic patients are at a higher risk of skin dryness and cornification. C
Patients' skin should be regularly examined. E
Use of urea-containing products and emollients reduces skin dryness in diabetic patients. The concentration of urea should be adjusted to the skin condition and care goals. B
Health education provided to diabetic patients with a low risk of foot ulceration improves their foot-care behaviors and reduces risk factors for ulceration: dry skin, corns, and calluses. C

If the skin examination shows dryness and itching, interventions should be undertaken to ensure proper skin care and hygiene to prevent further complications. Hyperglycemia and reduced insulin sensitivity may disturb epidermal homeostasis by decreasing hydration and weakening the function of sebaceous glands. Therefore, in almost all diabetic patients, the skin is excessively dry, sensitive, and prone to itching [1-3]. Dry skin is more susceptible to damage, irritation, and infection [4]. This produces a number of bothersome symptoms, such as redness, burning sensation, irritation, cracking, excessive peeling and cornification of the epidermis. As a result, patients experience chronic discomfort and tend to develop complications that may require a specialist's intervention.

Proper skin hygiene and self-care positively affects its overall condition and should be followed as a basic preventive procedure, contributing to better quality of life in diabetic patients.

Skin condition assessment by medical personnel

- Visual examination of the skin – to assess irritation, redness, peeling, coarseness, dryness on a simple 0-3 scale (0 – no irritation, 1 – slight irritation, 2 – moderate irritation, 3 – intense irritation).
- Examining hyperkeratosis and calluses on the feet.
- Increased dryness and thickening of the corneous layer of the epidermis are associated with increased risk of developing calluses on the feet. These processes may precede necrosis and lead to ulceration, a symptom of diabetic foot. Calluses are particularly often formed over bony prominences or protruding heads of the metatarsal bones. They are caused by increased plantar pressure in the area and foot skin dryness caused by diabetic neuropathy.
- The patient's subjective assessment of dryness, itching, and overall discomfort on a 0-3 scale (0 – no discomfort, 1 – slight discomfort, 2 – moderate discomfort, 3 – intense discomfort).

Education on prevention of complications associated with excessive skin dryness

Maintaining proper skin hygiene and hydration in diabetes is one of the easiest ways of preventing skin problems. Providing appropriate education as soon as the diabetes is diagnosed contributes to minimizing the cutaneous complications of the disease [5-6]. Education aims at developing patients' health-related behaviors and motivating patients to maintain skin hygiene by explaining its importance in diabetes. One important part of such education should involve explaining the rules for using individually-selected skin care products and moisturizers.

Guidelines for individuals with diabetes and carers

- Keep skin clean and dry. For daily care, use specialized moisturizing soaps that do not disturb the natural pH and hydrolipidic film of the skin. Diabetic patients should avoid drying and irritating products.
- Avoid hot baths – keep water temperature under 37°C. Wash your entire body within 5-7 minutes, and thoroughly dry your skin with no excessive rubbing. Dry skin folds and skin between the toes with particular care. Pay particular attention to keeping skin between the toes clean and dry at all times.
- Keep your skin moisturized and avoid scratching to prevent cracks and secondary bacterial or fungal infection.
- Dryness and itching prevention requires the patient to regularly use appropriate emollients, or topical products moisturizing and lubricating the skin. This accelerates the regeneration of the epidermal barrier, making the skin less sensitive to external factors [7-8].
- Daily care using emollients and products topically moisturizing and lubricating the skin not only strengthens the epidermal barrier by restoring adequate normal lipid levels, but also reduces dryness, peeling, eczema, bacterial and fungal infections, and itching [9].
- Emollients available on the market differ in composition. When selecting the appropriate product, consult a pharmacist and consider the diabetic patient's needs [10].
- Use of products containing various complementary moisturizing substances (including urea, natural oils and lipids) as well as nutrients, prebiotics, and vitamins is beneficial, contributing to the maintenance of proper hydration and reducing itchiness [3,11].
- To achieve the expected benefits of using appropriately selected topically moisturizing and lubricating products, use them regularly.

REFERENCES

1. Campos de Macedo GM, Nunes S, Barreto T. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. *Diabetol. Metab. Syndr.* 2016;8:63. <https://doi.org/10.1186/s13098-016-0176-y>
2. Fan L, Sidani S, Cooper-Brathwaite A, et al. Improving foot self-care knowledge, self-efficacy, and behaviors in patients with type 2 diabetes at low risk for foot ulceration: a pilot study. *Clin. Nurs. Res.* 2014;23(6):627-643. <https://doi.org/10.1177/1054773813491282>
3. Federici A, Federici G, Milani M. An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controlled trial. *BMC Dermatol.* 2012;12:16. <https://doi.org/10.1186/1471-5945-12-16>
4. Martini J, Huertas C, Turlier V, et al. Efficacy of an emollient cream in the treatment of xerosis in diabetic foot: a double-blind, randomized, vehicle-controlled clinical trial. *J. Eur. Acad. Dermatol. Venereol.* 2017;31(4):743-747. <https://doi.org/10.1111/jdv.14095>
5. Nguyen TPL, Edwards H, Do TND, et al. Effectiveness of a theory-based foot care education program (3STEPFUN) in improving foot self-care behaviours and foot risk factors for ulceration in people with type 2 diabetes. *Diabetes Res. Clin. Pract.* 2019;152:29-38. <https://doi.org/10.1016/j.diabres.2019.05.003>
6. Papanas N, Papazoglou D, Papatheodorou K, et al. Evaluation of a new foam to increase skin hydration of the foot in type 2 diabetes: a pilot study. *Int. Wound J.* 2011;8:297-300. <https://doi.org/10.1111/j.1742-481X.2011.00786.x>
7. Pham HT, Exelbert L, Segal-Owens AC, et al. A prospective, randomized, controlled double-blind study of a moisturizer for xerosis of the feet in patients with diabetes. *Stomach Wound Manage.* 2002;48:30-36.
8. Piérard GE, Seité S, Hermanns-Lê T, et al. The skin landscape in diabetes mellitus. Focus on dermocosmetic management. *Clin. Cosmet. Investig. Dermatol.* 2013;6:127-135. <https://doi.org/10.2147/CCID.S43141>
9. Polaskova J, Pavlackova J, Vlitasova P, et al. Moisturizing effect of topical cosmetic products applied to dry skin. *J. Cosmet. Sci.* 2013;64:329-340.
10. Seité S, Khemis A, Rougier A, et al. Importance of treatment of skin xerosis in diabetes. *J. Eur. Acad. Dermatol. Venereol.* 2011;25:607-609. <https://doi.org/10.1111/j.1468-3083.2010.03807.x>
11. Papanas N, Papazoglou D, Papatheodorou K, et al. Evaluation of a new foam to increase skin hydration of the foot in type 2 diabetes: a pilot study. *Int. Wound J.* 2011;8:297-300. <https://doi.org/10.1111/j.1742-481X.2011.00786.x>

X. PHYSICAL EXAMINATION OF THE SKIN AT SUBCUTANEOUS INSULIN INJECTION SITES IN PRIMARY AND SECONDARY PREVENTION OF LIPOHYPERTROPHY

Purpose: Performing the physical examination of the skin visually and by palpation for early identification of lipohypertrophy (LH) and monitoring of existing LH lesions

Individuals authorized to perform the procedure: nurse, midwife.

Multiple, subcutaneous injections of insulin (and of GLP-1 receptor analogues, increasingly used in Poland) may contribute to cutaneous complications in the injection site, including: LH – lipohypertrophy, atrophy, pain, bruises, minor bleeding [1-2]. What is significant in the clinical aspect is pain, due to the discomfort experienced by the patient, and lipohypertrophy, which is a subcutaneous tissue dysfunction that may affect blood glucose fluc-

tuations. Lipohypertrophy is described as adipose hypertrophy and edema and/or lumps of the adipose tissue in the subcutaneous insulin injection site. LH is also associated with changes in blood vessels and nerve fibers [1,3]. Insulin absorption may be impaired if it is injected in sites with LH [4-6]. To reduce the risk of cutaneous complications and the resulting impairment of the distribution of insulin and other medications to tissues, patients and their families/carers should be educated on the injection technique and preventative examination of injection sites [7-9].


■ Tab. 11. Key recommendations. Physical examination of the skin at subcutaneous insulin/ injection sites in primary and secondary prevention of lipohypertrophy
Lipohypertrophy is the most common skin lesion in patients using injectable insulin. C
Correct rotation of injection sites and correct use of needles are significant factors in LH prevention. B
Do not inject insulin into lipohypertrophic tissue. A
Insulin injection into lipohypertrophic tissue may contribute to blood glucose level fluctuations. C
Single use of needles is associated with a lower risk of lipohypertrophy. A
Insulin injection sites should be examined by medical personnel at each visit, depending on the type of insulin therapy, at a minimum once every 6-12 months. E
Physical examination of skin for LH and other complications associated with subcutaneous injection should also be performed in patients treated with medications other than insulin. E
The nurse/midwife should educate diabetic patients and their families/carers on the principles of LH prevention and self-examination of injection sites. E
To reduce the risk of cutaneous complications and the resulting impairment of the distribution of insulin and other medications to tissues, patients and their families/carers should be educated on the injection technique and preventative examination of injection sites. A

Examination technique

1. Prepare the room and equipment. The examination is best performed in a room with a temperature of 20-25°C, with both overhead and oblique lighting (at a 35-40 degree angle) [10-12]. Using a gel, e.g. ultrasound gel, is recommended.
2. Explain the purpose and procedure of the examination to the patient (carer, accompanying person) and obtain his consent [13].
3. Take the patient's history, including information on the course of diabetes, insulin injection technique, type(s) of insulin used, injection site self-examination.
4. Perform physical examination, including:
 - Visual examination of the skin at insulin injection sites, using both overhead and oblique lighting [9]. The following components of skin condition should be examined: color (overall, local discolorations), tension, integrity; presence and condition of scars, wounds, birthmarks; course and condition of subcutaneous blood vessels; discharge – presence, volume, color, odor, consistency; hair; tattoos and piercings; lipohypertrophy symptoms[9,12] – change in skin surface, mounds or areas of raised skin due to hypertrophic subcutaneous tissue at and around injection sites.
 - Palpation:
 - The nurse or midwife applies warmed gel to the examined skin surfaces (insulin injection areas), except for sites where tissue integrity is broken (e.g. grazed skin, wounds). Particular attention should be paid to avoid lesions associated with discharge, suspect cancerous lesions, areas of inflammation or allergy, and scars.
 - The nurse or midwife then places three fingers (index, middle, and ring finger) on the patient's skin, parallel to its surface. Maintaining soft pressure, the nurse or midwife palpates the skin along parallel lines, in a slight circular motion [9-10] (fig. 2).
 - During the palpation exam, the patient should be observed for any reaction to the touch, and asked

about discomfort or pain. If the patient experiences pain, its intensity should be evaluated using a pain scale.

- Follow the above procedure for each insulin injection area, either potential or indicated by the patient.
- If abnormal subcutaneous tissue is detected, the nurse should attempt to lift a fold of skin with subcutaneous tissue. Tissue resistance to fold lifting, tissue consistency within the fold, and the patient's experience during fold lifting are assessed [9,11].



■ Fig 2. Line of palpation examination of insulin injection areas

Source: own development Tobiasz-Kałkun N.

Guidelines for medical personnel

- Nurses and midwives are qualified to perform physical examinations of patients' skin in primary and secondary prevention of cutaneous complications of insulin injection (lipohypertrophy), under the Polish Minister for Health Regulation of February 28, 2017 on the type and scope of preventive, diagnostic, therapeutic, and rehabilitation services performed independently by a nurse or midwife without a physician's orders (Journal of Laws: Dz. U. 2017 item 497). Specific requirements are listed in section 3(2) [14].
- Physical examination of the skin should also be performed at sites used for continuous glucose monitoring system (CGM or FGM) sensor insertion or capillary blood sampling for measurement using a glucose meter.
- The examination should be performed at least once every 6 months, depending on injection frequency (excessively frequent examination, several times a month, does not increase the rate of lesion detection) [12].
- Do not palpate the injection sites immediately after insulin injection, as this may cause the medication to leak [12].
- Ultrasound gel is recommended [12], use of oils should be avoided to prevent permanent staining of the patient's clothing.
- The examination and its results should be documented (including description and pictures of the lesions and their locations).
- Verify and improve the patient's/carer's injection technique, specifically including remembering the most recent and previous injection sites, rotation procedure, needle replacement [15].
- In case of doubt as to the nature of any identified lesion, a more experienced nurse or midwife (and/or a physician) should be consulted [16].

²Examination technique is beyond the scope of the present procedure.

Guidelines for patients and carers

- Follow the correct technique for subcutaneous insulin injections (in the prevention of cutaneous complications of insulin injection, particular attention should be paid to rotating injection sites and areas, and changing needles) [7,10,14].
- Injection sites should be examined for LH regularly, every 6 months, but not immediately after an insulin injection [12].
- Sites used for subcutaneous insertion of glucose monitoring sensors and capillary blood sampling for measurement using a glucose meter should be examined as well.
- All abnormalities identified during an examination should be consulted with nurse/midwife/diabetes educator.
- Never inject insulin into sites with any pathological lesions [12].
- When the insulin injection area is changed, the insulin dosage may need to be modified [15,17-18].

REFERENCES

1. Barola A, Tiwari P, Bhansali A, et al. Insulin-related lipohypertrophy: lipogenic action or tissue trauma? *Front. Endocrinol. (Lausanne)*. 2018;9:638. <https://doi.org/10.3389/fendo.2018.00638>
2. Gentile S, Guarino G, Della Corte T. AMD-OSDI Study Group. Bruising: A neglected, though patient-relevant complication of insulin injections coming to light from a real-life nationwide survey. *Diabetes Ther.* 2021;12(4):1143-1157. <https://doi.org/10.1007/s13300-021-01026-w>
3. Hashem R, Mulnier H, Ghazaleh HA, et al. Characteristics and morphology of lipohypertrophic lesions in adults with type 1 diabetes with ultrasound screening: an exploratory observational study. *BMJ Open Diabetes Res. Care.* 2021;9(2):1-9. <https://doi.org/10.1136/bmjdrc-2021-002553>
4. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. *Br. Med. J.* 2003;327(7411):383-384. <https://doi.org/10.1136/bmj.327.7411.383>
5. Gupta SS, Gupta KS, Gathe SS, et al. Clinical implications of lipohypertrophy among people with type 1 diabetes in India. *Diabetes Technol. Ther.* 2018;20(7):483-491. <https://doi.org/10.1089/dia.2018.0074>
6. Ariza-Andraca CR, Altamirano-Bustamante E, Frati-Munari AC, et al. Delayed insulin absorption due to subcutaneous edema. *Arch. Invest. Med.* 1991;22:229-233.
7. Gentile S, Guarino G, Della Corte T, et al. AMD-OSDI Study Group on Injection Technique, Nefrocenter Research and Nyx Start-Up. Role of structured education in reducing lypodistrophy and its metabolic complications in insulin-treated people with type 2 diabetes: a randomized multicenter case-control study. *Diabetes Ther.* 2021;12(5):1379-1398. <https://doi.org/10.1007/s13300-021-01006-0>
8. Barnard-Kelly KD, Mahoney E, Baccari L, et al. Injection technique: development of a novel questionnaire and user guide. *Diabetes Spectr.* 2021;34(2):156-165. <https://doi.org/10.2337/ds20-0054>
9. Campinos C, Le Floch JP, Petit C, et al. An effective intervention for diabetic lipohypertrophy: results of a randomized, controlled, prospective multicenter study in France. *Diabetes Technol. Ther.* 2017;19:623-632. <https://doi.org/10.1089/dia.2017.0165>
10. Gentile S, Strollo F, Guarino G, et al. Factors hindering correct identification of unapparent lipohypertrophy. *J. Diabetes Metab. Disord. Control.* 2016;3(2):42-47. <https://doi.org/10.15406/jdmdc.2016.03.00065>
11. Gentile S, Guarino G, Guida P, et al. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. *Springerplus.* 2016;5(5):563-570. <https://doi.org/10.1186/s40064-016-1978-y>
12. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. *Mayo Clin. Proc.* 2016;91(9):1231-1255. <https://doi.org/10.1016/j.mayocp.2016.06.010>
13. Frid AH, Hirsch LJ, Menchior AR, et al. Worldwide injection technique questionnaire study: injecting complications and the role of the professional. *Mayo Clin. Proc.* 2016;91(9):1224-1230. <https://doi.org/10.1016/j.mayocp.2016.06.012>
14. Regulation of the Minister of Health of February 28, 2017 on the kind and scope of preventive, diagnostic, treatment, and rehabilitation services provided by a nurse or midwife independently, without a medical order (Journal of Laws 2017, item 497).
15. Chen L, Xing Q, Li J, et al. Injection technique education in patients with diabetes injecting insulin into areas of lipohypertrophy: a randomized controlled trial. *Diabetes Ther.* 2021;12 (3):813-826. <https://doi.org/10.1007/s13300-021-01013-1>
16. Shen M, Shi Y, Zheng S, et al. Systematic survey of physicians' insights into lipohypertrophy. *Front. Public Health.* 2021;23(9):738179. <https://doi.org/10.3389/fpubh.2021.738179>
17. Young RJ, Hannan WJ, Frier BM, et al. Diabetic lipohypertrophy delays insulin absorption. *Diabetes Care.* 1984;7:479-480. <https://doi.org/10.2337/diacare.7.5.479>
18. Ji L, Sun Z, Li Q, et al. Lipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact. *Diabetes Technol. Ther.* 2017;19(1):61-67. <https://doi.org/10.1089/dia.2016.0334>

XI. ORAL GLUCOSE TOLERANCE TEST (OGTT)

Purpose: Correct performance of an oral glucose tolerance test (OGTT).

Individuals authorized to perform the test: nurse, midwife.

■ Tab. 12. Key recommendations. Oral glucose tolerance test (OGTT)

Patient preparation for the OGTT is among the factors that affect its diagnostic value. The nurse/midwife should instruct the patient on how to prepare for the oral glucose tolerance test and what to do during and after the test. **E**

Nurses and midwives should instruct women diagnosed with gestational diabetes mellitus to undergo screening for diabetes once a year. **E**

In an OGTT, the patient drinks a solution of glucose in water. Then, glucose levels in venous blood plasma are measured strictly in accordance with the test protocol. The results reflect the mechanism of glucose level regulation in the patient's body. The test is used for diagnosis of glucose metabolism disorders, and for early diagnosis of prediabetes and all types of diabetes. The test involves administering glucose to the patient and observing his reaction, specifically insulin release, rate of blood glucose level regulation, and rate of glucose absorption in the tissue [1].

Preparation

- The patient is informed by the referring physician that they should fast overnight and that any medication which could increase blood glucose levels (such as glucocorticoids, diuretics, beta-blockers, L-thyroxine) should only be taken once the test is completed. This means that the patient should not eat anything for at least 8 hours, and may only drink water. For at least 3 days before the test, the patient should not modify his diet, lifestyle, or amount of exercise [2-6].
- In the pre-test interview, the nurse/midwife makes sure the patient is correctly prepared.
- Before the test, the patient should always be informed by the nurse/midwife that he may experience some pain during blood sampling, and that nausea and dizziness may occur after drinking the glucose solution.

Test technique

The test must be conducted under strict aseptic and antiseptic conditions.

1. For adults, dissolve 75 g of odorless glucose in 250 ml of boiled water (for children, the dose is 1.75 g

of glucose per kg of body weight, with a maximum dose of 75 g).

2. Obtain a venous blood sample to establish a fasting baseline for glucose levels, as well as for other diagnostic markers, such as insulin or plasma C-peptide, as directed by the physician.
3. Verify fasting blood glucose levels using a glucometer before proceeding with the Oral Glucose Tolerance Test (OGTT), ensuring that the levels are within a safe range.
4. Instruct the patient to consume the glucose solution within 5 minutes.
5. After consuming the solution, and for the duration of the test, the patient must remain seated.
6. The patient may experience symptoms such as nausea, sweating, or dizziness after drinking the glucose solution.
7. If the patient vomits after consuming the solution, the test must be immediately discontinued, and the physician informed.
8. Venous blood samples are to be collected at 0 and 120 minutes, as specified by the physician.
9. The patient must refrain from eating, physical exertion, smoking, or taking any medications until all required samples have been collected.
10. Additionally, no intravenous infusions should be administered until all subsequent samples have been obtained.

Note!

- Blood samples are drawn in accordance with the physician's orders and referrals.
- In pregnant women, the test is performed using 75 g of glucose, during week 24-28 of the pregnancy, and blood glucose is measured at 0 (fasting baseline), 60 and 120 minutes. T0 is the time of venous blood sampling for the fasting baseline.

- In patients after bariatric surgery (gastrectomy or gastric bypass), oral administration of glucose causes it to reach the intestine too rapidly, resulting in dumping syndrome and associated hypoglycemia [4].
- Patients may be referred for an OGTT by a physician or authorized nurse or midwife after a physical examination.
- Checking fasting blood glucose levels before performing an Oral Glucose Tolerance Test (OGTT) is critical for diagnostic safety, especially when screening for diabetes. Fasting blood glucose concentration exceeding 7.0 mmol/L – in such cases, administering a glucose solution during the test may lead to dangerously high blood glucose levels posing a health risk [7-8].

REFERENCES

1. Bogdanet D, O'Shea P, Lyons C, et al. The oral glucose tolerance test – is it time for a change? – A literature review with an emphasis on pregnancy. *J. Clin. Med.* 2020;9(11):3451:1-22. <https://doi.org/10.3390/jcm9113451>
2. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes – 2025. *Diabetes Care.* 2025;48(Suppl.1):S27-S49. <https://doi.org/10.2337/dc25-S002>
3. Management of type 2 diabetes: A handbook for general practice. The Royal Australian College of General Practitioners. East Melbourne, Vic: RACGP, 2020.
4. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
5. Scarpellini E, Arts J, Karamanolis G, et al. International consensus on the diagnosis and management of dumping syndrome. *Nat. Rev. Endocrinol.* 2020;16(8):448-466. <https://doi.org/10.1038/s41574-020-0357-5>
6. Jagannathan R, Neves JS, Dorcely B, et al. The oral glucose tolerance test: 100 years later. *Diabetes Metab. Syndr. Obes.* 2020;13:3787-3805. <https://doi.org/10.2147/DMSO.S246062>
7. Standardization of the oral glucose tolerance test. Report of the Committee on Statistics of the American Diabetes Association June 14, 1968. *Diabetes.* 1969;18 (5):299-307. <https://doi.org/10.2337/diab.18.5.299>
8. Regulation of the Minister of Health of January 18, 2018 on the list of active ingredients contained in drugs, foodstuffs intended for particular nutritional use and medical devices prescribed by nurses and midwives and the list of diagnostic tests which nurses and midwives are authorized to issue referral for (Journal of Laws 2018. 299).

XII. MEASUREMENT OF THE LEVEL OF KETONE BODIES IN CAPILLARY BLOOD USING A GLUCOSE METER

Purpose: Measurement of the level of ketone bodies in capillary blood using a glucose meter, whose results form the basis for monitoring the symptoms of diabetic ketoacidosis.

Individuals authorized to perform the measurement: nurse, midwife.

■ Tab. 13. Key recommendations. Measurement of the level of ketone bodies in capillary blood using a glucose meter

In diabetes, the lack or deficiency of insulin may cause severe metabolic disorders, including diabetic ketoacidosis. The patient should be educated on the principles and technique of measuring the level of ketone bodies in capillary blood using a glucose meter. **E**

Metabolic disorders in diabetes are characterized by hyperglycemia. Therefore, one should monitor the levels of both glucose and ketone bodies in capillary blood. **A**

A reliable and relevant reading of the level of ketone bodies in capillary blood is possible to obtain only if one follows the instructions provided in the manual for the glucose meter used for the measurement. **E**

Diabetic ketoacidosis (DKA) is an acute complication of diabetes, posing a direct life-threatening risk. The diagnosis of DKA is based on:

- Assessment of the patient's level of consciousness,
- Hyperglycemia (glucose > 11 mmol/l or > 200 mg/dl) or known diabetes,
- pH < 7.3,
- $\text{HCO}_3^- < 18 \text{ mmol/l}$,
- Ketonemia > 3.0 mmol/l or high ketonuria [1].

Ketone bodies are produced in the liver by the breakdown of fatty acids as a source of energy during periods of caloric restriction, physical effort and in individuals with insulin deficiency. Their presence in the blood of diabetic patients might indicate the risk of diabetic ketoacidosis. Ketone bodies are formed when insulin level is too low

to prevent lipolysis [1]. The presence of ketone bodies in the blood is called **ketonemia**. Capillary blood β -hydroxybutyrate testing is recommended for detecting the level of ketone bodies. The measurement should be performed **in the morning, on an empty stomach, at least 12 h** after the last meal, which allows for obtaining the most reliable result. The test should be repeated 2-3 hours after having a meal [2]. Viral infection in diabetic patients, just like any acute inflammation, may lead to an abrupt increase in blood glucose and increases the risk of DKA, especially in patients with type 1 diabetes [3-4].

Suspicion of DKA is an absolute indication for hospital admission. Therefore, it is important to monitor the level of ketone bodies in capillary blood using a glucose meter, as it allows for taking immediate therapeutic actions. The nurse/midwife should educate the patient/patient's carer about the principles of DKA prevention and rules to be followed when DKA symptoms occur, and situations in which the patient should measure the level of ketone bodies in capillary blood. These include: symptoms of infection, malaise or capillary blood glucose level above 200 mg/dl in the case of type 1 diabetes and above 300 mg/dl in the case of type 2 diabetes [4]. The results of ketone body level measurement determine the management in hyperglycemia and prevention or treatment of diabetic ketoacidosis [5].

Technique of measuring the level of ketone bodies in capillary blood using a glucose meter [5-12]

1. Perform the measurement in accordance with the instruction manual for the glucose meter and test strips.
2. Check the expiration date on the test strip and use it immediately after removing it from the package.
3. Test strips should not be used if the container is damaged or improperly sealed.
4. Perform hygienic handwashing and instruct the patient that in the house setting he should thoroughly wash his hands with warm water and soap, and then dry them well.
5. In health care facilities, disinfect the skin in the capillary puncture blood collection site before measuring the level of ketone bodies in capillary blood using a glucose meter.
6. In adults, the fingertip is typically the preferred site for capillary blood sampling. To measure the level of ketone bodies in capillary blood, you should only use blood samples collected from a fingertip.
7. When performing 2 measurements at the same time (glucose and ketone bodies), collect blood samples **from two different fingers!**
8. Use a disposable finger-prick for sampling and transfer the blood sample onto the test strip.
9. Having checked the result, remove and dispose of the used strip in accordance with the applicable procedure of handling medical waste.
10. Record the result after completing the test [6].

Instruments measuring ketone bodies in capillary blood and in urine using test strips detect different ketone bodies and the results obtained are not interchangeable [2]. The measurement performed in capillary blood detects β -hydroxybutyrate, and in urine – acetoacetate. Table 2 shows how to interpret the results of the measurement of the level of ketone bodies in capillary blood and in urine [8].

■ Tab. 14. Comparison of the level of ketone bodies in capillary blood and urine

Level of ketone bodies in capillary blood	Level of ketone bodies in urine	Result interpretation
Below 1.5 mmol/l	negative	It is recommended to measure the level of ketone bodies in capillary blood at least every 4-6 hours.
1.6 to 2.9 mmol/l	+or++	Increased risk of DKA. It is necessary to measure the levels of glucose and ketone bodies in capillary blood every 2 hours.
Above 3.0 mmol/l	+++or++++	High risk of DKA. Contact your diabetes team/GP/closest emergency medical care facility.

Source: Own work based on [1-13].

REFERENCES

1. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. Curr. Top. Diabet. 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
2. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes – 2025. Diabetes Care. 2025;48(Suppl.1):S59-S85. <https://doi.org/10.2337/dc25-S004>
3. Kilpatrick ES, Butler AE, Ostlundh L, et al. Erratum. Controversies around the measurement of blood ketones to diagnose and manage diabetic ketoacidosis. Diabetes Care. 2022;45(6):1490. <https://doi.org/10.2337/dc22-er06a>
4. Szewczyk A, Tobiasz-Kałkun N, Stefanowicz-Bielska A, et al. Practical guidelines for nursing and midwifery diabetes care – 2020. A position of the Polish Federation for Education in Diabetology. Pielęg. XXI wieku. 2020;3(72): 184-207. <https://doi.org/10.2478/pielxxi-2020-0022>
5. Song C, Dhaliwal S, Bapat P, et al. Capillary blood ketone level and the prediction of future diabetic ketoacidosis risk in type 1 diabetes. Diabetes Care. 2023;72(Suppl.1):S30-P. <https://doi.org/10.2337/dc23-0840>
6. Optium Xido Neo. Blood glucose monitoring system. User guide. Accessed: 2025-06-03. https://freestyleserver.com/Payloads/IFU/2024/q3/ART47206-001_rev-B-web.pdf
7. Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020;63:1530-1541. <https://doi.org/10.1007/s00125-020-05152-1>
8. Alonso GT, Coakley A, Pyle L, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017. Diabetes Care. 2020;43:117-121. <https://doi.org/10.2337/dc19-0428>
9. Aye T, Mazaika PK, Mauras N, et al. Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care. 2019;42:443-449. <https://doi.org/10.2337/dc18-1405>
10. Kościelniak-Merak B, Tomasiak P. Parameters useful when diagnosing metabolic acidosis – anion gap, osmol gap and bicarbonate gap. Practical Medicine. Pediatrics. 2016;3:97-107.
11. Ho J, Rosolowsky E, Pacaud D, et al. Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic. Pediatr. Diabetes. 2021;22(4):552-557. <https://doi.org/10.1111/pedi.13205>
12. Szypowska A, Ramotowska A, Grzechnik-Gryziak M, et al. High frequency of diabetic ketoacidosis in children with newly diagnosed type 1 diabetes. J. Diabetes Res. 2016;1(5):298-300. <https://doi.org/10.1155/2016/9582793>
13. NICE 2021. Terms and conditions. Notice of rights. Accessed: 2025-06-07. <https://www.nice.org.uk/terms-and-conditions#notice-of-rights>

XIII. DETERMINATION OF KETONE BODY AND GLUCOSE LEVELS IN URINE

Purpose: Determination of ketone body and glucose levels in urine, which serve as the basis for monitoring the symptoms of diabetic ketoacidosis.

Individuals authorized to perform the measurement: nurse, midwife.

■ **Tab. 15. Key recommendations. Determination of ketone body and glucose levels in urine**

In diabetes, the lack or deficiency of insulin may cause severe metabolic disorders, including diabetic ketoacidosis. The patient should be educated on the principles and technique of measuring the urinary levels of ketone bodies and glucose. **E**

Metabolic disorders in diabetes are accompanied by hyperglycemia, which is why the levels of glucose and ketone bodies in urine should be monitored simultaneously. **A**

A reliable and accurate result for ketone body and glucose levels in urine can only be obtained by following the instructions provided in the user manual of the diagnostic tests used for their determination. **E**

Hyperglycemia can be detected with a glucose urine test. Normal urine should not contain glucose or ketone bodies [1].

Note! Remember that in the case of reagent test strips, the detection threshold for glucose in urine is **50 mg/dl** [1].

Glucosuria occurs when the renal threshold for glucose (RTG) is exceeded. In the majority of people with normal renal function, RTG is about 180-200 mg/dl (about 150 mg/dl in pregnant women) [2]. According to the reference range, **ketone bodies** should not be present in urine. In diabetic patients, the presence of ketone bodies may indicate inadequate diabetes treatment or diabetic ketoacidosis, usually accompanied by intense hyperglycemia.

Ketonuria may also point to:

- starvation lasting more than 10 hours,
- excessive physical effort,
- use of ketogenic diets [3].

In cases listed above, intense hyperglycemia is usually not diagnosed [4]. The patient/patient's carer should be informed that indications for measuring the urinary level of ketone bodies as part of self-monitoring are as follows: infection, fever, vomiting, pregnancy, periods of starvation [5].

Technique of measuring the levels of ketone bodies and glucose in urine [6-10]

1. Collect a 30 ml sample of urine into a clean dry container.
2. Follow the instruction manual for test strips.
3. Perform hygienic handwashing, check the expiration date on the test strips, open the package and remove one test strip holding it by the plastic ending; do not touch the reagent area of the test strip.

4. Immerse the reagent area of the strip in urine and take it up immediately. To remove the excess urine, run the edge of the strip against the rim of the container with urine.
5. After dipping, wait for the exact time specified in the manufacturer's instruction manual and read the **level of ketone bodies** comparing the result on the strip with the color chart on the package.
6. Next, follow the instruction manual as to the exact time you need to wait after dipping and read the level of glucose comparing the result on the strip with the color chart on the package.

NOTE! It is necessary to follow the manufacturer's instructions as to the total waiting time. Changes in the reagent area color beyond the time specified should be ignored.

7. Having read the result, dispose of the used strip and urine container in accordance with the applicable procedure of handling medical waste.
8. Record the obtained results.

Test strip storage conditions [6-10]

To preserve proper quality of the test strips, closely follow the directions provided by the manufacturer:

1. Do not touch the reagent area with your finger or with any object before the test.
2. The strips should be stored at a room temperature between 15°C-30°C (59°-86° F).
3. To preserve unchanged activity of the reagent contained in the test strip, avoid exposing the bottle with test strips to direct sunlight, moisture and heat.
4. Discolored or darkened reagent area may indicate poor quality of the test. If the reagent area of the strip is discolored or darkened, toss this strip and take a new one from the packaging.
5. Test strips which are not being used should be stored in the original packaging with a tightly sealed cap.
6. Promptly replace the cap tightly each time you take out a strip.
7. Never put the test strips into another packaging.
8. Do not remove the drying agent from the bottle. The drying agent absorbs moisture and keeps the test strips dry.

REFERENCES

1. Kościelniak-Merak B, Tomasiak P. Parameters useful when diagnosing metabolic acidosis – anion gap, osmol gap and bicarbonate gap. *Practical Medicine. Pediatrics.* 2016;3:97-107.
2. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. *The position of Diabetes Poland – 2025. Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>

3. Lim K, Kang M, Park J. Association between fasting ketonuria and advanced liver fibrosis in non-alcoholic fatty liver disease patients without prediabetes and diabetes mellitus. *Nutrients*. 2021;13(10):3400. <https://doi.org/10.3390/nu13103400>
4. Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. *Diabetes Care*. 2018;41:1870-1877. <https://doi.org/10.2337/dc17-1583>
5. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes—2025. *Diabetes Care*. 2025;48(Suppl.1):S59-S85. <https://doi.org/10.2337/dc25-S004>
6. Hermanides J, Wentholt IM, Hart AA, et al. No apparent local effect of insulin on microdialysis continuous glucose – monitoring measurements. *Diabetes Care*. 2008;31(6):1120-1123. <https://doi.org/10.2337/dc08-0145>
7. Kim G, Lee SG, Lee BW, et al. Spontaneous ketonuria and risk of incident diabetes: a 12 year prospective study. *Diabetologia*. 2019;62(5):779-788. <https://doi.org/10.1007/s00125-019-4829-x>
8. National Institute for Health and Care Excellence 2021. Terms and conditions. Notice of rights. Accessed: 2025-06-04. <https://www.nice.org.uk/terms-and-conditions#notice-of-rights>
9. Kilpatrick ES, Butler AE, Saeed S, et al. The effectiveness of blood glucose and blood ketone measurement in identifying significant acidosis in diabetic ketoacidosis patients. *Diabetol. Metab. Syndr.* 2023;15(1):198. <https://doi.org/10.1186/s13098-023-01176-w>
10. Wierusz-Wysocka B, Zozulińska Ziolkiewicz D. Management of emergency and special conditions in patients with diabetes. Gdańsk: Via Medica; 2011, p. 1-541-50.

XIV. GENERAL GUIDELINES REGARDING SKIN – PENETRATING PROCEDURES

A. For the patient or his family members [1-2]

1. Wash your hands before performing a blood glucose measurement, insulin injection using a pen injector, infusion set insertion, or glucose monitoring sensor insertion.
2. If skin disinfection is required, wipe the skin with a gauze pad soaked in disinfectant (single-packed pre-soaked pads may be used). Wait until the disinfectant has dried [3-5].
3. After a finger-prick, secure the site with a sterile gauze pad.
4. If numbing cream is used, remove any residue with a clean wet gauze pad before disinfecting the skin. Apply the disinfectant only after the skin has dried.
5. Dispose of any sharp equipment (needles, lancets) safely.

B. For nursing staff [1-2,6-8]

1. Disinfect your hands before performing a clean/aseptic procedure.
2. Disinfect your hands after contact with a patient.
3. If skin disinfection is required, wipe the skin with a gauze pad soaked in disinfectant.
4. After a finger-prick, secure the site with a sterile gauze pad.
5. Wear diagnostic gloves if exposure to a patient's blood is expected.
6. In health care facilities, use safe equipment, i.e. insulin needles and disposable lancing devices, to prevent wounding incidents among nurses.
7. If a nurse/midwife performs insulin injection with a pen injector, the needle should be changed each time.
8. If numbing cream is used, remove any residue with a clean wet gauze pad before disinfecting the skin. Apply the disinfectant only after the skin has dried.

The recommendation to use a sterile gauze pad with an antiseptic agent to cleanse the site of lancet puncture for capillary blood sampling, and to protect the puncture site after blood collection, is based on protocols grounded in the principles of asepsis and antisepsis. Such procedures are particularly justified in medical facilities, in immunocompromised patients, in young children, and in situations where maintaining hygiene is difficult [6].

REFERENCES

1. The Act of 5 December 2008 on prevention and control of infections and infectious diseases in humans (Journal of Laws 2008 no. 234, item 1570, as amended).
2. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. *Mayo Clin. Proc.* 2016;91(9):1231-1255. <https://doi.org/10.1016/j.mayocp.2016.06.010>
3. Donihi AC, DiNardo MM, DeVita MA, et al. Use of a standardized protocol to decrease medication errors and adverse events related to sliding scale insulin. *Qual. Saf. Health Care*. 2006;15(2):89-91. <https://doi.org/10.1136/qshc.2005.014381>
4. Abdollahi M, Ayar A, Kouhpeikar H, et al. Interfering effect of alcohol swabbing on capillary blood glucose concentration using a glucometer: a brief report. *Mod. Care J.* 2024;22(1):e145591. <https://doi.org/10.5812/mcj-145591>
5. Jonca M, Krotki F, Tomaszik P. The effect of disinfecting procedure on the glucose concentration using a personal glucose meter. *Prim. Care Diabetes*. 2021;15(5):848-852. <https://doi.org/10.1016/j.pcd.2021.05.010>
6. Hoffman MSF, McKeage JW, Xu J, et al. Minimally invasive capillary blood sampling methods. *Expert Rev. Med. Devices*. 2023;20(1):5-16. <https://doi.org/10.1080/17434440.2023.2170783>
7. Boyce JM, Pittet D. Guideline for hand hygiene in health – care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *Infect. Control. Hosp. Epidemiol.* 2002;23(Suppl.12):S3-40. <https://doi.org/10.1086/503164>
8. Notice of the Minister of Health of 6 September 2024 on accreditation standards for healthcare services in the category of inpatient and 24-hour hospital care.

XV. ORAL ANTIHYPERGLYCEMIC AGENT ADMINISTRATION GUIDELINES

Purpose: To improve patient adherence and minimize the adverse effects of oral antihyperglycemic agents.

Guidelines for: nurses, midwives.

■ Tab. 16. Key recommendations. Assistance in treatment with oral antihyperglycemic agents

Regardless of diabetes type, antihyperglycemic treatment comprises health education, diet, exercise, and pharmaceutical treatment. A
To maximize the benefits oral antihyperglycemic agents, they must be taken strictly in accordance with the relevant guidelines. A
Health education provided to patients treated with oral antihyperglycemic agents is an indispensable part of therapy, contributing to a reduced risk of adverse effects from the medication and of chronic diabetes complications. B
Patients treated with oral antihyperglycemic agents from the SGLT-2 group should be taught to increase their fluid intake and maintain good intimate hygiene. Also in individuals with insulin deficiency and symptoms of DKA, after measuring ketone body levels. E
Patients' adherence to medication should be monitored. Educational interventions improve patients' health literacy in terms of adherence to treatment. A

In type 2 diabetes, the body retains some ability to produce insulin. There is, however, increased insulin resistance, which can be reduced by appropriate medication. Antihyperglycemic pharmaceutical treatment is a component of multidisciplinary treatment for type 2 diabetes. The key treatment objective is to prevent acute diabetes complications, as well as the development and progression of chronic neurovascular complications producing such clinical manifestations as retinopathy, diabetic kidney disease, neuropathy, and cardiovascular disease. The natural course of metabolic disorders leading to type 2 diabetes development is associated with increasing insulin deficit, and so treatment must be adjusted to the growing severity of the disorders. Type 2 diabetes treatment must be progressive and adapted to the subsequent stages of disease development [1]. Treatment success, especially in chronic disease, depends on multiple factors. Patient cooperation with the therapeutic team and adherence to all treatment recommendations is among the key factors for treatment effectiveness. Diabetes is a chronic disease that requires patients to take medication correctly and regularly for years. In each case of diabetes, and especially type 2 diabetes, the patient's attitude and education level must be taken into account when defining treatment objectives and selecting treatment strategies [2].

The following main groups of drugs are distinguished:

- **Sulfonylurea derivatives** – These drugs stimulate the pancreas to increase insulin secretion by beta cells. They are mainly used in patients whose insulin secretion reserves are still preserved.
- **Biguanide derivatives, with metformin as the most important representative** – Metformin is one of the most commonly used drugs in the treatment of type 2 diabetes. It works by reducing glucose production in the liver, increasing tissue sensitivity to insulin, and improving glucose utilization by muscles.

- **Intestinal α -glucosidase inhibitors** – These drugs delay the digestion and absorption of carbohydrates in the intestines, resulting in smaller fluctuations in blood glucose levels after meals.
- **Dipeptidyl peptidase-4 (DPP-4) inhibitors, known as gliptins** – These drugs increase the concentration of endogenous incretins, such as GLP-1, which help stimulate insulin secretion in response to meals and inhibit glucagon secretion, thereby aiding in glucose control.
- **Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, called SGLT-2 inhibitors** – These drugs inhibit the reabsorption of glucose in the kidneys, leading to the excretion of excess glucose in urine. They act independently of insulin and can contribute to weight reduction and improved blood pressure, and also exert nephroprotective and cardioprotective effects.
- **Thiazolidinedione derivatives, such as pioglitazone, which are PPAR- γ receptor agonists** – These drugs increase the sensitivity of peripheral tissues to insulin, allowing for better control of blood glucose levels. They mainly act on adipose, muscle, and liver tissues [1,3-5].

In modern diabetes treatment, combination drugs that combine different mechanisms of action, such as metformin with a gliptin or SGLT-2 inhibitor, are becoming increasingly popular. This allows for better glucose control and minimizes the risk of side effects. With the variety of available therapies, treatment can be tailored to individual patient's needs, taking into account their age, comorbidities, and lifestyle.

Biguanides

Metformin is currently the most commonly used oral antihyperglycemic agent, administered to obese patients with characteristics of metabolic syndrome and to patients with impaired glucose tolerance. It reduces liver gluconeogenesis, increases glucose uptake in tissues, reduces intestinal glucose absorption, reduces hunger, contributes to lower body weight, and improves lipid concentrations. Due to the risk of impaired renal function in elderly patients, metformin dosage is determined based on a renal function assessment performed before treatment initiation, and then modified during the course of treatment based on regular follow-up. Estimated glomerular filtration rate (eGFR) should be determined before the initiation of treatment with any product containing metformin, and then at least once a year [1]. If eGFR is between 45 and 30 mL/min, metformin dosage should be halved, and at eGFR < 30 mL/min, metformin should be discontinued.

- In patients at risk of further renal function impairment and in elderly individuals, renal function should be evaluated more frequently, every 3-6 months.

- Intravenous administration of iodine-based contrast media may lead to contrast-induced nephropathy, leading to metformin accumulation and increasing the risk of lactic acidosis. Metformin should be withheld before or during imaging examination, and for at least 48 hours afterwards, after which it can be restarted if a new renal function assessment shows stable renal function [6].
- Metformin should be withheld directly before OGTT, any surgical procedure performed under general, subarachnoid, or epidural anesthesia. Treatment can be restarted no earlier than 48 hours after the surgery or after resumption of oral feeding, provided that a new renal function assessment shows stable renal function [6].

Guidelines:

- The initial dose of metformin is usually between 500 mg and 850 mg 2 or 3 times daily, during or after a meal. Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain, or appetite loss may appear at the beginning of treatment and usually resolve spontaneously. To prevent these symptoms, the patient should take their metformin in 2 or 3 daily doses, during or after a meal. Increasing the dose slowly over time may improve the gastrointestinal tolerance.
- Extended-release forms of metformin (marked XR or SR) should be taken once daily, with the evening meal, and the tablets should not be split or chewed.
- Excessive alcohol intake during treatment with metformin SR increases the risk of lactic acidosis.

Sulfonylurea derivatives stimulate insulin secretion by acting on the ATP-sensitive potassium channel in pancreatic β -cells. Their additional effects include the inhibition of glucagon secretion by pancreatic α -cells and increased insulin sensitivity in peripheral tissues, which may be due to the extrapancreatic action of these drugs or reduced glucotoxicity.

Contraindications include: type 1 diabetes, ketoacidosis, precomatose state and diabetic coma, severe kidney or liver failure, pregnancy and breastfeeding, hypersensitivity to sulfonylureas, and conditions associated with increased demand for insulin (burns, trauma, surgery, fever, acute stage of myocardial infarction) [7].

Guidelines:

- Modified-release gliclazide should be taken in one dose, before the morning meal, with the tablet(s) swallowed whole. If a dose is missed, the next day's dose should not be increased.
- Glimepiride should be taken immediately before or during breakfast or another major meal, with the tablets swallowed whole and washed down with some fluid.
- The patient should be informed that skipping the meal after taking the medication, taking the medication earlier than at the beginning of the meal, or incorrect dosage increases the risk of hypoglycemia leading to loss of consciousness.
- The patient should be educated on possible hypoglycemia symptoms, such as headache, intense hunger, drowsiness, fatigue, nausea, vomiting, agitation, aggressiveness.

Dipeptidyl peptidase 4 (DPP-4) inhibitors – gliptins

The incretin hormones glucagon-like peptide (GLP) 1 and gastric inhibitory peptide (GIP, also known as glucose-dependent insulinotropic polypeptide) are intestinal hormones involved in the regulation of glucose homeostasis. Normally, they are continuously secreted at low baseline concentrations, which increase after a meal. In type 2 diabetes patients, the action of incretins is disturbed, with significantly reduced GLP-1 secretion and impaired activity of GIP.

Gliptins (or DPP-4 inhibitors) are very strong, selective, reversible, and competitive dipeptidyl peptidase (DPP-4) inhibitors. They inhibit the inactivation of GLP-1, improve the sensitivity of β islet cells to glucose, increase glucose-dependent insulin secretion, and improve the glucose sensitivity of α -cells, resulting in a more glucose-dependent glucagon secretion. The very low risk of hypoglycemia is a strength of these drugs, as is their neutral effect on body weight. The substances are very well tolerated and particularly recommendable in elderly patients [7].

Increased insulin/glucagon ratio during hyperglycemia, resulting from higher incretin concentrations, results in reduced glucose release from the liver, both when fasting and postprandially, and consequently, in lower glycemia. DPP-4 inhibitors also have a beneficial impact on lipid profile parameters:

- ↓ total cholesterol level,
- ↓ LDL cholesterol level,
- ↓ triglyceride level,
- ↓ HDL cholesterol level in the serum [4].

Guidelines:

- The tablets may be taken independently of meals, at any time of the day. If a dose is missed, the patient should take it as soon as they remember.
- Patients should not take a double dose on the same day.
- Tablets should be swallowed whole.

Oral GLP-1 analogue – the main effects of GLP-1 consist in stimulating insulin secretion (i.e. acting as an incretin hormone) and inhibiting the secretion of glucagon, thus contributing to the reduction of postprandial blood glucose spikes. It also inhibits gastrointestinal motor and secretory function, acting as an enterogastrone and forming part of the “ileal brake” mechanism. GLP-1 also seems to be a physiological regulator of appetite and feeding. The drug has the form of oral tablets taken once daily, on an empty stomach, at any time of the day. The tablet should be swallowed whole, with a small amount of water (half a cup, or 120 mL). The tablets must not be split, crushed, or chewed, as the impact on semaglutide absorption is unknown. Patients should wait at least 30 minutes before eating, drinking, or taking any other oral medication. A break shorter than 30 minutes will reduce the absorption of semaglutide. Any missed doses should be skipped, and the next one taken normally on the next day [7].

Sodium-glucose cotransporter-2 (SGLT2) inhibitors – gliflozins

SGLT2 inhibitors, also known as gliflozins, are drugs that reduce renal glucose reabsorption and cause glucose to be eliminated with urine, thus lowering the blood glucose level. Mechanism of action:

- They block the action of the SGLT2 cotransporter, reducing glucose reabsorption and causing glucose elimination with urine.
- They reduce both fasting and postprandial blood glucose levels.
- They cause body weight reduction through glycosuria, and are slightly diuretic, producing a moderate blood pressure reduction [9].

Guidelines:

- Patients treated with gliflozins should be informed of the risk of urinary tract infection associated with glycosuria.
- Patient education should include the following topics: drinking at least 7 glasses of fluids a day (more when physically active), proper hygiene, with particular attention to intimate areas, avoiding baths, avoiding excessive holding of urine, urinating at least once every 4 hours, wearing loose-fitting cotton underwear, increasing one's fluid intake if urine is dark (more concentrated). Female patients should regularly see a gynecologist, while male patients should see a urologist in case of frequent urination or difficulties when urinating.
- In patients with insulin deficiency, education on the risk of euglycemic diabetic ketoacidosis is essential, particularly when using SGLT-2 inhibitors. Regular gynecological consultations are recommended for women, while men should undergo urological consultations in the presence of symptoms such as frequent urination or difficulty urinating.
- The drugs can be taken with a meal or independently. Tablets should be swallowed whole and washed down with water.
- Drugs from this group cannot be used during prolonged fasting periods.
- In stressful situations, e.g. during severe infection or in perioperative periods, the patient should consult with their physician regarding the withholding of the medication.
- Treatment with these drugs is associated with glycosuria, and potentially, with ketonuria.

Thiazolidinedione derivatives — PPAR- γ agonists (pioglitazone)

Pioglitazone may be used as a single agent in obese patients with type 2 diabetes who cannot use metformin due to intolerance or contraindications. Pioglitazone appears to be particularly indicated in obese patients with a high degree of insulin resistance [7].

Mechanism of action: reduction of insulin resistance in peripheral tissues, reduction of liver gluconeogenesis, and reduction of blood glucose level accompanied by reduced levels of free fatty acids and triglycerides, and higher level of HDL cholesterol. This results in a positive effect of thia-

zolidinediones on the functioning of β islet cells. Adverse effects may include fluid retention, increased body weight, and higher liver enzyme levels, which may suggest liver toxicity [8].

Guidelines:

- Pioglitazone tablets should be taken once daily, with a meal or between meals.
- The tablets should be washed down with one glass of water.

Alpha-glucosidase inhibitors

Intestinal α -glucosidase inhibitors act on enzymes present in the brush border of the small intestine that are responsible for the decomposition of disaccharides into glucose and its subsequent absorption in the digestive tract. In the intestine, these drugs inhibit carbohydrate digestion, thus reducing glucose absorption and lowering postprandial glycemia. Due to significant individual differences in terms of glucosidase activity in the intestinal mucosa, there is no fixed dosage — treatment should be adjusted to the clinical response and tolerance for intestinal adverse effects. In adults, the recommended initial dose is 50 mg three times a day [9].

Guidelines:

- The tablets are only effective when swallowed whole, with a small amount of fluid, right before a meal or at the start of a meal.
- In the initial treatment period (first 6-12 months), liver enzyme levels must be monitored.
- When using Glukobay, patients should not consume foods containing sucrose, as this may cause diarrhea [9].

A chronically progressive course of diabetes requires combination therapy. To improve patient cooperation and simplify treatment protocols, combination drugs, most commonly containing metformin and gliptins or gliflozins, are increasingly often used in diabetes treatment. Products combining gliptins and gliflozins are also available [8].

Combination products containing 2 active substances with antihyperglycemic effects: dapagliflozin and metformin. The two substances have different mechanisms of action, and their combined use aims at improving blood glucose control in patients with type 2 diabetes [10-13].

REFERENCES

1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes – 2025. *Diabetes Care*. 2025;48(Suppl.1):S181-S206. <https://doi.org/10.2337/dc25-S009>
2. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
3. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. *Nat. Rev. Dis. Primers.* 2015;1:15019. <https://doi.org/10.1038/nrdp.2015.19>
4. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. *Diabetes Obes. Metab.* 2018;20(Suppl 1):5-21. <https://doi.org/10.1111/dom.13129>
5. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N. Engl. J. Med.* 2016;374(11):1094. <https://doi.org/10.1056/NEJMc1600827>
6. Kostrzewska-Ząbłocka E. Pharmaceutical methods. Oral Medication Treatment. In: Szewczyk A. (ed.) *Diabetes nursing*. Warsaw: PZWŁ; 2019.

7. Pawlaczyk K, Czekalski S, Zozulińska-Ziółkiewicz D. Modern diabetes treatment – non-insulin medication. Warsaw: Medical Education; 2020.
8. Evans M, Engberg S, Faurby M, et al. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. *Diabetes Obes. Metab.* 2022;24(3):377-390. <https://doi.org/10.1111/dom.14603>
9. Davidson MA, Mattison DR, Azoulay L, et al. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. *Crit. Rev. Toxicol.* 2018;48:52-108. <https://doi.org/10.1080/10408444.2017.1351420>
10. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43(2):487-493. <https://doi.org/10.2337/dc19-0066>
11. Cheen MHH, Tan YZ, Oh LF, et al. Prevalence of and factors associated with primary medication non-adherence in chronic disease: a systematic review and meta-analysis. *Int. J. Clin. Pract.* 2019;73(6):e13350. <https://doi.org/10.1111/ijcp.13350>
12. Clodi M, Abrahamian H, Brath H, et al. Antihyperglycemic treatment guidelines for diabetes mellitus type 2. *Wien. Klin. Wochenschr.* 2019;131:27-37. <https://doi.org/10.1007/s00508-019-1471-z>
13. Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. *BMJ Open Diabetes Res. Care.* 2020;8:e001279. <https://doi.org/10.1136/bmjdrc-2020-001279>

XVI. GUIDELINES FOR USING INFORMATION AND COMMUNICATION TECHNOLOGIES IN NURSING DIABETES CARE

Purpose: Supporting nurses and midwives in making decisions regarding patient care. Providing nursing care in accordance with the current state of knowledge, competences and resources using information and communication technologies.

Guidelines for: nurses and midwives.

■ Tab. 17. Key recommendations. Use of information and communication technologies in nursing diabetes care

Telenursing may support maintaining good metabolic control of diabetes, providing therapeutic education, reducing treatment costs, improving patient quality of life and reducing the number of patient visits to health care facilities and the number of nurse house calls. C
Consultation via electronic devices must not be the only form of service used in diabetic patient care and cannot replace periodical direct visits. It is recommended to use a hybrid therapy model. C
Using telemedicine is a good supplement to traditional forms of patient care especially in preparing patients for self-care and limiting acute complications of diabetes. C

Introduction

- Information and Communication Technologies (ICT) belong to the field of information technologies and combine telecommunication with tools and technologies related to the exchange and transmission of information. ICT includes hardware and software used for sending, presenting and protecting the data collected. The major services provided by nurses to diabetic patients using ICT are consultations via electronic devices, teleeducation and remote monitoring [1-2].
- According to the International Council of Nurses (ICN) telenursing is „the use of telecommunication technology in nursing to enhance patient care” [3]. The telenursing practice combines 3 areas: information technologies, nursing care and modern medical equipment. Telenursing practice allows for overcoming the issue of distance and providing support to individuals who do not have access to outpatient clinics or health services due to the time of day, distance or limited mobility caused by their condition [1-2,4].
- Telenursing must be practiced within the limits of professional qualifications. The guidelines presented herein are to support the nurse/midwife in cooperating with other members of a diabetes treatment teams. They are

intended for use in conjunction with national standards including the Recommendations of Diabetes Poland (DP) [1-2].

- Telenursing is a developing discipline which uses innovative technologies to improve nursing care standards. However, it does not change the character of professional practice [5-6].
- Teleappointment is a health service provided remotely using ICT systems or communication systems [2,7].
- Teleeducation is defined as health and therapeutic education provided using ICT systems or communication systems independently of health care services as part of comprehensive telemedical care. DP recommendations and the results of studies on the effectiveness of diabetes teleeducation provided by nurses indicate that there is potential in this type of service for diabetic patients and that developing and implementing it is justified. Teleeducation will improve access to therapeutic education experts and the patients will benefit from a broader spectrum of therapeutic education. There should be a possibility to provide diabetes education using telemedicine solutions [1,8].
- Teleconsultation is a health service provided by medical personnel (nurse/physician) calling the patient on the phone [2,6-7].
- Videoconsultation is a new method for providing medical services which allows for using modern technologies to improve communication between the patient and the physician/nurse/midwife. During a videoconsultation session the patient can connect from any location using a secure IT platform to participate in a medical consultation [5].
- Telemonitoring is a service that involves ongoing continuous supervision of the patient's health through the analysis of data provided by monitoring devices or a dedicated application and taking appropriate actions in life- and health-threatening situations [9].
- To provide effective cooperation between service providers it is recommended to introduce dedicated health services allowing for trilateral communication between the patient, medical professional (providing care to the patient as part of the service) and the diabetes specialist [5].

1. Infrastructure, technical requirements, software used in telenursing

Telenursing and teleeducation require adapting the service provider's digital infrastructure to offer high-quality telemedicine services. The teleconsultation office infrastructure should create an environment conducive to consultation.

- The room in which synchronous teleconsultation services are provided should be located far away from sources of noise. Patients and nurses should not be sitting with their backs towards the window as it produces a backlight effect that reduces image quality. If such arrangements cannot be made, curtains should be used to reduce the unwanted lighting effect.
- The primary tools required for providing telenursing services are: land-line or mobile telephone connection, social media account, email account and the capability of the system or product to guarantee technically effective exchange of patient information with other systems or products. Secure and stable Internet connection is required to organize videoconferences and provide uninterrupted communication. It is recommended to use at least two Internet providers to maintain reliable communication with patients [10].
- A computer system comprises software and hardware. The types of hardware most commonly used in telenursing consultations are desktop and laptop computers or tablets. Other required pieces of hardware include a camera and a microphone. A high resolution camera should be installed at eye level. Maintaining a professional image of the service provider during teleconsultations is very important for building relations with patients. Another important aspect of teleconsultations is active listening and maintaining eye contact (i.e. looking into the camera). The patient must always be informed if the nurse is making notes when obtaining their medical history, so that it is not perceived as a lack of focus. It is best to use a low-noise microphone with appropriate sensitivity and gain.
- The software should be easy to use and adaptable and it should provide uninterrupted communication with the patient. It is recommended to use a solution that is popular among the general public and provides full data security [6].

2. Communication methods used in telenursing

Similarly to telemedicine, telenursing uses all channels of communication with the patient available on IT platforms including voice, images, text and digital data exchange. Communication methods are further divided into synchronous and asynchronous. Each of these methods has its advantages and limitations when used for providing nursing care.

Synchronous communication methods

- Telephone: convenient, quick, unlimited range; it is an optimum solution for urgent cases; does not require separate infrastructure; provides greater pri-

vacy for the patient; allows for real-time interaction. The disadvantages of this method include the risk of non-verbal cues going unnoticed; the need to carefully identify the patient; not suitable for situations that require visual inspection of e.g. skin or tongue [5,10-11].

- Video chat using instant messaging platforms: a real-time interaction; a method most closely resembling an actual direct consultation. The advantages of this method include: patient identification is easy; the nurse can see the patient; the nurse can discuss the problem with the carer; visual cues can be seen; the condition of the patient can be inspected visually. The disadvantages include: the risk of invading the patient's privacy; communication depends on high-quality Internet connection that must be uninterrupted on both ends, otherwise it leads to less-than-optimal exchange of information [10-12].

Asynchronous communication methods

- Email, fax: a convenient and simple communication method that is easy to document; it is more useful when sending test reports or other data collected using monitoring devices; does not require an app to receive images, data or reports; does not require separate infrastructure. The disadvantages include: no real-time interaction, information sent one way at a given time; based on data/information provided by the patient; identification of the patient is based only on difficult to verify documents; no non-verbal cues; possible delays in response because the service provider may not receive messages immediately after they are sent by the patient; increased risk of data security breach. It is required to use encryption and strong passwords.

Methods combining synchronous and asynchronous communication

- Contact based on text messaging (e.g. chat, mobile applications, SMS): convenient and quick communication method, identification features may be built into the communication platform; can be used in urgent cases and for observation; allows for easy consultation with other specialists and does not require separate infrastructure. Real-time as well as asynchronous contact possible. Limitations include: uncertainty regarding the identity of the service provider and patient, no live image and no verbal communication; possible delays in messages reaching the service provider [6,10].

3. Rules for providing services using ICT

- Test the hardware (camera, microphone, Internet connection) before the planned contact with the patient. Make sure that you know whom to contact to get technical support and make sure you have an alternative channel of communication.
- Inform the patient that their privacy and personal information is protected. Do not conduct telenursing consultations in noisy rooms or in open spaces.

- Requirements for effective communication
 - First, identify the patient and greet them. Use a soft speaking voice so that the patient feels safe. Listen actively, without interrupting the patient. Present substantial information but use simple language that is understandable for the patient without referring to complex medical terminology. Use body language, e.g. lean towards the camera.
 - Do not express any signs of nervousness or impatience through e.g. facial expression.
 - React to verbal, non-verbal, emotional and behavioral cues from the patient.
 - Ask open-ended questions, making sure to put them in a logical order to collect reliable information about the patient.
 - Listen to the fears expressed by the patient and make sure to engage the patient in making decisions regarding the therapy. Be careful to treat the patient as a person and make sure that they are an empowered participant of the therapeutic process.
 - Do not make any decisions on the diabetic patient's behalf. Reinforce the patient's adherence by providing education and shaping self-care skills [13-14].
 - Do not overwhelm the patient with unnecessary information.
 - Always close the consultation with appropriate courtesies [11].

4. Professional responsibility

- The nurse bears professional responsibility for the care and therapeutic education provided via telenursing. Constantly monitor the educational needs of diabetic patients, including those related to the technical progress in telemedicine and telenursing.
- Telenursing services must be provided in accordance with strictly specified professional roles, standards and guidelines. Do not provide any advice outside of your professional competences.
- The nurse should be aware of the professional responsibility when using instant messaging, web conferencing software and social media (Facebook, WhatsApp, etc.), especially with regard to security of private and sensitive information.
- The entire treatment team is obliged to maintain professional secrecy. Do not provide any information and/or send images/videos related to the patient to anyone. Do not copy email messages from the patient without their permission.
- Act on behalf of your patients and provide them with technological solutions that protect their rights and interests. Conduct personnel training in the fields of telenursing and teleeducation.
- Remain within the boundaries of professional contact with the patient.
- Telenursing may involve greater risks as it does not allow for providing identical care as in the case of direct care. To mitigate these risks clearly establish the duties, employment conditions and policies that support telenursing.

- Nurses providing care using modern technological solutions should be engaged in identifying and documenting risks as well as in risk management and risk mitigation.
- Nurses providing telenursing services and/or diabetes teleeducation must constantly expand their knowledge on diabetic patient care, improve their professional interpersonal communication competences and technical skills related to using modern telemedicine solutions [5].
- Some patients feel a strong need to create personal relations with their physician/nurse („face to face contact”) and as a result consider telemedicine services inappropriate. If this is the case, do not impose using telemedicine solutions.

5. Legal and ethical considerations

- Privacy and protection of personal information must be guaranteed when collecting and processing data, especially information regarding patient's health. Always take into consideration the possibility of a failure or technical defect. Protection of privacy and data security are paramount for building trust in telemedicine solutions [15].
- The secrecy of patient information must be maintained at all times. Always inform the patient if other members of the treatment team will have access to personal information regarding their health. Do not disclose information regarding the patient without their permission to any third-party, including the patient's family.
- Nurses must take all the steps necessary to protect the patient against accidental disclosure of communications to unauthorized persons. This is particularly important if images or sound are transmitted when providing services.
- Telenursing and teleeducation are conducted based on the legal regulations in force, the Code of Conduct for Nurses and Midwives, the Nurses and Midwives Act and current standards. Provide security solutions in accordance with the regulation on the protection of natural persons with regard to the processing of personal data (GDPR).
- Using the technical infrastructure as well as legislative means will provide full access to the patient's medical data and will impact the effectiveness of health services.
- When providing services using ICT it is possible that situations will arise which require the provider to notify appropriate institutions about the encountered problems (e.g. suspected abuse of a child / elderly person). This must be done in accordance with the legal regulations in force, regardless of the patient's requests to maintain secrecy [1,6].

6. Framework for telenursing practice

- Telenursing may be practiced in public and in private healthcare. It is important to supplement this practice with consultations between the nurse and the primary care physician, diabetologist and experts in other fields of nursing as well as other members

of an interdisciplinary team. Consultations between nurses and physicians are particularly important in the case of poorly controlled diabetes.

- All consultations should be based on a nursing diagnosis. The nursing staff should be well prepared to decide if ICT-based consultations are a sufficient form of contact or if it is required to conduct a videoconsultation involving a physician or if a personal consultation with a nurse and/or physician is required. Do not continue to use telenursing if the patient is not interested in such form of consultation or if they ask for a personal consultation. Additionally, both the patient and the nurse have the right to terminate a teleconsultation. Nursing consultations should be anonymous.

7. Documentation

- Documentation may be collected on paper or in electronically and should be stored in accordance with the legal regulations in force (e.g. in a patient summary form). Every telenursing consultation should be documented in accordance with the legal regulations in force and other regulatory requirements and should reflect the nursing process. Never remove data from medical documentation. When creating telenursing consultation documentation follow the general principles of creating medical documentation. Pay close attention to the precision and correctness of the nursing diagnosis, make sure that the data is complete and that all information is up to date and organized logically using a correct layout and sequence of information. Only use abbreviations, symbols and acronyms that are found in the currently applicable list of abbreviations symbols and acronyms.
- Start creating the telenursing consultation documentation by entering the date and time and close it with the nurse's signature and nursing license number. Always note down the patient's name and surname, their telephone number, reason for consultation, information provided by them / collected, the advice provided, further recommendations and plan for future care. Insufficiently precise information will result in incorrect decisions regarding patient care. Using a chronological layout in documentation makes it clearer.
- Each of the documents should be signed by the service provider. To provide cohesion and precision of the telenursing documentation, the nurses should work with their employers to develop appropriate procedures. Employers should provide nurses with detailed guidelines regarding the documentation, containing suggestions on what documentation template should be employed in the telenursing practice.

8. Phases of telenursing consultation

The telenursing/teleeducation consultation should comprise the following phases:

- **Selection of communication method**

The most common communication methods include videoconference, telephone call or text (e.g. online chat, images, messages, email, fax, information collected from monitoring devices). The communication method should be suitable to the current situation and the patient's needs [10-12].

- **Identification of nurse and patient**

During the telenursing consultation the nurse and the patient should know each other's identity. The nurse should verify the identity of the patient – their name, surname, age, sex, home address, email address and phone number. Present a form for collecting the patient's data. An adult must be present during telenursing consultation with children (individuals under the age of 18). The nurse should obtain the patient's / patient family's permission to transfer the patient's information to a physician and other treatment team members. The nurse is identified by the nursing license number.

- **Obtaining patient's consent**

Before providing telenursing services using ICT the patient must express their informed consent. Telenursing is subject to the same legal regulations regarding patient's consent as nursing care provided in direct contact. Patient's consent may be implicit or explicit. If the patient initiates the telenursing consultation, their consent is implicit. Explicit patient's consent is required if the telenursing consultation is initiated by the nurse, by another healthcare employee or the patient's family. The explicit consent may be presented in any form, e.g. sent by email, SMS, voice/video message or a consent form, and must be recorded. The patient may express their consent for telephone contact or videoconsultation with the nurse using simple language. The patient's consent statement must be recorded in the patient summary form. Nurses providing telenursing services should work with their employees to develop procedures for obtaining the patient's informed consent.

- **Initial evaluation**

In this phase the initial evaluation of patient condition and of the risks related to remote contact is performed.

- The nursing staff should use their clinical skills and nursing skills to evaluate the condition of the patient and decide if telenursing consultation is the appropriate form of care in the given situation or if direct nursing consultation or consultation with a physician is required. Establish the preliminary purpose of the consultation and any new complaints. After resolving any issues with a physician the nursing staff should help the patient decide what type of care is needed on a given day. The service provider should develop protocols for preliminary patient evaluation to support the nurse in making decisions regarding the patient, also in an emergency situation. If there are no new complaints the consultation should continue based on the diagnosed nursing needs, including educational needs. Always maintain the same high nursing care standard as during direct consultations. This applies to preliminary visits, follow-ups as well as during consultations based on a referral from another specialist. The first visit,

regardless of its purpose, should be performed in direct contact and telemedicine using ICT should be introduced during the following visits.

- The nurse should consider if and to what extent the limited access to the patient's documentation and the inability to directly evaluate the patient's condition may affect the ability to provide comprehensive nursing care.
- Regardless whether the patient-nurse relation is developed in person or using ICT, they must be based on the evaluation of the patient's health and nursing needs. Therapeutic relations should always take into account the patient's cultural context (including language), spiritual needs and psychosocial preferences. Refer the patient to other specialists immediately if it is found that their needs exceed the knowledge, skills and competences of the nurse.

• Nursing diagnosis

The first telenursing consultation should be conducted in the presence of a physician, while further consultations can be conducted by the nurse alone [7]. Before formulating the nursing diagnosis, collect and analyze all information about the patient. It is easier to formulate a diagnosis if patient information is collected one or two days before the scheduled telenursing consultation. It is recommended that the patient sends general information about themselves to the email address provided. The information should include their current complaints, the occurrence of severe hypoglycemia, severe hyperglycemia or ketoacidosis since the previous direct or telenursing consultation, bodyweight, height, injection site condition, self-monitoring and insulin therapy. In the case of functional insulin therapy, the patient should provide the name of the insulin used, the number of injections and dose of insulin taken with meals, the total number of injections and correction doses from the preceding 3 days, the dose of insulin usually injected with individual meals and the number of carbohydrate exchanges per meal. When using pen injectors, the patient should specify the name and dose of basal insulin per day and the time of administration. When using an insulin pump, the patient should provide the basal dose at specified times of day and read out the following information from the bolus calculator: meal equivalent (number of insulin units per 1 carbohydrate exchange or quantity of carbohydrates in grams per 1 unit of insulin), insulin sensitivity (by how many mg% the glucose level decreases when administering 1 unit of insulin) and the target glucose level range. If the insulin pump has an integrated sensor, the patient should provide the „low glycaemia” alert setting value. The patient should provide readouts from glycaemia monitoring devices from the preceding 2–4 weeks (if the patient uses such devices), e.g. from monitoring devices integrated in the insulin pump, continuous glucose monitoring device (CGM) or flash glucose monitoring device (FGM), which present daily trends and weekly summaries. If the patient does not use any monitoring devices or is unable to send readouts from the insulin pump or reports from the application working with the glucose meter, they should note down the glyca-

emia value during the preceding 14 days in a journal or in a spreadsheet (e.g. an Excel file) and send the image of this journal or the file to the nurse. If the patient uses an insulin pump, they should also note down other information stored in the insulin pump memory: basal insulin, meal equivalents and insulin sensitivity. The patient should note down the glucose level results and the dose of bolus insulin at meals and corrections from several preceding days. The patient should also note down the results of the last HbA1c measurement [16]. Patients with type 2 diabetes who take oral medications or subcutaneous injections of GLP-1 receptor analogues should provide detailed information on the names and doses of the medications administered and report any adverse symptoms. The patients should also provide their blood pressure self-monitoring journal and the results of any biochemical tests performed recently, especially total cholesterol, triglycerides, LDL and HDL cholesterol fractions, creatinine, the last glomerular filtration rate (GFR), results of the last urine sample test and information whether proteinuria or microalbuminuria has been diagnosed in the preceding year. It is recommended that the diabetic patient provides discharge documentation if the hospitalization was related to diabetes and any other medical documentation.

It is recommended that the patient performs a fasting glycaemia measurement and urinary acetone level or blood ketone level measurements on the day of teleconsultation. Before the telenursing consultation, the patient should inform the nurse if they need any prescription medications or medical products (e.g. catheters, containers, sensors, transmitters) [7].

The nurse can run the patient's entire documentation (if it is agreed so), including medical records, collect test results and information on the treatment regimen ordered by physicians as well as any care provided by the nursing staff in accordance with the selected nursing care delivery model e.g. in accordance with the International Classification for Nursing Practice (ICNP). The classification provides standardized nursing terminology that facilitates the exchange of information [3].

9. Teleeducation in diabetes nursing

- Therapeutic education should be preceded by an interview to evaluate the readiness of the diabetic patient for self-monitoring and self-care. Establish individual therapeutic goals, prepare a diabetes education plan and provide the patient with information based on their individual therapeutic goals [14].
- The scope of education provided using telenursing is very broad and can cover: nutrition; physical activity; calculation of carbohydrate exchanges and protein-fat exchanges in food; self-monitoring and self-observation techniques; collecting information in a paper or electronic self-monitoring journal and analyzing them; insulin administration techniques; correcting insulin doses; administration of oral antidiabetic medications; causes and symptoms of hypoglycemia and hyperglycemia; the importance of periodical specialist consultations; feet monitoring techniques as well as primary, secondary and tertiary

a prophylaxis of diabetic foot; wound dressing and management; stress management techniques; detrimental effects of alcohol consumption.

- If the patient is a smoker and does not intend to quit, remind the patient about the detrimental effects of smoking during each teleeducation session and note the patient's refusal to quit in the medical documentation.
- Evaluate the progress made by the patient and prepare a reeducation plan for the following sessions every time.
- Over the course of the teleeducation process use various didactic tools and methods e.g. educational videos on self-injecting insulin, observation of injections sites, limiting glycaemia using various methods etc.
- Acting as an advisor the nurse provides information on the disease itself, the importance of following medical recommendations, follow-ups and tests to be conducted before the next session [13].
- The nurse is one of the mainstays of the emotional support system for the patients and their families.
- Maintain medical documentation related to diabetes teleeducation, documenting the provided recommendations (the formal – planned – and informal -unplanned- materials used for educational purposes, teaching methods, patient and/or their family engagement, evaluation of goal completion by the patient and/or their family, validation of their understanding, all future actions to be taken) [16].
- The goal of the nursing staff in diabetic care is to support the patient in following the treatment regimen ordered by the physician. The nurse often initiates additional teleconsultations with a physician to provide the patient with the best possible care [17].
- The nurse may use remote systems to monitor patient parameters and should verify if the patient adheres to the medication regimen, evaluate the condition of wounds (if present) and recommend applying the correct dressing, provide advice regarding foot care, consolidate skills in using a pen injector, a glucose meter and an insulin pump, provide advice on correcting the insulin dose, provide advice on administering GLP-1 receptor antagonists as subcutaneous injections, provide advice on administering oral antidiabetic medications [9,13].
- During teleeducation sessions the nurse should remind the patient of the required follow-ups with specialists and motivate them to attend these appointments as well as help provide the patient with referrals to physiotherapists, dietitians, psychologists, social workers and other members of an interdisciplinary team [18].

10. Telemonitoring – remote monitoring devices

- Monitoring the completion of therapeutic goals in diabetic patients is possible using modern medical devices and applications, e.g. remote glucose monitoring systems – real time continuous glucose moni-

toring (rtCGM) or flash glucose monitoring (FGM) / intermittently scanned continuous glucose monitoring (isCGM), as well as other products.

- Standard glucose meters with dedicated apps can also be used. Additionally there are pen injectors and insulin pumps that can be a source of data provided by the patient. This data can be collected using apps whose purpose is integrating and sending data from the patient to the service provider. The applications work with smartphones or tablets. In addition to blood glucose level monitoring, these applications allow for recording insulin doses, consumption of carbohydrate exchanges and protein-fat exchanges, identification of hypo- and hyperglycemia, alerting the patient to take medications or adjusting the operation of insulin pumps. There are also applications for diabetes education, for online contact with specialists and separate applications for pregnant diabetic patients.
- An electronic medical report at an outpatient telemedicine center allows for storing data from numerous health monitoring devices (tele-ECG; tele-spirometry; digital pulse oximeter; interactive stethoscope; remote monitoring of blood pressure, blood glucose level, temperature, body weight; fall detector; motion sensors and others) at a single site. The sensors collect information which is then transmitted wirelessly to an external mobile receiver, e.g. a mobile phone or smartphone. Then they are retransmitted in real time via telecommunication networks to the medical center where they are stored and analyzed. The patient is then sent feedback information with recommendations for further action in the form of an SMS, email or, in case of an emergency, a phone call. Measurements can be taken at a specified time e.g. during a planned teleconsultation with a nurse/physician or independently, based on the patient's needs. The results are sent to a database and archived there. They can be accessed at any time by a nurse/physician or by the patient.
- Remote monitoring solutions may also use artificial intelligence (AI) to create systems that automatically analyze data sent by monitoring devices and inform the service provider about any alarming changes in the patient's condition [10].
- Some patients, especially the elderly, may experience uncertainty and insecurity when using modern technical solutions. This stems from the lack of knowledge and skills required to operate electronic devices. Additional problems are related to the impediment of their motor and cognitive functions. As a result, the elderly find it more difficult to understand new information and adapt to ever-changing technologies and new self-monitoring solutions. It is important to prevent the digital exclusion of the elderly [9].

Telenursing – advantages and challenges

- Telenursing may involve greater risks as it does not allow for providing identical care as in the case of direct contact. Clearly establish the duties, employment conditions and policies that support the nursing practice involving ICT to mitigate these risks. Nurses providing telenursing care should be engaged in identifying and documenting risks [16].
- Telenursing may improve access to diabetic nursing care and improve the patient's comfort by reducing or eliminating their need to travel to a healthcare facility. However, these benefits cannot outweigh the safety of patient care. A thorough initial nursing examination combined with a physical examination is needed, which means that it may be necessary to organize a direct meeting [11,16,18-22].
- If at any point of the ongoing nurse-patient relation telenursing becomes insufficient, immediate steps must be taken to continue providing nursing care in direct contact.
- Telenursing as well as teleeducation that forms its part are dynamic processes in the nurse-patient relation, whose purpose is to meet the needs of the patient, based on trust and respect and protection of the patient's interests.
- Effective communication is necessary in developing all nurse-patient relations, but it is particularly important when using ICT [17].
- Nursing care delivery models are expanded thanks to the use of modern technologies. The telenursing practice will be continued and will evolve in the future [10-11,16,23-24].

REFERENCES

- College of Nurses of Ontario. Telepractice guideline. 2020. Accessed: 2025-06-22. https://www.cno.org/globalassets/docs/prac/41041_telephone.pdf
- Crawley R, Kuchta P. Telehealth Nursing Practice Special Interest Group. A telehealth manager's toolkit. American Academy of Ambulatory Care Nursing. 2012:1-70.
- Series ICN Regulation. „ICN framework of competencies for the nurse specialist.” 2009. Accessed: 2025-06-10. <https://www.commonwealthnurses.org/ARC/Documents/Resources/ICN%20Nursing%20Care%20continuum.pdf>
- Kilańska D, Grabowska H, Gaworska-Krzemińska A. E-zdrowie. Introduction to the use of ICT in nursing. Warsaw: PZWL; 2017.
- NSCN. Nova Scotia College of Nursing. Practice guidelines for nurses. Telenursing. 2023. Accessed: 2025-06-10. <https://www.nsncn.ca/professional-practice/practice-support/practice-support-tools/technology/telenursing-practice-guideline-nurses>
- Poreddi V, Kathiyani BV, Hatti NM, et al. NIMHANS-telenursing practice guidelines. Bengaluru 2020. Accessed: 2025-06-10. <https://nimhans.co.in/wp-content/uploads/2021/09/TeleNursing-Practice-Guideline-2020.pdf>
- Regulation of the Minister of Health of 23 September 2019 amending the Regulation on guaranteed specialist outpatient care services. (Journal of Laws 2019, item 1864).
- Bujnowska-Fedak MM, Tomczak M. Innovative telemedicine applications and e-health services in the care of older patients. Public Health and Governance. 2013;11(4):302-317. <https://doi.org/10.4467/208426270Z.14.030.2169>
- Report „How to use the potential of telemedicine in diabetology” by the Telemedicine Working Group Foundation in cooperation with experts from Diabetes Poland and representatives of the diabetes nursing community. Warsaw 2021.
- Wilson LS, Maeder AJ. Recent directions in telemedicine: review of trends in research and practice. Healthc. Inform. Res. 2015;21(4):213-222. <https://doi.org/10.4258/hir.2015.21.4.213>
- Souza-Junior VD, Mendes IAC, Mazzo A, et al. Application of telenursing in nursing practice: an integrative literature review. Appl. Nurs. Res. 2016;29:254-260. <https://doi.org/10.1016/j.apn.2015.05.005>
- Kord Z, Fereidouni Z, Mirzaei MS, et al. Telenursing home care and COVID-19: a qualitative study. BMJ Support Palliat. Care. 2024;14:e992-e1000. <https://doi.org/10.1136/bmjspcare-2021-003001>
- Bingham JM, Black M, Anderson EJ, et al. Impact of telehealth interventions on medication adherence for patients with type 2 diabetes, hypertension, and/or dyslipidemia: a systematic review. Ann Pharmacother. 2021;55(5):637-649. <https://doi.org/10.1177/1060028020950726>
- Aminuddin HB, Jiao N, Jiang Y, et al. Effectiveness of smartphone-based self-management interventions on self-efficacy, self-care activities, health-related quality of life and clinical outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Int. J. Nurs. Stud. 2021;116:103286. <https://doi.org/10.1016/j.ijnurstu.2019.02.003>
- Roussel J. Competencies for the clinical nurse specialist and nurse practitioner in Canada. In: Staples E, Pilon R, Hannon RA, ed. Canadian perspectives on advanced practice nursing. Toronto (ON): Canadian Scholars; 2020, p. 74-85.
- Yang S, Jiang Q, Li H. The role of telenursing in the management of diabetes: a systematic review and meta-analysis. Public Health Nurs. 2019;36(4):575-586. <https://doi.org/10.1111/phn.12603>
- Mamaghani HA, Tabrizi FJ, Seyedrasooli A, et al. Effect of empowerment program with and without telenursing on self-efficacy and glycosylated hemoglobin index of patients with type 2 diabetes: a randomized clinical trial. Scand. J. Caring Sci. 2020;10(1):22-28. <https://doi.org/10.34172/jcs.2021.001>
- Kotsani K, Antonopoulou V, Kountouri A, et al. The role of telenursing in the management of diabetes type 1: a randomized controlled trial. Int. J. Nurs. Stud. 2018;80:29-35. <https://doi.org/10.1016/j.ijnurstu.2018.01.003>
- Biermann E, Dietrich W, Rihl J, et al. Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial. Comput. Methods Programs Biomed. 2002;69(2):137-146. [https://doi.org/10.1016/s0169-2607\(02\)00037-8](https://doi.org/10.1016/s0169-2607(02)00037-8)
- American Diabetes Association Professional Practice Committee; 1. Improving care and promoting health in populations: standards of care in diabetes-2025. Diabetes Care. 2025;48(Suppl.1):S14-S26. <https://doi.org/10.2337/dc25-5001>
- Kilańska D. The nurse during the time of coronavirus. Teleappointments. Warsaw: PZWL; 2020.
- Decision of the National Health Fund President (no.182/2019/DSOZ) on specifying the conditions for concluding and implementing contracts for the provision of health services of the specialist outpatient care type.
- Kusnanto, Widyanata K, Suprajitno, Arifin H. DM-calendar app as a diabetes self-management education on adult type 2 diabetes mellitus: a randomized controlled trial. J. Diabetes Metab. Disord. 2019;18(2):557-563. <https://doi.org/10.1007/s40200-019-00468-1>
- Kim Y, Park JE, Lee BW, et al. Comparative effectiveness of telemonitoring versus usual care for type 2 diabetes: a systematic review and meta-analysis. J. Telemed. Telecare. 2019;25(10):587-601. <https://doi.org/10.1177/1357633X18782599>

XVII. GUIDELINES ON THE PREVENTION OF TYPE 1 DIABETES

Purpose: Supporting nurses and midwives in making decisions regarding prevention of type 1 diabetes. Providing nursing care in accordance with the current state of knowledge, competences and resources.

Guidelines for: nurses and midwives.

■ Tab. 18. Key recommendations. Tasks for the nursing staff in the prevention of type 1 diabetes

Early identification of pre-symptomatic type 1 diabetes can accurately predict clinical disease, and when combined with therapeutic education and monitoring, can lead to better health outcomes. B
Psychosocial needs, especially in young individuals with diabetes, require structured assessment in order to personalize care. B
Therapeutic education and tools for monitoring blood glucose levels can prevent premature deaths in young patients with type 1 diabetes. B
Interdisciplinary team care can enable the systematic collection of data during routine clinical practice to improve the quality of electronic medical records and create registries for surveillance, prevention, and treatment purposes. C

Prevention methods, including health and therapeutic education, should be based on current legal regulations and Evidence Based Medicine, and delivered at different levels of health care – Primary Health Care (PHC), Specialist Outpatient Care (SOC), and hospital care involving primary, secondary and tertiary prevention.

The nurse is part of the multidisciplinary specialist diabetes team and is the appropriate and competent person to undertake prevention tasks at various levels of health care, including the role of a diabetes educator. Patient care should be coordinated and systemic.

PRIMARY PREVENTION

The nurse's tasks in primary prevention dominate at the Primary Health Care (PHC) level. Primary prevention of type 1 diabetes focuses on:

- identifying individuals at increased risk of developing diabetes and providing them with appropriately targeted medical care (first-degree relatives of individuals with diabetes, genetically predisposed individuals with certain HLA antigens, individuals with antibodies against various components of pancreatic islet β -cells) [1-4],
- developing effective methods for identifying individuals predisposed to the disease, who are potential candidates for the implementation of preventive measures. To identify high-risk groups, the nurse collaborates with the medical team (pediatrician, diabetologist, endocrinologist) [5-6],
- in cases of preclinical type 1 diabetes, education should cover clinical symptoms of diabetes, normal blood glucose ranges, signs of hyperglycemia, methods of glucose monitoring, prevention of diabetic ketoacidosis, principles of a healthy lifestyle, and ongoing clinical studies in this area,
- modifying or eliminating environmental and/or behavioral risk factors before the onset of the autoimmune process, e.g. nutritional modifications in the neonatal and childhood period (promoting breastfeeding) [7],
- information on recommended vaccinations against enteroviruses – the impact of enterovirus infections (coxsackieviruses, rubella virus, swine flu virus, cytomegalovirus) in early childhood on the manifestation of type 1 diabetes [8],
- education on the importance of vitamin D3 supplementation [9-10],
- updating knowledge on research directions regarding the possibilities of prediabetes prevention [11-16].

The role and tasks of the primary health care nurse in primary prevention (having completed a diabetes educator course or with a specialization in diabetes nursing or having completed a qualification course in diabetes nursing or with a specialization in internal medicine nursing):

- continuous updates of knowledge on the possibilities of primary prevention of type 1 diabetes,
- collaboration with the medical team – pediatrician, diabetologist, endocrinologist, to identify high-risk groups,

- participation in genetic and family counseling – determining genetic and immunological risk,
- psychological support for high-risk individuals and instilling hope for finding effective methods of preventing type 1 diabetes in the future.

Continued progress in genetic and immunological research in the preclinical phase of the disease allows for improving our understanding of the pathogenesis of type 1 diabetes, reducing the number of cases of diabetic ketoacidosis at diagnosis, decreasing the overall number of hospitalization days (with a tenfold lower need for hospitalization at disease onset), reducing the number of days spent in hyperglycemia, and supporting prolonged C-peptide secretion. In 2023, teplizumab – the first drug for the treatment of pre-symptomatic type 1 diabetes – was approved in the United States. In Europe, including Poland, plans are underway to introduce population-wide screening of children for type 1 diabetes [17-19].

SECONDARY PREVENTION

Secondary prevention denotes early diagnosis of the disease and prompt initiation of treatment. The secondary prevention tasks are carried out by the treatment team, including competent nurses prepared to care for patients with diabetes, at different levels of health care. Cases of newly diagnosed type 1 diabetes generally come under the care of hospital and clinical departments with different levels of referral [3,20-23].

Secondary prevention tasks of the diabetes nurse in specialist outpatient care (SOC) facilities and hospital wards:

- stabilization of the emotional response to the disease,
- therapeutic education based on the core curriculum, initially providing the most essential information to the child and their guardians, necessary for implementing medical recommendations,
- providing support, ensuring the greatest possible sense of security, and offering educational influence to maintain motivation and highlight life perspectives for both the parents and the child,
- establishing cooperation with the specialist outpatient care (SOC) nurse, providing information and documentation, including the necessary scope and progress in education,
- a specialist nurse or diabetes educator, or a nurse who has completed a qualification course in diabetes nursing or a specialist course in caring for individuals with diabetes using CSII therapy, plays a crucial role in the lives of people with type 1 diabetes—solving patients' ongoing problems.

The diabetes team should plan, thoroughly document, and critically evaluate the education process. Educational methods and programs should be diverse and tailored to the child's age and intellectual abilities.

Standardization of documentation should be ensured to centrally collect patient data, e.g. observation chart, education progress chart, etc. The role of the specialized

treatment team is to provide continuous support and maintain motivation. Nurses involved in working with individuals with diabetes have a duty to continuously enhance their knowledge in diabetes education and new teaching methods. Facility managers should provide access to regular training in this area. Patients should be recommended sanatoriums focused on diabetes rehabilitation.

Secondary prevention tasks of the community-family nurse and the school-environment nurse in type 1 diabetes:

- assessment of the family and socio-environmental situation,
- coordination of activities – information flow,
- reeducation in the home environment,
- collaboration with the specialist outpatient care nurse,
- training of school or kindergarten staff by the school nurse,
- providing information about support groups and encouraging active participation in them,
- participation in arranging the transfer of the pediatric patient to the care of a facility for adults,
- providing practical advice and guidance, e.g. on peer interactions, functioning in school, supporting the family with psychosocial needs, and consistently conducting reeducation,
- attempting to raise awareness and deepen public knowledge of the special needs of children with diabetes and their families, especially in the child's learning environment,
- collaboration with the class teacher and school counselor.

At the primary health care (PHC) level, there should function a coordinated care system involving planned cooperation with outpatient specialist care (SOC). The nurse should participate in arranging the transfer of the pediatric patient to the care of a facility for adults to prevent neglect and treatment interruptions – the risk of vascular complications in pediatric patients with diabetes who are not provided with continuous care is very high. The diabetes care system should have procedures in place to identify and locate all pediatric patients with diabetes who have not attended their follow-up appointments.

It is particularly important to coordinate all activities and to ensure the flow of information between facilities of different levels, the patient and their family! [3,19, 24-25].

TERTIARY PREVENTION

Tertiary prevention, aimed at preventing complications, is implemented in all structures and at all levels of diabetes care [3,19,22,26]. The nurse's role in monitoring the course of type 1 diabetes and the development of complications includes:

- participation in screening for diabetes complications,
- constant renewal of therapeutic education and adaptation of its scope and methods to changes in the child's development and perceptiveness,

- monitoring of body weight and height at each visit based on age-appropriate percentile grids, assessment of puberty according to the Tanner scale; detection of developmental deviations,
- assessment of menstruation in girls, assisting with eye fundus examination, evaluation of microalbuminuria, blood pressure measurements (according to percentile values) in children >11 years old at each visit; in children >11 years old or patients with diabetes for more than 5 years, it is recommended to measure blood pressure 24 hours once a year,
- thyroid observation and participation in assessing thyroid function and testing for celiac disease (annually),
- monitoring the schedule of mandatory vaccinations. Additionally, annual vaccinations against influenza are recommended from the age of 6 months,
- depending on the age of the patient, participation in pre-pregnancy counseling,
- raising awareness of the importance of good glycemic control before and during pregnancy, explaining the genetic implications of diabetes, informing about specialized care centers for pregnant women (interdisciplinary team: diabetes nurse, community-family nurse, and midwife),
- assistance in referring the child and parents for ongoing psychological care and counseling regarding the choice of school, field of study, and future profession.

CONCLUSIONS

1. Population-based screening allows for the detection of pre-symptomatic type 1 diabetes. Diabetes education and education on a healthy lifestyle are essential for individuals at risk of developing diabetes.
2. Secondary and tertiary prevention of type 1 diabetes is effective and should be conducted in all diabetes care structures.
3. There is an internal division of roles within healthcare units. Nurses, along with other members of therapeutic teams, are the appropriate individuals to conduct health and therapeutic education.
4. Proper information exchange and cooperation between facilities at different levels are of great importance in type 1 diabetes prevention.
5. The development of the diabetes-trained Advanced Practice Nurse (APN) concept can contribute to the implementation of preventive tasks in type 1 diabetes.

REFERENCES

1. Bonifacio E, Weiß A, Winkler C, et al. An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. *Diabetes Care*. 2021;44(10):2260-2268. <https://doi.org/10.2337/dc20-2122>
2. Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. *Nat Rev Endocrinol*. 2023;19(9):542-554. <https://doi.org/10.1038/s41574-023-00853-0>
3. Chan JC, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. *Lancet*. 2020;396(10267):2019-2082. [https://doi.org/10.1016/S0140-6736\(20\)32374-6](https://doi.org/10.1016/S0140-6736(20)32374-6)
4. Eisenbarth GS. Trials of „Immunotherapy” to preserve beta-cell function in prediabetic and new-onset patient trials. *Curr. Diab. Rep.* 2004;4(2):85-86. <https://doi.org/10.1007/s11892-004-0061-1>

5. Ferrat LA, Vehik K, Sharp SA, et al. A combined risk score enhances prediction of type 1 diabetes among susceptible children. *Nat. Med.* 2020;26(8):1247-1255. <https://doi.org/10.1038/s41591-020-0930-4>
6. Simmons KM, Emily K. Sims. Screening and prevention of type 1 diabetes: where are we? *J. Clin. Endocrinol. Metab.* 2023;108(12):3067-3079. <https://doi.org/10.1210/cin/dgad328>
7. Primavera M, Giannini C, Chiarelli F. Prediction and prevention of type 1 diabetes. *Front. Endocrinol.* 2020;11:248. <https://doi.org/10.3389/fendo.2020.00248>
8. Carré A, Vecchio F, Flodström-Tullberg M, et al. Coxsackievirus and type 1 diabetes: diabetogenic mechanisms and implications for prevention. *Endocr. Rev.* 2023;44(4):737-751. <https://doi.org/10.1210/endrev/bnad007>
9. Harvey J. Vitamin D in the prevention of type 1 diabetes: would increasing food fortification reduce the incidence? *Br. J. Diabetes.* 2023;23(1):39-44. <https://doi.org/10.15277/bjd.2023.405>
10. Hyppönen E, Lääärä E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet.* 2001;358(9292):1500-1503. [https://doi.org/10.1016/S0140-6736\(01\)06580-1](https://doi.org/10.1016/S0140-6736(01)06580-1)
11. Jacobsen LM, Schatz DA, Herold KC, et al. Prevention of type 1 diabetes. In: Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT (ed.). *Diabetes in America*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2024. Accessed: 2025-06-10. <https://www.ncbi.nlm.nih.gov/books/NBK604182>
12. Chen X, Affinati AH, Lee Y, et al. Immune checkpoint inhibitors and risk of type 1 diabetes. *Diabetes Care.* 2022;45(5):1170-1176. <https://doi.org/10.2337/dc21-2213>
13. Jing Z, Li Y, Ma Y, et al. Leverage biomaterials to modulate immunity for type 1 diabetes. *Front. Immunol.* 2022;13:997287. <https://doi.org/10.3389/fimmu.2022.997287>
14. LeFevre JD, Cyriac SL, Tokmic A, et al. Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: a literature review. *Am. J. Health Syst. Pharm.* 2022;79(23):2099-2117. <https://doi.org/10.1093/ajhp/zxac244>
15. Johnson RK, Vanderlinde LA, DeFelice BC, et al. Metabolomics-related nutrient patterns at seroconversion and risk of progression to type 1 diabetes. *Pediatr. Diabetes.* 2020;21(7):1202-1209. <https://doi.org/10.1111/pedi.13085>
16. Hakola L, Mramba LK, Uusitalo U, et al. Intake of B vitamins and the risk of developing islet autoimmunity and type 1 diabetes in the TEDDY study. *Eur. J. Nutr.* 2024;63:1329-1338. <https://doi.org/10.1007/s00394-024-03346-6>
17. Hoffmann L, Kohls M, Arnolds S, et al. EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. *BMJ Open.* 2025;15(1):e088522. <https://doi.org/10.1136/bmjopen-2024-088522>
18. Narayan K, Mikler K, Maguire A, et al. The current landscape for screening and monitoring of early-stage type 1 diabetes. *J. Paediatr. Child Health.* 2025;61(5):676-684. <https://doi.org/10.1111/jpc.70016>
19. Hornik B, Przeorska-Najgebauer T, Włodarczyk I. The role of the nurse in the prevention of type 1 diabetes. *Ann. UMCS Sect. D.* 2005;60(2):154-157.
20. Allen L, Dayan C. Immunotherapy for type 1 diabetes. *Br. Med. Bull.* 2021;140(1):76-90. <https://doi.org/10.1093/bmb/ldab027>
21. Dayan CM, Besser RE, Oram RA, et al. Preventing type 1 diabetes in childhood. *Science.* 2021;373(6554):506-510. <https://doi.org/10.1126/science.abi4742>
22. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
23. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care.* 2019;42(5):731-754. <https://doi.org/10.2337/dc19-0014>
24. Dai H, Chen Q, Huang H, et al. The role of nurses in taking care of children with type 1 diabetes. *Altern. Ther. Health. Med.* 2022; 28(1):107-113.
25. Lahsen HAT, Ragala MEA, Halim K, et al. Investigation of the therapeutic education effect on glycemic control and quality of life of children and adolescents with type-1 diabetes mellitus: A non-randomized controlled study. *J. Educ. Health Promot.* 2024;13(1):228. https://doi.org/10.4103/jehp.jehp_1258_23
26. Mameli C, Triolo TM, Chiarelli F, et al. Lessons and gaps in the prediction and prevention of type 1 diabetes. *Pharmacol. Res.* 2023;193:106792. <https://doi.org/10.1016/j.phrs.2023.106792>

XVIII. GUIDELINES ON THE PREVENTION OF TYPE 2 DIABETES

Purpose: Supporting nurses and midwives in making decisions regarding prevention of type 2 diabetes. Providing nursing care in accordance with the current state of knowledge, competences and resources.

Guidelines for: nurses and midwives.

■ Tab. 19. Key recommendations. Tasks for the nursing staff in the prevention of type 2 diabetes

Type 2 diabetes can be prevented through lifestyle interventions. A critical component of any individual-based prevention strategy is the effective identification of individuals at sufficiently elevated risk of future diabetes to warrant intervention. A
The diverse environmental, behavioral and socioeconomic causes of type 2 diabetes call for a multi-level prevention strategy involving the entire community and population. A
Complications of diabetes can be minimized by providing continuous access to attentive and well-organized care and treatment, as well as structured therapeutic education. A
The use of modern technology can improve the effectiveness of lifestyle changes. C

Type 2 diabetes is a major medical, economic and social problem. Thus, its management requires the involvement of different public health and health care sectors. The quality of diabetes care depends on numerous factors including the composition and skills of the treatment team and the organization of medical services specifically intended for people with diabetes. Nurses are an important link in the medical care structure for people with diabetes and are involved in prevention, including health and therapeutic education, at all three levels of care. The care

of a patient with type 2 diabetes should be coordinated, comprehensive, and delivered at different levels of care – Primary Health Care (PHC), Specialist Outpatient Care (SOC), and specialist hospital care comprising primary, secondary and tertiary prevention.

PRIMARY PREVENTION

1. Population-wide strategy. The use of mass media, schools, local government and community organizations. The health care system plays an initiatory, advisory and opinion-making role [1-7].

- Actions are aimed at reducing the prevalence or the level of causal risk factors for the development of type 2 diabetes and, at the same time, atherosclerosis in entire populations or groups of people.
- Promotion of a healthy lifestyle – prevention or elimination of the disease of obesity by increasing physical activity, consuming a healthy diet, quitting smoking, avoiding diabetogenic drugs, avoiding stress and alcohol abuse.
- The nurse/educator is actively involved in prevention activities and programs promoting a healthy lifestyle.

2. Selective strategy.

Predominantly implemented at the PHC level. The community/family nurse is a natural co-provider of selective primary preventive care [2-3,6-20].

- The community interview allows for making connections between patients' health data and identifying some of the measurable diabetes risk factors in the patient population under care.

- Identification of individuals at risk of the disease and taking further action appropriate to the medical and nursing diagnosis – this can be purely non-pharmacological intervention or combined with pharmacotherapy.
- The nurse's actions at the stage of early risk factor identification allow for attempts to eliminate or reduce modifiable factors; preventive actions should not be random, they must be carefully planned!
- Monitoring of and education about cardiovascular risk factors (e.g. smoking, hypertension, lipid disorders) are also recommended as part of diabetes prevention.
- Obese individuals should be recommended to measure their weight and waist circumference every two weeks and record the results in a self-monitoring diary. The nurse should emphasize the benefits of moderate weight reduction and regular physical activity.
- The epidemic of the disease of obesity among children and adolescents is a serious risk factor for type 2 diabetes in this age group and creates a need for school-based preventive interventions. Identification of risk groups is carried out by the school nurse and the primary health care physician during preventive examinations, i.e. routine health checks; Overweight and obese children and their parents should be included in preventive interventions, especially targeted health counseling, education and the provision of individual care.
- It is recommended that people with risk factors have an Individual Chart for Diagnosis and Assessment of Individual Diabetes and Atherosclerosis Risk Factors containing an examination schedule and a description of preventive measures. This chart should be filled in for the first time during a scheduled preventive visit to a primary care clinic. The physician and nurse, as well as other members of the treatment team, fill out the card with information about preventive interventions. This prevention chart can be set up for any person who has at least one risk factor, especially for type 2 diabetes and atherosclerosis. Environmental and behavioral risk factors are also taken into account.

SECONDARY PREVENTION

Secondary prevention involves early diagnosis of the disease and immediate intervention after diagnosis. The aim of secondary prevention is to reverse the course of the disease or prevent a genetic predisposition being triggered into full-blown diabetes. **It should be implemented at the level of Primary Health Care (PHC), Specialist Outpatient Care (SOC) and in hospitals (non-specialist and specialist departments)** [2,7,9,17,21].

The nurse's tasks at this level include the following:

- Participation in screening, whose primary goal is to identify people with previously undiagnosed (asymptomatic) type 2 diabetes or high-risk individuals. The screening can be conducted among the general popu-

lation, high-risk subgroups and individuals. When assessing the patient's health condition, the nurse must demonstrate knowledge of the criteria for type 2 diabetes testing in adults and children and the current criteria for diagnosing diabetes and hyperglycemia (current guidelines of Diabetes Poland – PTD).

- Involvement in providing initial education following diagnosis of the disease, which should then be extended and carried out on the basis of a prepared curriculum.
- Provision of therapeutic education based on the core curriculum, scheduling of patient knowledge assessments and provision of re-education when necessary.
- Participation in activities of the treatment team that are complementary in terms of competence, forming an integrated whole. Therefore, the treatment team should discuss aspects of the work with the patient at least once a week.
- A diabetes and dispensary registry should be established in primary and family care institutions. There should be a designated person responsible for records and appointments. A prerequisite for effective action is the formation of strong motivational mechanisms in patients for daily adherence to medical recommendations.

TERtiARY PREVENTION

Tertiary prevention involves optimal diabetes treatment that prevents or reduces the development of acute and chronic diabetes complications. It is delivered in specialist inpatient care facilities (at different levels of referral), in general ward settings and in highly specialized diabetes university outpatient clinics or provincial and district clinics and primary care facilities. All these facilities should work closely together!!! An important role is also played by diabetes rehabilitation-oriented sanatoriums [2,5,7,9,17,22].

The treatment of diabetes is multifactorial. Therefore, a coordinated, comprehensive, and multidisciplinary care model is recommended, with the active, informed participation of patients in the treatment process. Primary or family care facilities should work closely with diabetes facilities in the same area to provide further professional training on the implementation of new medical advances, diabetes patient education and social problems.

Tertiary prevention is implemented through a system of intensified diabetes care, in which the nurse plays an essential role. It involves:

- Proper metabolic control and self-monitoring, education and pharmacological prevention (basic markers for self-monitoring: blood glucose, acetonuria, microalbuminuria, blood pressure, lifestyle management: diet, exercise, stress and work, medications and medical equipment to facilitate self-monitoring: glucometers, strip tests, oral antidiabetic drugs, insulin therapy, pens).
- Prevention of acute diabetes complications.
- Keeping an outpatient diabetes care chart for each patient. Every general clinic should have a nurse responsible for educating patients with diabetes.
- Assessment of the patient's level of knowledge about diabetes at least once a year and provision of re-education, if necessary. The basic requirement for obtaining

this type of patient cooperation is to provide the patient with information based on the principles of educational pedagogy, appropriate in terms of the content, scope and language. With properly conducted therapeutic education, it is possible to obtain the desired attitude of the patient, which is a prerequisite for achieving cooperation in the process of intensive treatment.

- Participation of the nurse in screening tests to detect early stages of chronic complications of diabetes.
- Participation of the nurse in the care of patients with diabetic foot syndrome; amputation prevention.
- Participation of the nurse in vaccinations in accordance with the schedule of mandatory and recommended immunizations.
- Informing patients and their families about diabetes associations and encouraging them to actively participate in these communities.
- Encouraging nurses to participate in diabetes nursing associations, such as the PFED, which facilitates cooperation, further education and exchange of experience with the PTD and similar organizations abroad, and cooperation with diabetes associations.

CONCLUSIONS

1. It is possible to prevent type 2 diabetes or at least delay the onset of the disease. Prevention of type 2 diabetes can be implemented through lifestyle changes as well as pharmacotherapy.
2. A competent and well-trained nurse is one of the pillars of diabetes prevention at every level.
3. The prevention structure is based on the health care system structure. The nurse is required to participate in prevention at all three levels, acting on the basis of current regulations and the results of scientific research (EBM and EBN).
4. In light of these challenges, there is a need to continuously improve nurses' knowledge about diabetes through postgraduate training – specialization in internal medicine nursing with a diabetes care module, qualification courses in diabetes nursing and specialist courses such as Educator in diabetes, Care of patients with diabetes using continuous subcutaneous insulin infusion (CSII), or Wound management.
5. Information exchange between personnel working at different facilities is crucial. It is important to pay attention to the growing role of new methods of providing nursing advice, such as telemedicine, and the legislation on this issue.
6. The development of the diabetes-trained Advanced Practice Nurse (APN) concept can contribute to the implementation of preventive tasks in type 2 diabetes.

REFERENCES

1. Tuomilehto J, Uusitupa M, Gregg EW, et al. Type 2 diabetes prevention programs from proof-of-concept trials to national intervention and beyond. *J. Clin. Med.* 2023;12(5): 1876. <https://doi.org/10.3390/jcm12051876>
2. Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. *Lancet.* 2020;396(10267):2019-2082. [https://doi.org/10.1016/S0140-6736\(20\)32374-6](https://doi.org/10.1016/S0140-6736(20)32374-6)
3. Albright AL, Gregg EW. Preventing type 2 diabetes in communities across the US: the National Diabetes Prevention Program. *Am. J. Prev. Med.* 2013;44(4):S346-S351. <https://doi.org/10.1016/j.amepre.2012.12.009>
4. Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. *JAMA Intern. Med.* 2017;177:1808-1817. <https://doi.org/10.1001/jamainternmed.2017.6040>
5. Malecki HL, Gollie JM, Scholten J. Physical activity, exercise, whole health, and integrative health coaching. *Phys. Med. Rehabil. Clin. N. Am.* 2020;31(4):649-663. <https://doi.org/10.1016/j.pmrj.2020.06.001>
6. Golovaty I, Ritchie ND, Tuomilehto J, et al. Two decades of diabetes prevention efforts: a call to innovate and revitalize our approach to lifestyle change. *Diabetes Diabetes Res. Clin. Pract.* 2023;198:110195. <https://doi.org/10.1016/j.diabres.2022.110195>
7. Hornik B, Kopczyńska E, Przeorska-Najgebauer T. Role of the nurse in a prevention of type 2 diabetes. *Ann. UMCS Sect. D.* 2005;60(2):158-162.
8. Bun R, Tounkara B, Leruste S, et al. Prediabetes in a French overseas territory: clinical characteristics, risk factors, and implications for type 2 diabetes prevention. *Prev. Med. Rep.* 2024;47:102893. <https://doi.org/10.1016/j.pmedr.2024.102893>
9. Araszkiewicz A, Borys S, Broncel M, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. *Curr. Top. Diabet.* 2025;5(1):1-157. <https://doi.org/10.5114/ctd/203685>
10. Rintamäki R, Rautio N, Peltonen M, et al. Long-term outcomes of lifestyle intervention to prevent type 2 diabetes in people at high risk in primary health care. *Prim. Care Diabetes.* 2021;15(3):444-450. <https://doi.org/10.1016/j.pcd.2021.03.002>
11. Diabetes Prevention Program Research Group. Longterm effects of metformin on diabetes prevention: identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study. *Diabetes Care.* 2019;42:601-608. <https://doi.org/10.2337/dc18-1970>
12. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet.* 2017;389(10077):1399-1409. [https://doi.org/10.1016/S0140-6736\(17\)30069-7](https://doi.org/10.1016/S0140-6736(17)30069-7)
13. Gilis-Januszewska A, Lindström J, Tuomilehto J, et al. Sustained diabetes risk reduction after real life and primary health care setting implementation of the diabetes in Europe prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. *BMC Public Health.* 2017;17:1-7. <https://doi.org/10.1186/s12889-017-4104-3>
14. Yost O, DeJonckheere M, Stonebraker S, et al. Continuous glucose monitoring with low-carbohydrate diet coaching in adults with prediabetes: mixed methods pilot study. *JMIR Diabetes.* 2020;5(4):e21551. <https://doi.org/10.2196/21551>
15. Sussman JB, Kent DM, Nelson JP, et al. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. *BMJ.* 2015;350:h454. <https://doi.org/10.1136/bmj.h454>
16. Raynor HA, Davidson PG, Burns H, et al. Medical nutrition therapy and weight loss questions for the evidence analysis library prevention of type 2 diabetes project: systematic reviews. *J. Acad. Nutr. Diet.* 2017;117(10):1578-1611. <https://doi.org/10.1016/j.jand.2017.06.361>
17. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care.* 2019;42(5):731-754. <https://doi.org/10.2337/dc19-0014>
18. Seyoum T, Tesfaye S, Shiferaw Y, et al. Knowledge of behavioral risk factors for type 2 diabetes mellitus and its associated factors among women of reproductive age. *PLoS One.* 2025;20(2):e0275700. <https://doi.org/10.1371/journal.pone.0275700>
19. Jastreboff, AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. *N. Engl. J. Med.* 2025;392(10):958-971. <https://doi.org/10.1056/NEJMoa2410819>
20. Chai X, Wang Y, Yin X, et al. Effects of lifestyle interventions on the prevention of type 2 diabetes and reversion to normoglycemia by prediabetes phenotype: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Metab. Syndr.* 2025;19(1):103184. <https://doi.org/10.1016/j.dsx.2025.103184>
21. Peer N, Balakrishna Y, Duro A. Screening for type 2 diabetes mellitus. *Cochrane Database Syst. Rev.* 2020;5(5):CD005266. <https://doi.org/10.1002/14651858.CD005266.pub2>
22. Marsim E, Prisma FA, Prianggi H. Meta-analysis: application of health belief model on the tertiary prevention of type 2 diabetes mellitus. *J. Health Promot. Behav.* 2021;6(4):284-297. <https://thejhpb.com/index.php/thejhpb/article/view/338>

ORCID

Alicja Szewczyk  <https://orcid.org/0000-0003-4167-0361>
Natasza Tobiasz-Kałkun  <https://orcid.org/0000-0002-1184-1871>
Anna Stefanowicz  <https://orcid.org/0000-0002-1896-5551>
Ewa Kobos  <https://orcid.org/0000-0001-7231-8411>
Justyna Kapuściok  <https://orcid.org/0009-0003-1294-0489>
Kamila Mazuryk  <https://orcid.org/0009-0002-3947-7722>
Beata Hornik  <https://orcid.org/0000-0002-0106-9216>

Manuscript received: 02.07.2025

Manuscript accepted: 02.09.2025

Translation: Przetłumacz.to translation agency